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Abstract
Encapsulation of pancreatic islets in alginate microbeads and microcapsules show great promise
for the treatment of Type 1 diabetes mellitus. Significant progress has been made in developing
a biocompatible capsule that allows sufficient exchange of nutrients and products with the en-
capsulated cells, while at the same time maintaining a barrier to immune cells and preventing
rejection of the transplanted cells. However, a truly biocompatible capsule has, as yet, not been
developed, and implanted capsules often trigger low levels of inflammation leading to fibrosis,
diminished insulin secretion, and sometimes death of the encapsulated cells.
A lepirudin-based human whole blood model was used to demonstrate the inflammatory
potential of a set of different alginate microcapsules and microbeads. This was performed to
elucidate the effect of different capsule and bead parameters, such as the effect of a hollow versus
solid inner core, polycation type, polycation concentration, alginate type, and capsule and bead
diameter. Complement activation after incubation of capsules in whole blood was measured
as sTCC generation. In addition, the secretion of chemokines, inflammatory cytokines, anti-
inflammatory cytokines, and growth factors was analyzed by ELISA and Bio-plex. Leukocyte
activation as measured by CD11b expression was detected using flow cytometry. Finally, Confo-
cal Laser Scanning Microscopy (CLSM) was used in order to screen for a set of plasma proteins
and observe what proteins adsorbed to the capsule surface.
TAM alginate microbeads did not trigger complement activation, secretion of cytokines, or
up-regulation of CD11b expression, and thus appeared to have a minimal inflammatory poten-
tial. In addition, the protein adsorption assay showed no apparent protein surface deposition on
the microbeads after 6 hours of incubation in plasma of the proteins screened for (complement
protein C3, complement regulatory proteins factor H, factor I, C1 inhibitor, and vitronectin, as
well as coagulation cascade proteins fibrinogen, plasminogen, and HMWK).
Solid alginate APA microcapsules containing poly-L-lysine (PLL), on the other hand, showed
an increase in complement component sTCC levels, in chemokine levels (IL-8, MCP-1, and MIP-
1α), in inflammatory cytokine levels (IL-6, IL-1β, and TNFα), in anti-inflammatory cytokine
levels (IL-1RA and IL-10), and in growth factors levels (PDGF, HGF, and VEGF), as well as
a decrease in cytokine IP-10 levels. In addition, the capsules also stimulated leukocyte acti-
vation by up-regulating the expression of CD11b. The solid APA micrcapsules showed heavy
C3 adsorption, coupled with vitronectin and factor H surface deposition, indicating increased
complement activity on these capsules.
Hollow APA microcapsules with PLL triggered a rapid and strong sTCC response, as well
as significantly increased secretion of the chemokine MCP-1. At the same time, a significant
decrease in secretion of chemokines (IL-8 and MIP-1α) and inflammatory cytokines (IL-1β and
iii
TNFα), as well as a decrease in secretion of growth factor VEGF, and cytokine MIF, and an
increase in cytokine IP-10 was observed. All these cytokine levels except the chemokine MCP- 1
and the complement complex sTCC suggested reduced inflammatory potential for hollow APA
capsules. It was proposed that these capsules adsorbed the anaphylatoxins C3a and C5a, thus
preventing the complement mediated activation of leukocytes. No increased surface adsorption
of C3 was detected on hollow APA capsules compared to solid APA capsules. Conversely, the
C3 adsorption was higher on solid APA capsules, thereby not reflecting the increased sTCC
generation seen for hollow APA capsules. One explanation for this might be that the hollow
capsules secreted some soluble molecule capable of triggering sTCC generation.
No apparent change in inflammatory potential could be observed by exchanging the polyca-
tion PLL with PLO (poly-L-ornithine), except for abolishing the strong sTCC response observed
for hollow APA capsules with PLL as well as lowering the MCP-1 response. It was suggested
that this observation could be the result of PLO reducing the permeability of the capsules, thus
preventing the diffusion of the hypothesized soluble trigger of sTCC.
Increased sTCC was detected with increasing PLL concentration in High G alginate APA
capsules. The same could not be observed for High M alginate capsules, however, the chemokine
IL-8 and the inflammatory cytokines IL-1β and TNFα increased with increasing PLL concen-
tration, suggesting increased inflammation with increasing PLL concentration. No change in
inflammatory potential could be detected with varying alginate microbead diameter. Nor could
any change in inflammatory potential be observed by the addition of HEPES in the gelling
solution.
TAM alginate microbeads appear to have the lowest inflammatory potential of the capsules
tested, and are therefore the most suited for in vivo application from an inflammatory aspect,
as demonstrated by the whole blood assay. A recent study in Type 1 diabetes patients however
showed increased fibrosis when encapsulating human islet cells in barium alginate microbeads
[61]. Further studies where incubation of TAM microbeads with isolated monocytes are co-
cultured with fibroblasts could further elucidate the mechanisms of fibrosis on the microbeads.
In addition, continued screening of protein adsorption on the bead surface should be performed.
iv
Sammendrag
Innkapsling og transplantering av Langerhansk øyvev i alginat-mikrokapsler viser potensiale in-
nenfor behandling av Diabetes Mellitus type 1. Fremsteg har blitt gjort innenfor utviklingen av
kapsler som er biokompatible og som tillater tilstrekkelig diffusjon av næringsstoffer og cellepro-
dukter inn og ut av kapslene, samtidig som kapslene fungerer som en barriere mot pasientens
immunceller og forhindrer frastøting av implantatet. Men fullstendig biokompatible kapsler har
enda ikke blitt utviklet, og kapsler trigger ofte lav inflammasjon som kan føre til overvekst på
kapslene, minsket insulin sekresjon, og i visse tilfeller også celledød.
En lepirudin-basert fullblodsmodell ble brukt til å teste forskjellige alginat-kapsler og deres
inflammatoriske potensiale. Dette ble utført i et forsøk på å kaste lys over forskjellige kapsel-
parametere slik som løselig eller fast kjerne, polykation type, polykation konsentrasjon, alginat
type og kapsel diameter, og hvilken effekt disse parameterene har på inflammasjon. Komplement-
aktivering ble målt som sTCC-dannelse etter inkubering av kapsler i fullblod. I tillegg ble
sekresjon av chemokiner, cytokiner, og vekst faktorer målt ved hjelp av ELISA og Bio-plex.
Leukocytt-aktivering ble målt som CD11b-ekspresjon ved hjelp av flow cytometri. Tilslutt ble
et konfokal laser scanning mikroskop tatt i bruk til å studere deponering av plasma-proteiner
på overflaten av kapslene.
TAM-alginatkuler aktiverte hverken komplement, sekresjon av cytokiner eller oppregulering
av CD11b, og hadde derfor et tilsynelatende lavt inflammatorisk potensiale. I tillegg ble det
ikke oppdaget noe protein-adsorpsjon på disse kapslene etter 6 timers inkubering i plasma (kom-
plementprotein C3, de regulatoriske komplementproteinene factor H, factor I, C1 inhibitor or
vitronectin, så vell som koagulasjonsproteinene fibrinogen, plasminogen og HMWK)
APA-kapsler med fast kjerne inneholdende poly-L-lysine (PLL) viste derimot økt komplemen-
taktivering (sTCC), i tillegg til økte chemokine-verdier (IL-8, MCP-1, and MIP-1α), cytokine-
verdier (IL-1β, IL-6, TNFα, IL-1RA og IL-10) og vekstfaktorer (PDGF, HGF og VEGF). Det
ble også påvist en nedgang i IP-10 verdier, oppregulering av CD11b, så vell som C3, vitronectin
og factor H overflatedeponering, noe som indikerte økt komplementaktivitet.
APA-kapsler med løselig kjerne inneholdende PLL viste en rask og høy sTCC-respons, og
signifikant økning i MCP-1 sekresjon. Men samtidig viste de signifikant minskning i chemokiner
(IL-8 and MIP-1α) og inflammatoriske cytokiner (IL-1β and TNFα), vekstfaktor VEGF og cy-
tokin MIF, samt en økning i cytokin IP-10. Alle disse nivåene unntatt MCP-1 og sTCC indikerte
et redusert inflammatorisk potensiale for APA-kapsler med løselig kjerne. Det ble foreslått at
kapslene adsorberte anafylatoksinene C3a og C5a, og dermed forhindret komplementmediert
aktivering av de hvite blodcellene. Ingen økt C3-deponering kunne observeres for APA-kapsler
med løselig kjerne sammenlignet med fast kjerne. Isteden var det kapslene med fast kjerne som
v
viste høyest C3-deponering. Dette samsvarte ikke med de forhøyede sTCC nivåene observert for
kapslene med løselig kjerne, og det ble foreslått at et løselig stoff diffunderte ut av disse kapslene
og trigget sTCC dannelse.
Ved å bytte ut PLL med PLO (poly-L-ornithine) i kapsler med løselig kjerne, ble den
forhøyede sTCC- og MCP-1 responsen for disse kapslene senket. Ellers påvirket ikke PLO
kapslenes cytokin-profil nevneverdig. Det ble foreslått at PLO kunne redusere permeabiliteten
til kapslene og på den måten forhindre diffunderingen av eventuelle stoffer ut av kapslene som
kunne føre til sTCC-dannelse.
Økte sTCC-nivåer ble observert i takt med økende PLL-konsentrasjon i kapsler med høy-G
alginat. Det samme kunne ikke observeres i kapsler med høy-M alginat. Man kunne derimot
se økte IL-8, IL-1β og TNFα-nivåer, noe som likevel tydet på økt inflammatorisk potensiale i
tråd med økende PLL-konsentrasjon. Ingen forandring i inflammatorisk potensiale kunne ob-
serveres med varierende kapseldiameter. Det virket heller ikke som om tilsetningen av HEPES
i gelingsløsningen påvirket dette.
TAM-alginatkuler viste seg å stimulere inflammasjon i minst grad av de kapslene som ble
testet her i fullblodsmodellen. Det kan derfor virke som om disse kapslene er best egnet til in
vivo bruk, ut fra et inflammatorisk synspunkt. Men i en studie hvor Diabetes type 1 pasienter
ble behandlet med øyvev innkapslet i barium-alginatkuler [61], ble det påvist overvekst på kulene
og svekket sekresjon av insulin. Muligheter for videre studier kan derfor inkludere inkubering
av TAM-kuler med isolerte monocytter og fibroblaster for å studere mekanismene bak overvekst
nøyere. I tillegg bør det fortsettes med protein-adsorpsjonsstudier hvor flere plasmaproteiner
screenes, og hvor kapslene inkuberes over en lenger periode.
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1 INTRODUCTION
1.1 Encapsulation
Encapsulation of biologically active materials to protect and allow for controlled administration
of chemicals, drugs, proteins, vaccines, and food additives, is a well-established method. Living
cells may also be encapsulated, either for use in industry, agriculture, or cell therapy. Materials
that have been utilized for cell encapsulation include alginate, collagen, gelatin, chitosan, and
agarose. Although there are many applications of encapsulation for cell therapy, one of the most
studied systems, and perhaps also the most promising, is the encapsulation of insulin producing
cells into alginate capsules for transplantation and treatment of Type 1 diabetes.
1.1.1 Encapsulation of cells for treatment of Type 1 diabetes
The main goal of cell encapsulation in cell therapy is to overcome the problem of graft rejection.
As all transplanted cells are recognized as foreign, patients having undergone a transplantation,
be it a whole organ transplant or just individual cells, need to be on a lifelong regime of immuno-
suppressive drugs to prevent or minimize the rejection of transplant by the host immune system.
As these drugs suppress and limit the immune system, the patient will be more susceptible to
infections as well as having an increased risk of tumor development [1].
By encapsulating cells in a biomaterial such as alginate, the aim is to mask the cells from
the body’s immune system but still allow for products and substrates to pass through. In the
case of encapsulation of insulin producing islets, the capsule must permit insulin and glucose to
pass through the capsule, allowing normal regulation of the patient’s blood glucose. If success-
ful, this technique would remove the need of immunosuppression and be a major step toward a
functional cure for Type 1 diabetes.
Type 1 diabetes is an autoimmune disease where the immune system targets and destroys
the insulin-producing beta cells of the pancreas. This leads to a shortage of insulin in the blood
which subsequently results in increased blood glucose. Complications include cardiovascular
disease, and damage to the nerve system, the retina, and the kidneys, if the disease is poorly
managed [2]. If left untreated the disease will result in death. The current therapy of choice is
treatment with insulin where daily injections must be administered indefinitely. Transplantation
of islets of Langerhans or a whole pancreas has been successful in normalizing blood glucose
levels, however, because Type 1 diabetes is an autoimmune disease, the host immune system
will continue to target and destroy the transplanted beta cells even if a close donor match is
found with limited graft rejection. A strict immunosuppression regime is therefore required. In
addition, as many as 3 million people in U.S.A may have Type 1 diabetes [3], a number that
way exceeds the supply of human pancreases.
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1.1.2 Immunoisolation of cell transplants
The human immune system is programmed to distinguish self from non-self. This allows it to
recognizes pathogens that have infected the body, as well as deal with self-cells that have devi-
ated from their original role and purpose, such as cancer cells. This defense, which is crucial for
survival in an environment where the body continuously is bombarded with pathogenic microbes
trying to invade our body, is at the same time what makes it so difficult to transplant organs
and cells into the body. Even when the transplant donor is a close match, e.g. a relative, small
differences in the molecules coating the cells can result in the host immune system reacting to
the transplant and rejecting the graft. Lifelong immunosuppression must be administered along
with its numerous side effects. Sometimes these side effects might even outweigh the benefits of
the transplant itself. And for the case of using organs or cells from other animals (xenografts)
as opposed to from humans (allografts) the complications are even greater.
The transplantation of a graft from a donor that is not closely related to the patient will
result in rejection. This happens mainly because of differences between host and graft MHC
molecules that are positioned on the surface of the cells. These molecules are meant to help
the immune system detect infections. Immune cells (T-cells) can, however, detect differences
between the MHC molecules present on host cells, and those on graft cells. If this happens and
the T-cells subsequently become activated, a highly specific attack will be initiated towards the
graft cells presenting the foreign MHC molecules. MHC matching between donor and host is
therefore performed for whole organ transplantation so as to minimize the likelihood of rejection.
However, even with a close MHC match, rejection might still occur. MHC is an abbreviation
of major histocompability complex, and differences here is the major reason for incompatibility
between host and donor. There are also minor histocompability antigens that differ between
members of the same species. These antigens are proteins that are expressed and secreted by
the graft, taken up by host cells and presented on MHC molecules on the surface of antigen
presenting cells. As they differ from the proteins of the host, immune cells will recognize them
as foreign and target the cells expressing them, i.e. the graft cells. The immune cells will believe
the graft cells are infected and start killing them, thereby rejecting the graft.
Immunoisolation of the graft, e.g. by encapsulating the graft cells in alginate microcapsules,
prevents the direct contact between graft cells and host immune cells. No T-cells can thereby
attach to graft cells and recognize the different MHC molecules present. Alginate microcapsules
are however porous and proteins might leak out of the capsules. Immunoisolation can therefore
prevent the direct targeting of the graft cells, but may still indirectly activate the host immune
system, see figure 1.1. Cytotoxic T-cells, a major participant in graft rejection, requires direct
contact with the target cell and thus may be prevented from attacking the graft. The release of
cytokines and the productions of antibodies might be harder to counteract. Molecules secreted
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by immune cells such as IL-1β, TNF-α, and IFN-γ, and antibodies, as well as complement
components, are all small enough that they might diffuse into the capsule and target the graft
cells. This might in turn damage the cells and result in lysis. Still, a big part of an immune
attack involves the direct contact of immune cells which may be eliminated by encapsulating
the cells in alginate microcapsules.
Figure 1.1: An overview of possible responses aimed toward encapsulated cells. Adapted from [4].
1.2 Alginate
Alginate is a biopolymer widely used in industry mainly for its stabilizing and viscosifying
abilities as well as for retaining water and forming gels [5]. More recently alginate has been im-
plemented in medical applications such as dressings in surgery and wound management [6]. In
addition, because of its abundance, biocompatibility, and biodegradability properties, alginates
are regarded as the most suitable biomaterial for cell microencapsulation. This work focus on
the encapsulation of cells for transplantation into patients.
To date all commercially available alginate is produced from algae, where its main function
is conferring strength and flexibility to the algal tissue. It exists as a gel containing Na+, Ca2+,
Mg2+, Sr2+, and Ba2+ions, and is located in the intercellular matrix of the algae. Alginate
is also produced by certain bacterial strains, however microbial fermentation is thus far not
economically favorable mainly due to the low cost of cultivating seaweeds in under-water farms
[7].
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1.2.1 Composition
Alginate is a biopolymer produced by brown seaweeds and by the Gram-negative bacteria
Pseudomonas and Azotobacter, and is made up of 1-4-linked α-L-guluronic acid (G) and β-
D-mannuronic acid (M) as shown in figure 1.2. These sugar acids are distributed in blocks
of continuous M-residues, G-residues, or as alternating MG-residues. High resolution 1H- and
13C-nuclear magnetic resonance spectroscopy (NMR) can be used to determine the composition
and sequence parameters of the alginate polymer.
Figure 1.2: Composition of sodium alginate [5]. a The 4C1 conformation of β-D-mannuronic acid (M) and 1C4
conformation of α-L-guluronic acid (G). b Ring conformation of the different blocks in alginate.
The composition of alginate varies widely depending on the source of the alginate. For algi-
nate produced by algae the fraction of G-residues (FG) can vary in the range of 0.20 to 0.85 [8].
Alginates isolated from Macrocystis pyrifera are characterized by a lower content of G-blocks
(FG=0.4) while, in general, high contents of G are found in alginates from Laminaria hyperborea
algae (FG=0.6) [9]. Caution should be exercised here as alginate from M. pyrifera is frequently
mentioned in encapsulation literature as high-M alginate to distinguish it from the L. hyper-
borea alginate. Nevertheless, the M fraction is not as high as the M rich alginate (86-99.9%
M-blocks) also going under the name high-M alginate seen to stimulate cytokine production
in monocytes [10]. Alginates produced by the bacterial strains Azotobacter and Pseudomonas
often show increased variability in the composition of the polymer, with Pseudomonas species
lacking G-blocks [11]. The biggest difference between algal and bacterial alginates is, however,
the capability of bacteria to add O-acetylations on C-2 and/or C-3 on mannuronic acid residues,
affecting the swelling and water-binding properties of the alginate gel [11, 12].
The stabilizing and viscosifying abilities as well as the properties of retaining water and form-
ing gels, for which alginate is widely used, are dependent on the composition of the biopolymer
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with different combinations of the monomers M and G giving the polymer different physical
properties. For example, the formation of gels depends on G-repeats interacting with divalent
cations (e.g. Ca2+or Ba2+) in the solution, making the gel strength dependent on the amount
and length of G-blocks present [7].
1.2.2 Alginate gels
Alginate forms a gel by binding to divalent cations, a process that is highly specific with an
affinity for the ions depending on the composition of the alginate. The process of gelation is
explained by the egg-box model [13]. Repeats of G-residues create cavities which function as
binding sites for ions, allowing a lateral association of the polymer chains, see figure 1.3. This
co-operative binding gives the gel a rigidity depending on the gelling ion which decreases in
the order of Ba2+>Sr2+>Ca2+>‌>Mg2+. This appears also to be the cationic selectivity for
G-blocks while M- and MG-blocks are almost without selectivity [14]. Thus the main structural
feature contributing to gel-formation is the length of these G-blocks [15], giving alginate gels
with a high M content (FG=0.4) such as alginate from M. pyrifera lower strength and stability
as compared to those made from high G alginates (FG=0.6) such as L. hyperborea alginate [16].
Figure 1.3: The egg-box model. Lateral association of chains by chelation of divalent cations. Figure adapted
from [17]. Zigzag regions represent blocks of G-residues.
1.3 Alginate microcapsules
1.3.1 Formation of alginate beads and capsules
Alginate beads are formed by dripping an alginate solution into a mixture containing divalent
cations causing the polymer to cross-link and form a gel, see figure 1.4. This happens rapidly and
irreversibly, and the alginate bead will have a shape and property depending on the composition
of the alginate as well as the gelling solution. The usual choice of gelling ion is Ca2+ because
of its selective binding to G-blocks and non-toxicity. Ba2+ is also commonly used because of
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its potential to stabilize the bead even further, however, as Ba2+ is toxic to the human body,
lower concentrations are used to prevent leakage of ions out of the bead. Usually Ba2+is only
used for alginate beads (where gelled alginate is the only component) while alginate-polycation-
alginate (APA) microcapsules consists of a stabilizing polycation layer outside of the alginate
core making the use of Ba2+redundant.
Figure 1.4: Capsule formation by dripping an alginate solution into a gelling bath. Depending on the gelling
solution we will get either homogenous or in-homogenous alginate capsules. These can be further given a
polycation layer and coated with a new alginate solution to create alginate-polycation-alginate (APA) capsules.
If these capsules are then treated with citrate, the inner core will be liquefied and the capsules will be termed
hollow. For encapsulation of cells, the alginate solution in the first step will be mixed with a cell suspension.
Figure adapted from [4]
1.3.2 Capsule types
The first step in the encapsulation process is the formation of an alginate bead, as described
in section 1.3.1. Two types of alginate beads can be made depending on the gelling condi-
tions, homogenic and inhomogenic beads. The difference lies in the distribution of the polymer
throughout the bead, with inhomogenic beads being characterized by a higher concentration
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of alginate towards the surface of the bead than in the center. Homogenic beads, in contrast,
formed in the presence of non-gelling cations such as sodium or magnesium, will have an even
distribution of alginate throughout the bead. If only the gelling ion is present in the gelling
solution it will rapidly and almost irreversibly bind to the alginate polymer thereby causing
it to gel, creating a gelling zone which moves towards the center of the bead. The alginate
will in turn move towards the gelling zone creating a lower concentration of alginate in the
center. However, the presence of non-gelling ions, e.g. sodium, will slow down this diffusion of
the alginate towards the gelling zone, thus allowing a more evenly distribution of the polymer
throughout the bead as the polymer gels [18].
The polymer distribution in the capsule is an important factor to consider when encapsulat-
ing cells. Inhomogeneous alginate beads have a lower porosity at the surface due to the higher
polymer concentration here [10], and will also exhibit a higher resistance towards swelling [18].
The porosity of the beads determines the permeability, a crucial factor for allowing nutrients to
diffuse into and products out of the bead containing cells. At the same time the alginate capsule
is supposed to function as an immunobarrier preventing not only immune cells from enter-
ing the capsule, but also molecules such as certain, but not all, cytokines, immunoglobulins and
proteins of the complement system. All capsules made in this work were inhomogenous capsules.
Choice of alginate type is also an important factor, as this influences the stability of the
alginate bead, as well as having an effect on the biocompatibility of the bead, as mentioned in
section 1.2.2. The first capsules made by Lim and Sum for the treatment of Type 1 diabetes
[19] had a poly-L-lysine (PLL) coating around the bead, see figure 1.4, which main function
was to confer a stabilizing effect so that the capsules did not break after being implanted.
As it has been shown repeatedly that the PLL layer is immunostimulating [20], an additional
coating layer of alginate is required, shielding the polycation layer from the immune system.
The alginate composition also plays a part here as medium G alginates (FG=0.4-0.6) result
in increased longevity of these capsules and less over-growth, as compared to high G alginates
[21]. This was shown to be due to an inadequate binding of high G alginate to PLL, and not a
response to the alginate itself, as capsules without PLL did not elicit the same fibrotic response.
Progress in the choice of alginate, as well as choice of gelling conditions, has also furthered
the potential of alginate beads. Alginate beads have now been made that withstand prolonged
incubation in vivo [22]. This was performed using inhomogenous, intermediate G alginate beads,
gelled in the presence of CaCl2 with a small concentration of BaCl2. Nevertheless, because of
discrepancies in the methods used by the different research groups over the last couple of decades,
a truly biocompatible alginate microcapsule that sustains prolonged survival of the encapsulated
cells has not yet been identified. This work attempts to get a better overview of the many
different parameters involved in capsule formation, and how they affect the biocompatibility of
the capsules.
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1.4 Biocompatibility and inflammation
A new definition of biocompatibility was recently put forth. Here, biocompatibility is defined as
“the ability of a material to locally trigger and guide non-fibrotic wound healing, reconstruction
and tissue integration” [23]. This was a response to what was generally observed for implants
previously considered to be biocompatible, an observation termed the foreign body response
(FBR). FBR refers to the envelopment of an implant into a thin, tough collagen capsule (fi-
brosis) which is nonadherent to the implant, with little vascularity in the collagen capsule, but
with macrophages and foreign body giant cells attached to the surface of the implant [24]. Evi-
dence suggests this is due to low-levels of inflammation triggered by the implant, which persists
indefinitly [23]. The isolation of the implant prevents it from efficiently performing its purpose,
whether it be sensing body metabolites, controlled drug delivery, or electric recording of nerve
cells, to name a few [23].
In today’s medicine it is increasingly common to make use of implanted foreign materials
to treat patients, be it with prostheses, dialysis membranes, catheters, stents, or other medical
devices. As most of these materials come in contact with blood, interactions between the
biomaterial and the defense system in our blood may initiate responses ranging from systemic
inflammation to thrombosis. There are two reasons why our bodies react to these implanted
materials [25]. One is that they are recognized as foreign and thereby potentially dangerous,
and the other is that they lack the regulatory molecules present on our own cells preventing
an immunologic attack. The only truly biocompatible surface is the intact endothelial cell
layer lining the blood vessels [26]. When this surface is disrupted, or when foreign materials
(biomaterials or microorganisms) are introduced into the blood stream, the complement system
and the coagulation cascade becomes activated so as to remove the foreign material or clot and
seal the disrupted area [27]. Because of tight crosstalk between these two systems as well as
with the other cells in the blood (platelets, leukocytes) and the cells lining the blood vessel
(endothelial cells), activation of one part may lead to a combined response of the whole defense
system [28]. It is therefore important to minimize the activation of the complement system and
the coagulation cascade upon contact with the biomaterial, in order to reduce the side effects
as much as possible.
1.4.1 The complement system
The complement system is a part of the innate immune system and is made up of a large number
of different plasma proteins that interact with each other to help fight infection by opsonizing
pathogens (induces phagocytosis of the pathogens) and inducing inflammatory responses. The
innate immune system is a primary protection against pathogens that prevents the body from
being overwhelmed by the vast number of microorganisms that we regularly come in contact
with. Only when the innate defense is bypassed is an adaptive immune response required.
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The complement system is made up of an intricate network of more than 30 different plasma
proteins, with many of them being proteases that are activated only after cleavage [27]. These
proteins compose a cascade where the cleavage and activation of a small number of proteins will
be able to cleave and activate a large number of downstream proteins resulting in a dispropor-
tionally large complement response. The three main consequences of complement activation are
the opsonization of pathogens, the recruitment of inflammatory and immunocompetent cells,
and the direct killing of pathogens [27].
There are three distinct pathways through which complement can be activated at the sur-
face of a pathogen: the classical pathway (CP), the lectin pathway (LP) and the alternative
pathway (AP) [27], see Figure 1.5. However, these three pathways all converge in cleavage and
activation of complement component C3 into C3a and C3b. C3b is deposited on the surface
of the pathogen promoting phagocytosis, and, together with other complement components, is
able to cleave downstream proteins allowing the cascade to propagate. The end product of the
cascade is the terminal complement complex (TCC), sometimes also called the membrane at-
tack complex (MAC), which inserts into the membrane of the pathogen leading to the eventual
destruction of the pathogen. Furthermore, at each step in the cascade a complement component
is cleaved into a bigger part acting as a protease, and a smaller part acting as an anaphylatoxin.
These anaphylatoxins help recruit immune cells to the site by inducing adhesion molecules in
the endothelial cells lining the blood vessels, as well as inducing inflammation, smooth muscle
contraction, and increased vascular permeability.
The classical pathway
The first protein of the classical pathway is the C1 protein, composed of the subunits C1q, C1r
and C1s [27]. C1 links the adaptive humoral immune response to the complement system by
binding to antibodies complexed with antigens. In addition, C1 can also trigger the complement
activation in the absence of antibodies as it can bind to surfaces of certain pathogens. Binding
of C1q to the surface of a pathogen or the constant region of an antibody, will lead to a
conformational change in the C1 complex. This is followed by C1r cleaving C1s thus exposing
a serine protease able to cleave two other proteins in the complement cascade, C4 and C2. As
C4 and C2 are cleaved by the active C1 protein, two small components will diffuse away, C2b
and C4a, while the larger C2a and C4b will attach to the surface of the pathogen and form the
C3 convertase C4b2a. The chronological order of this event is C4 being cleaved by C1 with the
subsequent attachment of C4b to the surface of the pathogen. C4b then binds C2 which enables
C1 to cleave C2 into C2b and a. The C3 convertase C4b2a will then cleave and deposit large
amounts of C3b on the pathogen surface.
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Figure 1.5: The complement cascade. Adapted and modified from [27]
The lectin pathway
Instead of C1q binding to pathogen surfaces or antigen antibody complexes, the LP makes use
of a mannose-binding lectin (MBL) or a ficolin which binds directly to mannose residues present
on many pathogens [27]. Mannose is also present on the body’s own cells, but then it is cov-
ered by other sugar groups such as sialic acid. MBL forms a complex with the two zymogens
MASP-1 and MASP-2 in a similar fashion as in the C1 complex. Binding of MBL to a pathogen
enables MASP-2 to cleave C4 and C2 forming the same C3 convertase as in the classical pathway.
The alternative pathway
The alternative pathway is the complement activation pathway most associated with activation
upon contact with biomaterials [28]. The pathway is triggered directly by foreign surfaces which
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do not provide sufficient down regulation of the C3 convertase. Host cells do not activate the
alternative pathway because of the numerous regulatory proteins located on their membranes
capable of controlling the cascade. The pathway can be activated in at least three different ways
[27]. Either by a spontaneous formation of C3(H2O) as shown in figure 1.6, by C3b deposited
by the classical or the lectin pathway, or by the positive regulator properdin. The alternative
pathway will function as an amplification loop helping the complement system to enhance an
initially weak stimulus. It has been shown that from an initial specific activation of the CP, the
AP is capable of contributing to more than 80 % of the C5a and the membrane attack complex
C5b-9 formed [29].
C3 is abundant in plasma and C3b is produced constantly by spontaneous cleavage, also
known as the “tick-over” process [27]. This process generates C3(H2O) by spontaneous hydrol-
ysis of the thioesterbond in C3. Once C3(H2O) is generated it can bind to the plasma protein
factor B, which will subsequently be allowed to be cleaved by a plasma protease called factor
D. Just as for C2 and C4 the small part of factor B will diffuse away while the bigger Bb will
remain bound to C3(H2O). C3(H2O)Bb will then function as a fluid phase C3 convertase cre-
ating C3b. If there is a pathogen surface close by C3b might bind to this surface through its
exposed thioester group. Surface bound C3b is able to bind factor B which can then be cleaved
to Bb by factor D just as was the case for C3(H2O)-bound B. However, if no surface is present
C3b will rapidly become inactivated by hydrolysis of the thioester group. The surface bound
C3bBb is the C3 convertase created by the alternative pathway, and will go on and cleave more
C3 depositing more C3b on the pathogen surface.
The pathway might also be activated through deposition of C3b on the surface by CP and
LP as described earlier. The C3b will bind factor B and will end up with the same C3 conver-
tase as mentioned in the paragraph above. Thus the alternative pathway can be viewed as an
amplification loop of the already activated classical or lectin pathways.
The positive regulatory plasma protein properdin, or factor P, is able to bind to the C3bBb
C3 convertase increasing the stability up to 10 times [27]. Properdin might also bind directly
to a pathogen surface. Surface bound properdin might then bind C3b which again binds factor
B. Factor B then becomes cleaved by factor D creating the C3 convertase PC3bBb [30].
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Figure 1.6: The alternative pathway depicted here as triggered by spontaneous hydrolysis of the thioester
bond in C3, and attachment to a pathogen surface. This pathway may also be triggered by already present
C3 convertases generated from the classical or lectin pathway, or by properdin binding directly to a pathogen
surface. Adapted and modified from T.S. Jokiranta, Univ. of Helsinki
The terminal pathway
Once the C3 convertases have formed, huge amounts of C3b will become deposited on the
surface of the pathogen [27]. As many as 1000 C3b molecules can attach to the surface of a
pathogen due to a single C3 convertase, and C3 is the most abundant of all the complement
proteins, circulating freely in the plasma at a concentration of 1.2 mg/ml [27]. As the C3
convertase cleaves C3, C3b will attach to the convertase complex creating either C4b2a3b or
C3b2Bb depending on which pathway initiated the cascade. When C3b attaches to the C3
convertase the complex will now be able to cleave C5 into C5a and C5b and is therefore called
a C5 convertase. C5 binds to the C3b molecule and is cleaved by the protease activity of C2a
or Bb. As C5b is generated it will facilitate the assembly of the membrane attack complex
(or TCC) and its insertion into the cell membrane. This begins with C5b binding C6 and C7,
creating a conformational change in the proteins exposing a hydrophobic site on C7 allowing
the C5b67 complex to attach and insert into the lipid bilayer of the cell membrane. This again
will allow C8 to bind to the complex and insert itself into the membrane as well. It all ends
with 10 to 16 C9 molecules binding to the complex, inserting into the membrane and creating
a pore spanning the lipid bilayer. This leads to the disruption of the proton gradient across the
membrane, the penetration of lysozymes into the cell and finally the destruction of the pathogen.
Even though the complement cascade ends up with the membrane attack complex and the
final destruction of the pathogen, an important function of complement is to facilitate the up-
take and destruction of pathogens by phagocytic cells [27]. A major function of C3b is the
opsonization of pathogens which occurs through binding of a C3b molecule to the receptor CR1
(also called CD35). CR1 is expressed on monocytes and neutrophils, and binding of C3b to
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CR1 can lead to phagocytosis in the presence of other immune mediators such as for instance
the anaphylatoxin C5a. The receptors CR2 (CD21), CR3 (CD11b) and CR4 (CD11c) all bind
to inactivated forms of C3b that remain attached to the pathogen surface. CD11b can be ex-
pressed by both monocytes and granulocytes and is often used as a marker for activation of
these cells. CD11b is known to be important for leukocyte adhesion and migration [27]. The
anaphylatoxins (so named because of their potential to cause anaphylactic shock) C3a, C4a,
and C5a all act on specific receptors on endothelial cells, mast cells, and phagocytes to produce
inflammatory responses. They induce smooth muscle contraction and increase vascular perme-
ability increasing blood flow and allowing leukocytes to reach areas of infection. C3a and C5a
also induce expression of adhesion molecules. C3a and C5a activates mast cells and macrophages
to produce TNFα and histamines contributing further to the inflammatory response. IL-8 (also
called CXCL8) is another cytokine produced by among other monocytes when activated by the
complement system [31]. IL8, which is also pro-inflammatory, will attract neutrophiles to the
site of inflammation.
Regulators of the complement system
As uncontrolled complement activation can cause extensive damage to cells, there needs to be
a mechanism to protect host cells from the detrimental effects of an inappropriate complement
response. The complement system is therefore tightly regulated at several steps of the cascade
by proteins present both in the plasma and on host cell membranes.
As the complement activation is heavily dependent on the C3 convertase, most of these
regulatory proteins interact with C3b to either prevent the formation of the convertase, or
promote its dissociation. One such protein is the membrane bound, factor B antagonist, decay-
accelerating factor (DAF), competing with and displacing Bb from C3b thus preventing the
formation of the AP C3 convertase, see figure 1.7. Another membrane attached regulator is
CR1, also capable of displacing Bb. Binding of C3b to CR1 can, as mentioned above, also
lead to phagocytosis in the presence of other immune mediators. Yet another membrane bound
regulator is the membrane cofactor of proteolysis (MCP) which do not displace Bb but acts
as a cofactor for factor I. Two membrane bound regulators acting on a different part of the
complement cascade than the ones above is protectin and vitronectin, which inhibits the binding
of C9 to the C5b6-8 complex. The difference between protectin and vitronectin is that protectin
is a membrane bound regulator on almost all tissues in the body as well as on circulating cells
[32], while vitronectin is a multifunctional, soluble, plasma protein with other functions as well
[33].
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Figure 1.7: Complement regulation of C3b. Factor H, DAF, CR1, and MCP bind to C3b and inhibit the
formation of a C5 convertase by either displacing Bb, or by acting as a cofactor for factor I, cleaving C3b into
inactive iC3b. Adapted and modified from [27].
Factor I is a soluble protein capable of cleaving and inactivating both soluble and membrane
bound C3b and C4b in the presence of a cofactor, for instance MCP [34]. Factor I circulates
in plasma in an active form, but is able to cleave C3b or C4b only when they are bound to
a cofactor protein. Both C3b and C4b will then be cleaved into iC3b and iC4b. iC3b will be
further cleaved into C3dg while iC4b will be cleaved into C4c and C4d, and thus permanently
inactivated.
The C3b molecule is not only affected by membrane attached regulators. The circulating
factor H for instance, the most important fluid phase regulator of the AP, is also capable of
binding to C3b and displacing Bb. Factor I will then attach to the factor H:C3b complex and
be able to cleave C3b. Other soluble plasma circulating regulators include the C4b-binding
protein (C4BP), the major fluid phase regulator of the CP and LP. C4BP works in a similar
way for the CP C3 convertase as the soluble factor H does for the AP C3 convertase, namely
by displacing C2a. C4BP bound C4b can then be inactivated by factor I, just as for factor H
bound C3b.
Another soluble regulator of the complement system is the inhibitor of C1 (C1i). C1i acts on
an upstream part of the cascade by binding to the active enzyme complex C1r:C1s. This causes
C1r:C1s to dissociate from C1q and thereby dissolving the C1 protein and preventing further
cleavage of C4 and C2. A summary of these regulators can be found in table 1.1
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Table 1.1: Regulatory proteins of the complement system [27]
Name Role in the regulation of Localization
complement activation
C1 inhibitor (C1i) Binds to activated C1, dissociating C1r and Circulating in plasma
C1s from C1q. Also functions as a cofactor
for factor I
C4-binding protein Binds to C4b displacing C2a, and cofactor Circulating in plasma
(C4BP) for factor I
Complement receptor 1 Binds C3b or C4b and displaces C2a and Mainly on surfaces of
(CR1, CD35) Bb respectively. Also cofactor for factor I erythrocytes and leukocytes
Factor H Binds C3b displacing Bb, and Circulating in plasma
a cofactor for factor I
Factor I Serine protease that cleaves C3b and Circulating in plasma
C4b bound to a cofactor
Decay-accelerating Binds C3b and C4b and Found on most cells in
factor (DAF, CD55) displaces C2a and Bb respectively the body
Membrane cofactor Cofactor for factor I Found on most cells in
protein (MCP, CD46) the body
Protectin Prevents formation of Circulating in plasma
(CD59) membrane attack complex
Vitronectin Prevents formation of Found in almost all tissues
membrane attack complex in the body, and on all
circulating cells [32]
The complement system can be seen as in a continuous struggle between the regulatory
proteins preventing the body’s own cells from being attacked, and the complement proteins
binding to pathogens and keeping the body clear of infections. The presence of regulatory
proteins on the cell membranes determines if the cell will become targeted by the complement
cascade or not. Complement regulators such as DAF and MCP effectively compete with factor
B for binding to C3b attached to the surface of cells. On host cells these regulatory proteins
will “win” over factor B and prevent the complement from triggering. On pathogen surfaces, as
well as on biomaterials, lacking regulatory proteins, factor B will effectively bind to C3b and
result in complement activation. Nevertheless, the presence of regulators is not always exclusive
for host cells. Some bacteria, viruses, and parasites express proteins that recruit regulators
of complement which protects them during an infection. One example is the M-protein of
Streptococcus pyogenes which binds among others the regulator C4BP, aiding the bacteria in its
fight against the body’s immune system [35].
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1.4.2 Hemostasis
Hemostasis describes the process of solidifying blood in order to prevent excessive bleeding, for
instance in the case of vascular injury. This happens by vasoconstriction, the formation of a
platelet plug, and the final activation of the coagulation system resulting in the formation of
a fibrin clot. It is not only vascular injury that results in hemostasis however, the presence of
biomaterials might also induce this response. For example cardiovascular devices are associated
with numerous complications due to bioincompatibility of the material coming in contact with
blood. The risk of thrombotic complications appears to be varying between 2 % and 10 %
depending on the device [28]. These complications may result in fatality, in addition to high
costs associated with follow-up intervention.
The anticoagulant and antithrombotic properties associated with the endothelium layer mak-
ing up the blood vessels, prevents the blood from coagulating as it flows through the body. An
inserted medical device does not have the properties of the endothelium and will therefore trig-
ger interactions between the blood and the biomaterial, resulting in protein adsorption, the
activation of the complement and the coagulation cascade, and the adhesion of cells. All these
interactions are highly interconnected and it therefore requires that they are all considered when
discussing biocompatibility.
The coagulation system is a complex cascade composing several proteolytic reactions which
result in the formation of a fibrin plug. The cascade involves a number of zymogens, similar
to that of the complement cascade, that are all sequentially activated into enzymes capable of
cleaving and activating the next zymogen in the cascade. Initiation of the coagulation occurs
either by the exposure of tissue factor (TF), or by surface-mediated contact activation. TF is
present in the connective tissue that surrounds the blood vessels and will be exposed in the
case of vascular injury [36]. TF may also be expressed on endothelial cells as well as circulat-
ing monocytes [37, 38]. The two pathways converge into a common pathway resulting in the
formation of a stable fibrin clot upon cleavage of fibrinogen into fibrin by thrombin, and the
subsequent cross-linking of the fibrin fibers by factor XIIIa, see figure 1.8.
For activation through the contact activation pathway, also called the intrinsic pathway,
factor XII has to come in contact with a negatively charged surface to become activated. As
there are not many negatively charged surfaces inside the body, the importance of this pathway
to normal blood coagulation is uncertain. Also, no observable bleeding disorders are seen in
patients that do not have factor XII [39]. Some hematology textbooks therefore omit the intrinsic
pathway along with factor XII, and rather begin with tissue factor and the factor VIIa-TF
complex. Nonetheless, activation of the intrinsic pathway has been detected in the presence of
artificial surfaces [40, 41]. It is also important to keep in mind that the coagulation cascade
consists of several feedback loops, see figure 1.8. Activated thrombin will for instance interact
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with and promote the activation of factor V, factor XI, and factor VIII, and activated factor Xa
will act on factor VIII and factor VII-TF. These feedback loops highly amplifies the “coagulation
signal” as it travels down the cascade. One mole of activated factor XI, X, and prothrombin
can give rise to as much as 2·108 moles of fibrin [42]. When analyzing the responses of blood
upon different biomaterials in vitro, as is done in this work, it is essential that the coagulation
cascade is inhibited in order to keep the assays manageable. The addition of lepirudin to blood
directly inhibits the enzyme thrombin which is crucial for the formation of a blood clot. This
prevents the blood from coagulating which would otherwise rapidly occur when handling blood
in test tubes outside of the body.
Figure 1.8: Simplified view of the coagulation system, along with the action of heparin and lepirudin on the
cascade. Adapted and modified from [28, 43] Heparin increases the affinity of antithrombin which will then
inhibit thrombin, Xa, XIa, XIIa. Feed-back arrows are drawn in blue
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1.4.3 Inflammatory response following microcapsule implantation
As alginate microcapsules are meant to exchange nutrients and products with their environment,
they will come in contact with different bodily fluids depending on where they are inserted. This
might, in addition to causing injury during the implantation procedure itself, induce complement
activation and trigger the coagulation cascade, promote the activation and adhesion of leukocytes
resulting in inflammation, as well as cause fibrous over-growth on the capsules. The first thing
that happens when a biomaterial comes in contact with blood, is the adsorption of plasma
proteins such as albumin, IgG, and the complement proteins C1, C3, and C4 [25] on the surface
of the material, see figure 1.9. Some proteins are known to adopt a new conformation when
they are adsorbed to a surface as for instance is the case for C3 [44] and IgG [45]. Both
these proteins, and especially when having an altered shape [26], may induce activation of the
complement system. In addition, adsorbed factor XII is reported to trigger contact activation
[46], and adsorbed fibrinogen may bind to and activate platelets [47]. Once the complement
component C3b is made and bound to this initial layer of plasma proteins, the alternative
pathway amplification loop can be initiated. Formation of anaphylatoxins will recruit and
activate leukocytes which will then induce an inflammatory response. During the implantation
of the microcapsules, the injury to vascularized connective tissue might further promote the
adsorption of proteins on the capsule surface through initiation of inflammatory responses and
thrombus formation [48].
Figure 1.9: An illustration of protein adsorption, complement activation and leukocyte recruitment on a
biomaterial surface. Plasma proteins will be adsorbed on the surface of the biomaterial triggering a conformational
change in some of the proteins. This change will facilitate the activation of the complement system, leading to the
release of the anaphylatoxins C3a, C4a, and C5a, and the subsequent recruitment and activation of leukocytes
inducing inflammation. Adapted from [25]
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If factor XII is part of this initial protein layer, then alginate microcapsules might theo-
retically trigger the intrinsic coagulation pathway. Moderate amounts of factor XII have been
observed on other biomaterials such as vascular grafts and hemodialysers, however not in its
activated form [49, 50, 51]. As mentioned before, activation of the intrinsic pathway has been
detected in the presence of artificial surfaces. But because patients with factor XII deficiency
show similar levels of thrombin as do normal patients during a cardiopulmonary bypass [52], it is
uncertain how much the activation of the intrinsic pathway contributes towards the activation of
coagulation by biomaterials. Monocytes, recruited by complement activation, coming in contact
with the biomaterial surface, might be triggered to express tissue factor. It is therefore possible
that the extrinsic pathway rather than the intrinsic pathway is what contributes to activation of
the coagulation. The role of leukocytes in biomaterial induced coagulation has previously been
emphasized in experiments showing low levels of thrombin-antithrombin complex-formation in
plasma, while higher in whole blood upon contact with a biomaterial [53].
Inflammation following the initial blood to material interaction will occur. The degree of
inflammation depends on the extent of injury during the implantation, the implantation site,
as well as the composition, conformation, and concentration of protein adsorbed on the surface
[48]. Because of the capsule size, and the fact that they are implanted in the peritoneal cavity,
minimal injury to surrounding tissue is achieved. Attachment of neutrophils and monocytes to
the protein layer, as shown in figure 1.9, may trigger the secretion of chemokines such as IL-8
and MCP-1 (monocyte chemotactic protein 1, not to be confused with the complement regu-
latory protein MCP) [27]. IL-8 and MCP-1 attracts other cells by acting on leukocytes rolling
along the endothelial cells lining the blood vessels, and up-regulating certain adhesion molecules
on the leukocytes allowing them to attach and cross the blood vessel wall by squeezing between
the cells [27]. In addition, if the capsules trigger the coagulation cascade or the complement
cascade, components of these cascades will act as chemokines as well, as mentioned previously
for the complement system. The molecules IL-8 and MCP-1 will not only recruit leukocytes,
but will also activate them [27]. Activated leukocytes, in particular the monocytes, will start
secreting more chemokines, as well as different inflammatory cytokines that is supposed to help
contain the assumed infection. Among the cytokines are TNFα which activates the endothe-
lium and increases the vascular permeability of the blood vessels facilitating the migration of
leukocytes out of the blood stream, in addition to antibodies and complement proteins [27]. It
also relaxes the smooth muscle cells lining the blood vessel, increasing the diameter, and thus
causing increased blood flow to the site of inflammation. The complement proteins C5a, C3a,
and C4a, have a similar influence on the blood vessels. Platelet adhesion to the protein layer, as
well as clot formation, will also release chemoattractants such as TGF-β, PDGF, and IL-1 that
can direct leukocytes to the capsules [48]. Monocytes will start developing into macrophages
and begin secreting even more cytokines. Secreted molecules include chemokines such as IL-8,
MCP-1, and MIP-1α, and inflammatory cytokines such as TNFα, IL-1β, and IL-6, as well as a
group of other molecules, see table 1.2. TNFα, IL-1β, and IL-6 have a wide spectrum of biologi-
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cal activities including raising body temperature and inducing synthesis of acute-phase proteins
[27], and are therefore well suited for measuring inflammation in vitro.
As monocytes adhere to the capsules and start developing into macrophages, their natural
function is to phagocytize pathogens and cell debris [27]. When they are unable to do so, for
particles larger than 10 μm, they start developing into foreign body giant cells [48]. This inabil-
ity to phagocytize the alginate microcapsules, a process called frustrated phagocytosis, might
lead to the release of mediators of degradation such as reactive oxygen intermediates, degrading
enzymes, and acids damaging the capsules.
Macrophages may also secrete fibroblast growth stimulating factors and factors promoting
angiogenesis [54], see figure 1.10. As the stimulation of fibroblasts has been shown to correlate
with the in vivo fibrosis [55], macrophages may therefore affect the formation of over-growth
on alginate microcapsules. Over-growth prevents proper nutrient and oxygen diffusion to the
encapsulated cells leading to loss of cell viability and functionality [56], and should be minimized
as much as possible. Capsules therefore have to be as inert towards leukocyte activation as
possible, with minimal complement activation and triggering of the coagulation cascade. This
is again linked with the composition, conformation, and concentration of proteins adsorbed on
the surface of the capsules. A list of potentially important proteins screened for in this work is
shown in table 1.3.
Figure 1.10: Fibrosis and angiogenesis stimulation by macrophages attached to an implanted biomaterial. The
biomaterial is for our purposes alginate microcapsules. Adapted and modified from [56]
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Table 1.2: Cytokines involved in inflammatory responses [25, 27].
Chemokine Produced by Target cells Major effects
IL-8 Monocytes, macrophages, Neutrophils, naive T cells, Mobilizes, activates and
epithelial and endothelial fibroblasts degranulates neutrophils.
cells Angiogenesis
MIP-1α Monocytes, T cells, Monocytes, NK cells, Antiviral defense, induction of
platelets and fibroblasts T cells and dendritic cells synthesis of pro-inflammatory
cytokines
MCP-1 Monocytes, macrophages, Monocytes, NK cells, Recruits monocytes and
and fibroblasts T cells and dendritic cells activates macrophages
Inflammatory
Cytokine
IL-1β Macrophages, epithelial Macrophage and T cells Cell activation and fever,
cells pro-inflammatory
TNFα Macrophages, NK cells, Pro-inflammatory. Promotes
T cells endothelial activation
IL-6 T cells, macrophages, T and B cells T and B cell growth and
and endothelial cells differentiation. Acute phase
protein production, fever
Anti-inflammatory
Cytokine
IL-1RA Monocytes, macrophages, Anti-inflammatory.
and neutrophils IL-1 receptor antagonist
IL-10 Monocytes Macrophages, Potent suppressant of
lymphocytes macrophage functions
Growth Factors
PDGF Platelets and other cells Smooth muscle cells Important for vasculogenesis,
including eosinophils and fibroblasts angiogenesis, and cell division
HGF Mesenchymal stem cells Epithelial and endothelial Regulates cell growth, cell
cells motility, and morphogenesis
VEGF Mast cells, platelets Endothelial cells Important for vasculogenesis
and neutrophils and angiogenesis. Stimulates
monocytes and macrophages
Other
MIF T cells, pituitary cells Macrophages Inhibits macrophage migration,
stimulates macrophage
activation
IP-10 Monocytes, endothelial cells Monocytes, NK cells Immunostimulant, antiangiogenic,
and fibroblasts and resting T cells inhibited secretion by
iC3b and C4b
IFN-γ Leukocytes, dendritic cells Macrophages, Pro-inflammatory, antiviral,
lymphocytes increased MCH class I
expression
RANTES T cells, endothelium, Monocytes, NK cells, Activates T cells,
and platelets T cells and dendritic cells chronic inflammation
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Table 1.3: Plasma proteins screened for in this work.
Proteins of the complement Function
system [27]
C1-inhibitor Binds to activated C1, dissociating C1r and C1s from C1q.
Also functions as a cofactor for factor I
C3 Part of the complement cascade by
acting as a C5 convertase
Factor H Binds C3b displacing Bb, and
a cofactor for factor I
Factor I Serine protease that cleaves C3b and
C4b bound to a cofactor
Vitronectin Prevents formation of
membrane attack complex
Proteins of the coagulation
cascade
Fibrinogen Cleaved into fibrin by thrombin. Cross-linked fibrin forms blood clot.
Also mediate phagocyte binding to implant surfaces [48]
High molecular weight Part of the contact activation pathway of the coagulation cascade.
kininogen Cofactor of factor XI activation [28]
Plasminogen Enzyme involved in hemostasis
by degrading fibrin clots
1.4.4 Biocompatibility of alginate microcapsules in vivo
Alginate microcapsules have proven its potential in some animal models, while having had less
success in others. They have been tested numerous times in vivo, with a varied outcome. The
use of different animal models, variable sites of implantation, the state the cells are in when
encapsulated, and compatibility between host and implanted cells, all affect the outcome of the
experiment. In addition, because of a many times poor description of the alginate composition,
and the use of different encapsulation protocols, it is often difficult to compare the results of the
many experiments performed.
Successful implantation of encapsulated islet cells has clearly been easier to achieve in smaller
animals than in larger ones. Lim and Sum reported in 1980 the first successful reversal of dia-
betes in Wistar rats for up to 3 weeks [19]. This was achieved by implanting islet isografts (from
a genetically identical rat) enclosed within alginate microcapsules. The capsules were hollow
alginate-poly-L-lysine capsules with an outer coating of polyethyleneimine. In 2001, Duvivier
Kali et al. managed to reverse diabetes for up to 350 days for syngenic (identical) and allogenic
(from the same species) transplantation in BALB/c and NOD mice by using barium alginate
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beads [57]. More recently, human islet cells have also been encapsulated and tested in vivo.
In 2008, human islet cells encapsulated in Ca2+/Ba2+ beads were transplanted into diabetic
nude mice, resulting in insulin independence until the end of the study (260-329 days after
transplantation) [22]. The capsules were then extracted and observed free of overgrowth and
containing viable islets. Since nude mice, that lack a thymus and therefore have an inhibited
immune system, was used, no immunosuppression was necessary. This might be the reason for
the low over-growth observed on these capsules.
Experiments have also been performed in larger animals. In 1993, Soon Shiong et al. suc-
cessfully managed to transplant islet allografts into diabetic dogs with and without immuno-
suppression [58]. Insulin independence was observed for up to 172 days. In 2005, R. B. Elliott
et al. went one step further and transplanted piglet islets, encapsulated in APA capsules, into
nondiabetic cynomolgus monkeys [59]. It was shown that after 8 weeks the piglet islets were
healthy, however they did not evaluate the insulin production of the cells. Recently, there has
also been experiments in humans where human islet cells were transplanted into patients with
type 1 diabetes [60]. Cells were encapsulated in alginate-PLO capsules which were shown to
preserve islet function without immunosuppression throughout the course of the trial (3 years).
The grafts did not elicit any immune response, but the low number of islets transplanted per
patient has limited the success of the trial as insulin independence was only achieved transiently
in one of the patients. Additionally, in one of the patients a fibrotic lump was excised 5 years
post implantation, consisting of capsules without any viable islet cells inside. Another study
performed in 2009 with human islets encapsulated in barium beads, showed prolonged detec-
tion of C-peptide (used as an insulin production marker) in only one of four patients [61]. In
addition, after 16 months capsules recovered were surrounded by fibrous tissue and contained
necrotic islets. However, no major side effects or infection occurred, indicating the safety of the
procedure.
1.4.5 Towards increased biocompatibility
Despite of intense research over several decades, there still do not exist a truly biocompatible
material. Many different approaches are being put forward in order to increase the biocom-
patibility of a material, one being to modify the material itself. Chemical structure, including
hydrophobicity and charge, as well as the surface properties such as topography and roughness
of a material will greatly influence the biocompatibility [62]. In the case of alginate microcap-
sules, this is reflected in the composition of the alginate. Before Soon Shiong et al. managed to
transplant islet cells into diabetic dogs, researchers had experienced difficulties with the larger
animal model because of a high proliferation of fibroblasts stemming from IL-1, IL-6, and TNFα
production [58]. This was discovered to be because of the low FG alginate that was used in
the early encapsulation experiments. The high M content (86-99.9 % M) stimulated the cy-
tokine production as well as giving the capsules a weak integrity. Coating the capsules with
23
a stabilizing polycation layer was therefore necessary. Different types of layers that have been
tested include poly-L-Lysine (PLL), poly-L-ornithine (PLO), and poly(methylene-co-guanidine)
(PMCG). Evidence suggests that these coating layers are in various degrees immunostimulating
with PLL perhaps the most [20]. A more recently proposed idea is to use a polymer that consists
of zwitterions that give the coating an equal number of positive and negative surface charges,
in an attempt to mimic the excellent resistance to protein adsorption and hemocompatibility of
the zwitterionic phosphorylcholine group of cell membranes [63].
Another approach, perhaps more focused on solid biomaterials such as stents and catheters,
could be to attach complement regulators to the surface of the biomaterial, or use surface coat-
ings that might recruit these proteins. Factor H has previously been attached to biomaterial
surfaces resulting in decreased activation of the complement system [64]. More inert surfaces
has also successfully been obtained by immobilizing heparin and heparin-conjugates onto the
biomaterials [65], which is thought to selectively bind certain regulatory proteins such as factor
H and C1i [66, 67], as well as reduce adsorption of proteins undergoing surface-induced denat-
uration [68]. One might consider inhibiting the coagulation cascade using thrombin inhibitors
such as lepirudin [69], or inhibit the activation of platelets by using platelet inhibitors such
as aspirin [70]. However, the applicability of these approaches towards alginate microcapsules
might be more limited.
1.5 Aims
The aim of the present study was to investigate the biocompatibility of a set of different alginate
microcapsules. This was to be performed by incubating the capsules in whole blood, and then
analyzing the activation of leukocytes, and production of cytokines and complement components.
The capsule parameters that were investigated was:
• Polycation concentration
• Polycation type
• Alginate type
• Capsule type
• Capsule size
• Gelling conditions
High cytokine and complement responses in vitro could indicate increased risk of inflammatory
responses and over-growth on capsules in vivo, limiting the efficacy of the encapsulated cells.
It was also sought to investigate if the lower complement responses towards TAM-capsules,
as seen earlier compared to APA and also saline control, might be the result of adsorption of
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complement inhibitors on the bead surface. Plasma-incubated capsules were therefore tagged
with different fluorescent labeled antibodies towards complement and coagulation cascade com-
ponents, and analyzed in a confocal laser scanning microscope.
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2 MATERIALS AND METHODS
2.1 Formation of alginate microcapsules
Alginate-polycation-alginate (APA) with a hollow core, APA with a solid core, and TAM-
capsules were made with varying alginate type and needle size, as well as with different polyca-
tion type and increasing concentration.
2.1.1 Alginate solution
Two types of ultrapure High-G sodium alginate from FMC BioPolymer AS (Novamatrix, Nor-
way) and one ultrapure High-M sodium alginate, see table 2.1, was used throughout this study.
The protein contents were less than 0.3% for all alginates as specified by the manufacturer, and
endotoxin levels ≤100EU/g. UP-LVG* is similar to UP-LVG but of a new batch, as the GMP
license had expired on the original UP-LVG alginate. As batch variation might occur, this new
alginate was included in the whole blood assay.
Table 2.1: Alginate solutions
Name Algae Batch Mw[g/mol] FG FGG NG≥1
UP-LVG Laminaria hyperborea FP-603-04 75-200 0.67 0.55 12
UP-LVG* Laminaria hyperborea BP-1108-01 75-200 0.67 0.55 12
UP-100M Macrocystis pyrifera FP-209-02 0.44
Ultra-pure alginate (1.8 g) was dissolved overnight in sterile, endotoxin free, non-pyrogenic,
water (50 ml, B. Braun, Melsungen, Germany) with agitation. D-mannitol (50 ml, 0.6 M, BDH
Anala R., VWR International Ltd, Pool, England) was added to the alginate solution creating
an alginate concentration of 1.8 %. The pH of the solution was adjusted to between 7.2 and 7.4
with sterile NaOH and HCl. Finally, the alginate solution was filtered with a 0.2 μm filter to
sterilize it, and kept refrigerated.
2.1.2 Gelling solution
The gelling solution was made by dissolving analytical grade CaCl2*2H2O (50 mM, Merck,
Darmstadt, Germany), D-mannitol (0.15 M, HPLC degree, BDH Anala R., VWR International
Ltd, Pool, England), and HEPES (10 mM, Sigma-Aldrich, St. Louis, MO, USA) over night
in sterile, endotoxin free water. For the preparation of TAM capsules the gelling solution was
added analytical grade BaCl2 (1 mM, Merck, Darmstadt, Germany). The solution was then pH-
calibrated to lie inside the physiological range of 7.3-7.4, using sterile NaOH and HCl. Lastly,
the solution was filtered with a 0.2 μm filter to sterilize it, and then kept refrigerated.
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2.1.3 Bead preparation
Ca-alginate capsules were made by dripping an alginate solution into the gelling solution de-
scribed in section 2.1.2. For TAM-capsules 1 mM BaCl2 was added to the gelling solution. A
syringe containing alginate (1.8 %, 5 ml) was mounted on an infusion pump and connected to
a needle through a thin, plastic tube. The needle was attached in a bead generator apparatus
[71], and placed approximately 2 cm above the gelling bath which was continuously agitated
using a magnetic stirrer. The droplet size was controlled using the high-voltage electrostatic
bead generator (7 kV, 10 ml/h) and by using different needle sizes (0.25 mm, 0.35 mm, and
0.40 mm), that resulted in capsules with a diameter of between 400 and 700 μm depending on
the method, the alginate type and the polycation concentration. The first capsule set was made
using 4 needles attached in a multi-head scaffold, the second set was made using a single needle.
All capsules were made with a flow of 10 ml/h, except TAM capsules made with 0.25 mm needle,
0.35 mm needle, and 0.40 mm needle, which were made using a flow of 6 ml/h, 8 ml/h, and 8
ml/h, respectively, see section 3.1. The beads were incubated in gelling solution for 10 minutes
after the last alginate droplet was observed. The beads were then washed once with washing
solution (sterile 0.9 % NaCl, 30 ml, B. Braun, Melsungen, Germany). For TAM-capsules, the
beads were kept refrigerated in washing solution (12 ml).
For the preparation of APA capsules, the washed beads were placed in a polycation bath (25
ml) on agitation for 10 minutes. The polycation type and concentration was varied between poly-
l-lysine (PLL Hydrochloride, Sigma-Aldrich Corp., St. Louis, MO, USA) and poly-l-ornithine
(PLO Hydrobromide, Sigma-Aldrich Corp., St. Louis, MO, USA) at concentrations of 0.05 %,
0.1 %, and 0.14 %. After 10 minutes incubation in the polycation solution, the beads were
washed once with washing solution before being placed in an alginate coating bath (0.1 % M.
pyr alginate, 10 ml) on agitation for 10 minutes. The capsules, now APA with a solid core,
were washed once with washing solution before being either stored in washing solution (12 ml),
or treated with a analytical grade citrate solution (55 mM Na-citrate tribasic dihydrate, 20 ml,
Merck, Darmstadt, Germany) on agitation for 10 minutes. Citrate-treated capsules, now APA
hollow, had a soluble core which was observed in increased sedimentation time. The beads were
then washed once with washing solution before being stored in the fridge in washing solution
(12 ml).
The capsules were diluted to a workable concentration before being tested in the whole blood
assay. They were also washed in order to remove any residual protein content that might have
been still present. The alginate capsules stored in washing solution (12 ml) was aliquoted by
suspending the capsule mixture, and transferring 1 ml of the mixture into 10 sterile eppendorf
tubes. Residual capsules were divided over the eppendorf tubes, and an equal capsule volume
was confirmed visually. The eppendorf tubes now had an approximate concentration of 0.5 ml
beads in a total of 1.2 ml NaCl (sterile, 0.9 %). Each eppendorf tube was then washed twice
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in washing solution before being diluted in a total of 5.5 ml NaCl (sterile, 0.9 %). Aliquots of
500 μl solution was divided into 10 sterile NUNC polypropylene tubes. The supernatant (400
μl) was removed leaving approximately 45.45 μl capsules in a total volume of 100 μl NaCl.
2.2 Whole blood assay
The whole blood model allows testing of microcapsules in vitro, using blood that still contains
an intact complement cascade [31]. A potential indicator of the ability of the capsules to trigger
inflammatory reactions is the activation of the complement cascade, as the level of complement
activation often goes hand in hand with the properties of the biomaterial surface. Whole blood
contains all the potential cellular and fluid phase mediators of inflammation, and is therefore
ideal for studying the biocompatibility of the microcapsules in vitro. By using the highly spe-
cific thrombin inhibitor lepirudin, the blood is anti-coagulated while still avoiding complement
and leukocyte activation. However, to minimize the activation by the tubes themselves, low
activating polypropylene tubes had to be used.
Whole blood from voluntary donors was collected in polypropylene tubes (4.5 ml NUNC,
Roskilde, Denmark) using BD vacutainer tops (Belliver Industrial Estate, Plymouth, UK) with
added lepirudin (2.5 mg/ml, 80 μl, Celgene Europe, Boudry, Switzerland). Approximately 4 ml
of blood was collected per tube, giving a final lepirudin concentration of 0.05 mg/ml lepirudin.
Dulbecco’s PBS (100 μl, with Mg2+ and Ca2+, Sigma-Aldrich, St. Louis, MO, USA) was added
to NUNC tubes containing capsules (45.45 μl in a total volume of 100 μl NaCl) and NUNC tubes
containing negative and positive controls. Negative controls were T0 and Saline containing ster-
ile NaCl (100 μl, 0.9 %), while positive controls contained Zymosan A (20 μg/ml, Sigma-Aldrich,
St. Louis, MO, USA, Z-4250) or LPS (2 μg/ml, Invivogen, E.coli 0111-B4) in sterile NaCl. All
tubes were pre-heated to 37ºC before anti-coagulated blood (500 μl) was added to each vial,
carefully avoiding blood contamination of the screw cap. T0 was immediately added EDTA (14
μl, 10 mM final concentration), while other samples were incubated for 60 and 240 minutes in an
incubator (37ºC) under continuous rotation, prior to adding EDTA. EDTA (ethylenediaminete-
traacetic acid) acts by chelating calcium and thereby stops the complement activation as many
of the steps in the complement cascade are calcium-dependent. After the complement reaction
had been stopped, the samples were centrifuged (3000 rpm, 15 minutes) and the plasma was
stored in the freezer (-20ºC) for later cytokine analysis.
The use of human whole blood for basal experiments was approved by the Regional Ethic
Committee (REK) at NTNU in Norway. The experiments were performed in accordance with
their guidelines.
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2.3 Flow cytometry
Flow cytometry (FCM) was used to measure leukocyte activation upon incubation of whole
blood with alginate capsules. FCM is a widely used technique for counting and examining cells.
It works by passing a stream of sample solution through a laser and detecting side and forward
scatter of the light, as well as any fluorescence. This permits close examination of each cell
as it passes through the laser. Forward scatter correlates with the volume of the cell, while
side scatter correlates with the granularity, making it possible to distinguish certain cell types
from each other depending on size and inner complexity. Using fluorescent labeled markers one
can further discriminate between different cells of interest. Fluorophore-conjugated antibody
towards the membrane protein CD11b was used to detect the activation of monocytes and gran-
ulocytes as this protein gets up-regulated when the cells are activated. The membrane protein
CD14, a coreceptor for TLR4 recognition of LPS [27], is found predominantly on monocytes and
macrophages, and fluorophore-conjugated antibody towards CD14 was therefore used to gate
for monocytes.
Expression of CD11b was measured in whole blood after one hour incubation with the
capsules. Blood (50 μl) was taken from the samples and fixed with PFA (1 %, 50 μl, Sigma-
Aldrich, St. Louis, MO, USA). Fixated blood (25 μl) was then added an antibody mix (5 μl)
containing PE anti-CD11b (BD Biosciences, USA) and FITC anti-CD14 (BD Biosciences, USA)
in equal amounts, and incubated dark for 15 minutes. Samples were transferred to flow-vials
and added EasyLyse erythrocyte lysis buffer (500 μl, Dako Cytomation, Glostrup, Denmark),
followed by incubation for 15 minutes. CD11b expression on granulocytes and monocytes was
then measured on flow cytometer by detecting CD11b+ cells. Monocytes and granulocytes
were distinguished by side scatter and CD14 detection, as monocytes express more CD14, and
granulocytes, containing granules, have a higher side scatter. Red blood cells were removed by
addition of erythrocyte lysis buffer.
2.4 ELISA
Enzyme-linked immunosorbent assay (ELISA) was performed on plasma from whole blood as-
says. ELISA is a powerful assay used to detect the presence of an antigen in a sample, and was
in this work used to detect the cytokines IL-8 and TNF-α, as well as the complement component
TCC. Antigen specific antibodies are allowed to attach to a plastic multiwell plate before the
sample plasma is added, see figure 2.1. Any antigen present in the plasma sample will bind
to the high affinity antibodies coating the plate. Unbound antigen is then washed away. Fi-
nally, a labeled detection antibody that recognizes a different epitope to the coating antibody, is
added, and bound antigen is detected. Here, the detection antibody was conjugated to biotin.
Streptavidin-conjugated horse radish peroxidase (HRP) was then linked to the biotin antibody,
before 3,3’,5,5’-tetramethylbenzidine (TMB) was added. HRP is, in the presence of H2O2, able
to oxidize TMB into its corresponding diimine resulting in the solution taking on a blue color
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which can be detected by a spectrophotometer.
Figure 2.1: Principle of sandwich ELISA.
2.4.1 IL-8
IL-8 specific capture antibody (4.0 μg/ml in PBS, 50 μl/well, R&D Systems, USA) was added
to NUNC 96-well microplate and left to incubate over night at room temperature. The plate
was then washed three times (275 μl PBST/well), before being blocked with BSA (1 % BSA
in PBS, 200 μl/well, R&D Systems, USA) for one hour at room temperature. The plate was
then washed as before, and samples were loaded. For samples incubated for one hour, capsules
along with negative controls were diluted 1:4 in reagent diluent (0.1 % BSA and 0.05 % Tween
20 in tris-buffered saline). Positive controls were diluted 1:10 and 1:20. For samples incubated
for four hours, T0 was diluted 1:4, saline and TAM-capsules were diluted 1:8, APA-capsules
were diluted 1:16, and positive controls were diluted 1:20 and 1:40 in reagent diluent. IL-8
standard was diluted to 2000 pg/ml in reagent diluent, and further serially diluted 1:2 in seven
wells on the plate. All samples (50 μl/well) were loaded in triplicates. The plate was then left
to incubate for two hours at room temperature, washed as before, and IL-8 specific detection
Ab (20 ng/ml, 50 μl/well, R&D Systems, USA) was added. After two hours of incubation on
bench at room temperature, the plate was washed again, and streptavidin-HRP (diluted 1:200
in reagent diluent, R&D Systems, USA) was added and left dark for 20 minutes. The plate was
washed a final time as before, and TMB substrate reagent A and B (R&D Systems, USA) was
mixed in equal amounts, and added to the plate. The plate was left dark for 20 minutes as the
coloring reaction was taking place, and then H2SO4 (2 M, 50 μl/well, R&D Systems, USA) was
added and the optical density determined at 450 nm using a spectrophotometer. Wavelength
correction was set to 570 nm.
2.4.2 TNF-α
TNF-α ELISA (Human TNF-α DuoSet ELISA kit, R&D Systems, USA) was performed similarly
to IL-8 described above. TNF-α specific capture Ab (4.0 μg/ml in PBS, 50 μl/well) was added
to NUNC 96-well microplate and left over night. The plate was washed as for IL-8 (three times,
275 μl PBST/well) and blocked with reagent diluent (1 % BSA in PBS, 200 μl/well). After one
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hour the plate was washed and samples were added. Samples were diluted 1:2 in reagent diluent
except for the positive controls which were diluted 1:10 and 1:20. Standard was diluted to 2000
pg/ml and further 1:2 serially diluted on the plate. All samples were loaded in triplicates, and
incubated for two hours. The plate was then washed and TNF-α specific detection Ab was added
(250 ng/ml, 50 μl/well). After a two hour incubation and a new washing step, streptavidin-HRP
(diluted 1:200 in reagent diluent, 50 μl/well) was added. The plate was left dark for 20 minutes,
washed, and equal amounts of TMB substrate A and B (50 μl/well) was added. The reaction
was stopped with H2SO4 (2 M, 50 μl/well) and absorbance was detected at 450 nm along with
wavelength correction at 570 nm.
2.4.3 sTCC
sTCC ELISA, developed by Mollnes et al. [72], was performed similarly to IL-8 and TNF-α,
but with other incubation times, and with a specific streptavidin-HRP. The reagent diluent was
added EDTA to avoid further activation.
TCC specific capture Ab (αE11 specific for C9, AntiBodyShop, Gentofte, Denmark) diluted
1:1000 in PBS was added to NUNC 96-well ELISA plates and incubated (overnight, 4ºC). Plates
were then washed (three times, 275 μl PBST/well) using a 96-well plate washer. Blocking
solution (0.1 % BSA in PBS, 200 μl/well) was added and plates were incubated for a minimum
of one hour at room temperature. This was followed by another washing step, before samples
were diluted in reagent diluent (PBS with 0.2 % Tween 20 and 10 mM EDTA, 50 μl/well) and
loaded onto the plates. Plasma samples from one hour incubation was diluted 1:5 while plasma
samples from four hour incubation was diluted 1:10, except for positive controls which were
diluted 1:10 and 1:20 for one hour incubated plasma, and 1:20 and 1:40 for four hour incubated
plasma. Standard (zymosan activated serum, 10 AU/ml) was serially diluted 1:2 on the plates.
All samples were loaded in triplicates. After 1.5 hours incubation at room temperature, the
plates were washed and detection Ab was added (diluted 1:5000, 50 μl/well, Biotinylated Anti-
human SC5b-9, Quidel, San Diego, USA), and incubated for 45 minutes at room temperature.
Streptavidin-HRP (diluted 1:1000, 50 μl/well) was added and the plates were left for 20 minutes
covered in aluminum in order to avoid direct light. This was followed by a final washing step,
TMB substrate was added (equal amounts of substrate A and substrate B, 50 μl/well), and
plates were covered anew. Approximately 20 minutes later the reaction was halted by adding
H2SO4 (2 M, 50 μl/well), and absorbance was detected at 450 nm with a wavelength correction
set to 570 nm, using a spectrophotometer.
2.5 Bio-plex
The Bio-PlexTM Pro Assay (Bio-Rad Laboratories, Inc., Hercules, California, USA) was used
to detect 15 different cytokines at once. It uses a principle not very different from a sandwich
ELISA, but with magnetic beads covered with antibodies towards a specific cytokine instead of
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using an antibody-covered plastic multiwell plate. The beads bind to the cytokine of interest
through the covalently attached capture antibodies. After removing unbound protein, a biotiny-
lated detection antibody is added which creates a sandwich complex, see figure 2.2. Finally, the
addition of streptavidin-phycoerythrin (SA-PE) will allow quantification of the cytokine con-
centration by PE serving as a fluorescent indicator. As each type of bead has its own color
code or spectral address, discrimination of the different beads is possible. Using a two laser flow
cytometer, it is thus possible to detect which bead is present, and then quantify the presence
of cytokine on the bead by determining the PE fluorescence. A red (635 nm) laser excites the
fluorescent dyes within each bead, while a green (532 nm) laser excites PE.
Figure 2.2: Bio-Plex sandwich immunoassay. The magnetic bead has a distinct color code which permits the
direct determination of cytokine type. Phycoerythrin on the other hand allows for determination of the amount
of cytokine present on the bead.
The xMAP Technology uses 5.6 micron polystyrene microspheres prepared in 96-wells Bio-
Plex Pro flat bottom pates for magnetic based washing. The procedure using the Bio-plex kit
(Bio-Rad Laboratories, Hercules, CA) is described in detail in the manufacturers instruction
manual [73] and was performed accordingly, with the following exception: A volume of 25 µl
per well of beads, samples, standards and streptavidin-PE, was added. This was based on
knowledge from previous experiments performed at the department of Cancer Research and
Molecular Medicine, yielding satisfying results [74]. Plasma samples were prepared by diluting
in Bio-Plex sample diluent (20 μl plasma in 60 μl sample diluent). Beads were read using the
Bio-Plex 200 System. The concentration of 15 different cytokines was determined. The different
cytokines are shown in table 2.2.
Table 2.2: Bio-Plex analyzed cytokines in plasma after whole blood assays
IL-1β IFN-γ RANTES
IL-1ra IP-10 TNFα
IL-6 MCP-1 VEGF
IL-8 MIP-1α HGF
IL-10 PDGF-BB MIF
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2.6 Protein adsorption assay
In order to understand what mechanisms are involved when the body responds to alginate micro-
capsules, it is important to know what proteins are adsorbed on the surface of the capsules. Do
the capsules trigger the complement system? Are there inhibitory processes going on? And how
does the coagulation cascade react to the capsules? To do this, capsules were incubated in ei-
ther lepirudin conjugated plasma, or lepirudin conjugated whole blood. They were then washed
(sterile 0.9 % NaCl, 500 μl, B. Braun, Melsungen, Germany) and incubated with fluorochrome
labeled antibody (50 μg/ml, 37ºC, 30 min, see table 2.3). Antibodies were first diluted to a 2x
working solution in NaCl before 100 μl was added to the capsules giving a final concentration
of 50 μg/ml. After incubation the capsules were washed once (sterile 0.9 % NaCl, 500 μl) and
stored in 200 μl wash solution protected from light. In the case where a 2º antibody was used,
the capsules were washed (sterile 0.9 % NaCl, 500 μl) after treatment with 1º antibody, and
incubated with 2º antibody (10 μg/ml, 37ºC, 30 min, see table 2.3), before being washed again
and stored in 200 μl wash solution protected from light.
Table 2.3: Antibodies used in the protein adsorption assay
Antibody Additional information Company
αC3c FITC labeled rabbit anti-human C3c Dako
αFibrinogen FITC labeled rabbit anti-human fibrinogen Dako
Neg. Control FITC labeled rabbit anti-mouse IgG Dako
αFactorH Sheep anti-human factor H The Binding Site
αFactor I Sheep anti-human factor I The Binding Site
αPlasminogen Sheep anti-human plasminogen The Binding Site
αVitronectin Sheep anti-human vitronectin The Binding Site
αHMW Kininogen Sheep anti-human HMW Kininogen The Binding Site
αFibrinogen Sheep anti-human fibrinogen The Binding Site
αC1 inactivator Sheep anti-human C1-i The Binding Site
Neg. Control Sheep IgG Sigma-Aldrich
2º Ab CF 633 labeled donkey anti-sheep IgG Sigma-Aldrich
The capsules were then observed in a confocal laser scanning microscope (CLSM). For FITC
labeled antibodies, a 488 nm Argon laser was used to excite the fluorochromes, for the CF 633
labeled antibodies a HeNe 633 nm laser was used. Microscope settings are shown in table 2.4.
Pictures were taken as optical cross sections through the equator using both laser and differential
interference contrast (DIC), as well as z-stack 3D projections of the surface using only laser.
Table 2.4: Setting for the CLSM in the protein adsorption assay.
Laser Argon (488 nm), HeNe (633 nm)
Objectives C-Apochromat 10x/0.45W, C-Apochromat 40x/1.2W
Beamsplitters HFT 488, HFT 633
Filters BP 505-530, LP 650
Pinholes 200 μm
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2.7 Statistical methods
The Wilcoxon signed-rank test was used to define statistical differences in cytokine response
between the different capsules in the whole blood assay. It was assumed that the data was not
normally distributed due to the low sample numbers (n=5). The Wilcoxon signed-rank test
is a non-parametric, statistical hypothesis test that can be used when comparing two matched
samples to assess whether their population means differ. As there are biological differences
between each blood donor in the whole blood assay, this kind of paired difference test was
preferred. In addition, the test does not assume normally distributed populations as it is non-
parametric. The software SPSS Statistics (v. 20, IBM) was used for statistical calculations.
Differences were considered significant at P<0.05.
34
3 RESULTS
3.1 Capsule diameters
In order to study how different alginate microcapsule parameters such as size, alginate type,
and polycation, affected the biocompatibility of the capsules, a set of 21 different capsules were
made, and their diameter was measured, see table 3.1. The capsules were alginate beads, APA
solid capsules, and APA hollow capsules.
Table 3.1: Overview of the different alginate capsules made and tested. TAM4 capsules were made with a new
type of UP-LVG alginate marked with a *. The diameter is given as the mean of 20 capsules. Capsules were
made with 4 needles and with a flow of 10 ml/h unless otherwise stated.
Capsule type Alginate Polycation Polyation Needle Additional Capsule % CV
concentration size (mm) comments diameter (μm)
(%)
APA hollow M. pyr PLL 0.10 0.40 683.0 10.3
APA hollow M. pyr PLL 0.14 0.40 645.0 8.8
APA hollow M. pyr PLO 0.14 0.40 651.5 7.4
APA solid M. pyr PLL 0.05 0.40 647.0 13.1
APA solid M. pyr PLL 0.10 0.40 588.5 9.0
APA solid UP-LVG PLL 0.05 0.40 566.0 7.9
APA solid UP-LVG PLL 0.10 0.40 572.0 3.8
APA solid UP-LVG PLL 0.05 0.35 573.0 7.0
APA solid UP-LVG PLL 0.10 0.35 554.0 4.7
APA solid UP-LVG PLL 0.05 0.35 No HEPES 619.5 9.6
TAM UP-LVG - - 0.40 No BaCl2 545.0 4.9
TAM UP-LVG - - 0.40 502.0 8.3
TAM M. pyr - - 0.40 513.0 8.0
TAM4 UP-LVG* - - 0.40 483.5 12.0
TAM UP-LVG - - 0.35 No BaCl2 435.0 4.9
TAM UP-LVG - - 0.35 422.5 8.2
TAM M. pyr - - 0.35 377.0 8.1
TAM4 UP-LVG* - - 0.35 427.5 7.8
TAM UP-LVG - - 0.25 Single needle 342.5 4.0
6 ml/h
TAM UP-LVG - - 0.35 Single needle 477 6.7
8 ml/h
TAM UP-LVG - - 0.40 Single needle 588.5 2.5
8 ml/h
3.2 C3 and fibrinogen depositions on the capsule surface
To get a first indication of complement activation, capsules were stained for C3 adsorption on
the surface. As protein C3 plays a central part of the complement system, being the most
abundant of the complement proteins [27], it is a good indicator of potential activation of the
cascade. The detected C3c fragment of the C3 molecule is present both in the native C3 form,
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as well as in the active C3b form. Detected C3 may therefore indicate adsorption of either na-
tive C3, or active C3 and C5 convertase (C3bBb and C3b2Bb). One APA capsule (0.1 % PLL,
UP-LVG, 0.4 mm) and one TAM bead (UP-LVG, 0.4 mm) was incubated in human lepirudin
anti-coagulated plasma overnight, and stained with fluorescent labeled antibody towards C3c,
see figure 3.2. Capsules were also stained with antibodies toward fibrinogen to get an indication
of possible interaction and activation of the coagulation cascade. C3 adsorption was detected
on the APA capsule, but not on the TAM bead. No fibrinogen adsorption was detected except
for on collapsed and deformed APA capsules. These collapsed capsules did not represent the
general capsule population, but, as there were always some collapsed capsules present, a picture
was included to show the often increased protein adsorption seen on these capsules. The staining
was specific for C3 and fibrinogen as demonstrated by the negative controls.
Additionally, capsules were incubated in both lepirudin anti-coagulated plasma and whole
blood in order to determine if there were any differences in protein deposits on the surface of the
capsuels in the presence of cells, see figure 3.1. No difference in C3 and fibrinogen adsorption
was detected.
Figure 3.2: Protein adsorption on APA and TAM capsules after overnight incubation in plasma. Capsules
were stained with FITC labeled rabbit αhuman C3c, rabbit αhuman fibrinogen, and rabbit αmouse IgG control
antibody. Figures to the left and right of each column show optical sections through the equator and 3D
projections, respectively.
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Figure 3.3: To determine if treatment with CaCl2 would affect fibrinogen deposit, capsules washed in CaCl2
and in NaCl were incubated for 6 hours in plasma and in blood. APA capsules are shown in figure A, while TAM
capsules are shown in figure B. Capsules were stained with FITC labeled rabbit αhuman fibrinogen antibody, and
rabbit αmouse IgG negative control antibody. Pictures of deformed capsules are shown for the APA capsules.
These pictures do not represent the general capsule population, but are included as special cases. Only shrunk
or damaged capsules display fibrinogen deposit with no apparent difference between CaCl2 and NaCl treatment.
Pictures are shown as optical sections through the equator and as 3D projections.
Finally, the effect on fibrinogen adsorption after treating the capsules with CaCl2 are shown
in figure 3.3. CaCl2 treatment prevents the depletion of Ca2+ ions inside the capsule, and limits
the ongoing dissolution of the polymer network, as Ca2+ ions are otherwise exchanged with
Na+ ions in the alginate polymer. But, as Ca2+ ions are involved in many of the steps in both
the complement and the coagulation cascade, it was debated whether an increased presence
of Ca2+ions would affect the deposition of proteins on the capsule surface. No difference in
fibrinogen adsorption between capsules stored in CaCl2 and NaCl was observed.
39
3.3 Complement activation and leukocyte response
3.3.1 TCC response
Capsules were tested in the whole blood assay and incubated in lepirudin anti-coagulated whole
blood for 1 hour and 4 hours. The plasma was obtained and analyzed for different cytokines as
well as the terminal complement complex (sTCC). The formation of sTCC was measured after
1 hour and 4 hours, see figure 3.4. sTCC indicates activation of the complement cascade and is
suggested to be the most sensitive and specific marker of complement activation. After 1 hour
we could see a high increase in sTCC in APA hollow capsules, in some cases even as high as the
positive control zymosan. These levels of sTCC was only observable for hollow APA with PLL,
as the PLO capsule was at about the same level as the solid APA. After 4 hours we could still
see a high response towards the hollow APA with PLL, but it would appear like the gap between
hollow and solid APA was decreasing. An increase in PLL concentration resulted in a significant
increase in sTCC levels, as shown in section 3.3.9. This corresponded with previous findings
where PLL was observed to be sTCC stimulating and leukocyte activating [20]. TAM capsules
showed a very low sTCC response which was also consistent with what has been observed earlier
[20].
In order to see if the sTCC results could be reflected in C3 adsorption on the capsule surface,
as well as to see how an increase in PLL concentration would affect the protein deposition, a
set of different capsules was incubated in plasma for 4 hours. Moreover, the effect of replacing
PLL with PLO was investigated, and if increasing TAM capsule size would affect the outcome.
Figure 3.5 shows an increase in C3 adsorption with increasing PLL concentration. Pictures of
0.14 % PLO capsules should here be compared with pictures of 0.10 % PLL capsules, as 0.14 %
PLO corresponded mole-wise to 0.10 % PLL with the PLO and PLL that was used in this work.
The solid APA capsule appeared to have a much higher protein adsorption than did the hollow
capsules. No adsorption could be seen on either TAM capsule. The high sTCC levels observed
for hollow APA capsules with PLL could thus not be reflected in C3 adsorption on the capsule
surface.
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Figure 3.4: TCC after 1 hour (A) and 4 hours (B) incubation in whole blood. Data are expressed as means ±
SEM, n = 5 except for TAM UPLVG 0.25 mm and TAM UPLVG 0.4 mm, where n = 4. White bars are controls,
grey bars are APA hollow capsules, blue bars APA solid, and light grey bars TAM capsules. Difference between
saline and the other additives were considered statistically significant at P<0.05 and marked with *. It should
be noted that as the values of TAM UPLVG 0.25, 0.35, and 0.4 mm are similar, it is reasonable to assume that
had n = 5 for TAM UPLVG 0.25 and 0.4 mm in B, they would also have been statistically significant towards
saline.
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Figure 3.5: C3 adsorption on TAM capsules, and hollow and solid APA capsules, displayed as cross sections
through the equator and as 3D projections. The same FITC labeled antibodies as described earlier were used.
APA capsules were made with 0.40 mm needles. Pictures of the general capsule population are shown in the C3
left column, while broken capsules are shown in the C3 right column. The number of broken capsules was higher
for 0.10 % PLL hollow APA than for 0.14 % PLL hollow APA
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3.3.2 IL-8 response
The chemokine IL-8 was also measured after 1 hour and 4 hours, see figure 3.6. IL-8 is produced
by macrophages, monocytes, epithelial cells and endothelial cells, but in the whole blood model
monocytes are considered the main source of IL-8. IL-8 secretion is up-regulated when cells are
activated, and functions as a pro-inflammatory molecule by inducing the chemotaxis of mainly
neutrophil granulocytes to the site of inflammation. Figure 3.6A and B show the IL-8 response
after 1 hour and 4 hours respectively. Significant difference between capsule and saline (P<0.05)
after 5 blood donors are shown. Because of a large deviation between different donors, especially
after 1 hour incubation, it was not easy to see any clear-cut trends in the data, except that we
could see a lower response for TAM capsules than APA capsules. In some cases the TAM cap-
sules even gave a lower response than the saline control. After 4 hours, however, it appeared
like the solid APA capsules gave a higher response than both hollow APA capsules and TAM
capsules. In addition, the PLO capsule was the only APA capsule that was not significantly
different from the saline control. In some donors, which was also observable in the mean after 1
hour, it appeared like increased PLL concentration gave an increased IL-8 response. However,
in other donors the trend was the opposite.
3.3.3 Leukocyte activation as measure by CD11b expression
CD11b is an early activation marker of leukocytes, and is a receptor for inactivated C3b (iC3b).
Expression of CD11b on granulocytes and monocytes was measured using flow cytometry 1 hour
after addition of the capsules in the whole blood assay. Results from 3 donors are shown in figure
3.7. Individual donor comparisons of CD11b expression, sTCC generation, and IL-8 secretion
are shown in appendix B. TAM capsules appeared to be less activating than APA, and in some
cases also less activating than the saline negative control, which was in accordance with earlier
observations [20]. However, not enough data was gathered to be able to say anything about
the statistical significance of the differences. No difference between hollow APA and solid APA
could be observed, but it looked like PLO capsules gave a slightly lower CD11b expression than
PLL. Higher PLL concentration appeared to give a higher response for capsules with UPLVG
(high G) alginate, and either no difference, or a lower response for increasing PLL concentration
in capsules with high M alginate. This trend was also observed in sTCC levels after 1 hour.
More data have to be gathered to be able to determine any significant difference between the
capsules.
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Figure 3.6: IL-8 after 1 hour (A) and 4 hours (B) incubation in whole blood. Data are expressed as means ±
SEM, n = 5 except for TAM UPLVG 0.25 mm and TAM UPLVG 0.4 mm, where n = 4. White bars are controls,
grey bars are APA hollow capsules, blue bars APA solid, and light grey bars TAM capsules. Zymosan values for
IL-8 after 1 and 4 hours are 349.8 ± 57.9 pg/ml and 9214.7 ± 1458.0 pg/ml respectively. Differences between
saline and the other additives are considered statistically significant at P<0.05 and marked with *.
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Figure 3.7: Leukocyte CD11b expression after 1 hour incubation in lepirudin anti-coagulated whole blood.
Data is expressed as means ± SEM, n = 3. CD11b expression was measured as median fluorescence intensity
(MFI) on monocytes and granulocytes.
3.3.4 Chemokines
It was also screened for a set of different chemokines, cytokines, and growth factors, using a
multiplex assay. This was only performed on whole blood after 4 hours incubation with capsules.
A similar, although not as defined, picture as sTCC was observed for MCP-1, figure 3.8. Hollow
APA capsules with PLL gave a stronger response than hollow APA capsules with PLO, and
solid APA. Additionally, a lower response was observed for increasing PLL concentration for
capsules with high M alginate, as was also observed in the up-regulation of CD11b. TAM
capsules gave a weak response. MIP-1α levels showed a clear increase for solid APA capsules
with hollow APA capsules at the same level as TAM capsules, and only slightly higher than
the saline control. These levels reflected the increased IL-8 response for solid APA capsules as
shown earlier. For MIP-1α, as was also the case for IL-8, it was hard to detect any effect of
increasing PLL concentration, alginate type, or capsule diameter.
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Figure 3.8: MCP-1 (A) and MIP-1α (B) after 4 hours incubation in whole blood. Data are expressed as means
± SEM, n = 5 except for TAM UPLVG 0.25 mm and TAM UPLVG 0.4 mm, where n = 4. White bars are
controls, grey bars are APA hollow capsules, blue bars APA solid, and light grey bars TAM capsules. Zymosan
values for MCP-1 and MIP-1α are 229 ± 54 pg/ml and 2986 ± 345 pg/ml respectively. Difference between saline
and the other additives are considered statistically significant at P<0.05 and marked with *.
3.3.5 Inflammatory cytokines
The inflammatory cytokine IL-6 showed a small increase in response to solid APA capsules,
compared with the other capsule types, see figure 3.9. This increase was even more apparent in
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IL-1β and TNFα levels, figure 3.10. No apparent effect of PLL concentration, alginate type, or
capsule diameter, could be observed. These cytokines, along with IL-6, are produced by among
other the monocytes in the blood, and increased levels of these cytokines indicate an activation
of the cells secreting them. However, it should be noted that all three cytokines showed a
very low response compared to the positive control zymosan, which had cytokine levels several
magnitudes higher than the other additives.
Figure 3.9: IL-6 after 4 hours incubation in whole blood. Data are expressed as means ± SEM, n = 5 except
for TAM UPLVG 0.25 mm and TAM UPLVG 0.4 mm, where n = 4. White bars are controls, grey bars are
APA hollow capsules, blue bars APA solid, and light grey bars TAM capsules. Zymosan response is 9081 ± 1616
pg/ml. *P<0.05.
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Figure 3.10: IL-1β and TNFα after 4 hours incubation in whole blood. Data are expressed as means ± SEM,
n = 5 except for TAM UPLVG 0.25 mm and TAM UPLVG 0.4 mm, where n = 4. White bars are controls, grey
bars are APA hollow capsules, blue bars APA solid, and light grey bars TAM capsules. Zymosan values for IL-1β
and TNFα are 1960 ± 338 pg/ml and 12724 ± 3036 pg/ml respectively. *P<0.05.
3.3.6 Anti-inflammatory cytokines
The anti-inflammatory cytokine IL-1RA showed a small increase for solid APA capsules, figure
3.11. No such increase could be observed for IL-10. Standard deviations were however quite big
between the different donors.
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Figure 3.11: IL-1RA and IL-10 after 4 hours incubation in whole blood. Data are expressed as means ± SEM,
n = 5 except for TAM UPLVG 0.25 mm and TAM UPLVG 0.4 mm, where n = 4. White bars are controls,
grey bars are APA hollow capsules, blue bars APA solid, and light grey bars TAM capsules. Zymosan values for
IL-1RA and IL-10 are 1400 ± 473 pg/ml and 8.6 ± 1.3 pg/ml respectively. *P<0.05.
3.3.7 Growth factors
As for the growth factors, a small increase in response to solid APA capsules and TAM capsules
could be observed for PDGF-BB, figure 3.12. An increase in HGF levels in response to solid
APA capsules was also observed, accompanied by a decrease in levels for TAM capsules below
the saline control. VEGF levels showed yet again an increase in response towards solid capsules,
with hollow APA capsules and TAM capsules at about the same level as the saline control, figure
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3.13.
Figure 3.12: PDGF-BB and HGF after 4 hours incubation in whole blood. Data are expressed as means ±
SEM, n = 5 except for TAM UPLVG 0.25 mm and TAM UPLVG 0.4 mm, where n = 4. White bars are controls,
grey bars are APA hollow capsules, blue bars APA solid, and light grey bars TAM capsules. Zymosan values for
PDGF-BB and HGF are 1479 ± 416 pg/ml and 1246 ± 299 pg/ml respectively. *P<0.05.
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Figure 3.13: VEGF after 4 hours incubation in whole blood. Data are expressed as means ± SEM, n = 5
except for TAM UPLVG 0.25 mm and TAM UPLVG 0.4 mm, where n = 4. White bars are controls, grey bars
are APA hollow capsules, blue bars APA solid, and light grey bars TAM capsules. Zymosan value for VEGF is
55 ± 24 pg/ml. *P<0.05.
3.3.8 MIF, IP-10, IFN-γ, and RANTES
MIF levels were higher for TAM capsules than seen before, at about the same level as APA
capsules. IP-10 levels showed an opposite trend of what was seen for many of the other cytokines,
with lower levels for solid APA, and higher levels for TAM capsules, figure 3.14. Lastly, IFN-γ
and RANTES levels showed no apparent difference between additives and the saline control,
figure 3.15.
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Figure 3.14: MIF and IP-10 after 4 hours incubation in whole blood. Data are expressed as means ± SEM, n
= 5 except for TAM UPLVG 0.25 mm and TAM UPLVG 0.4 mm, where n = 4. White bars are controls, grey
bars are APA hollow capsules, blue bars APA solid, and light grey bars TAM capsules. Zymosan values for MIF
and IP-10 are 6451 ± 2356 pg/ml and 1221 ± 157 pg/ml respectively. *P<0.05.
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Figure 3.15: IFN-γ and RANTES after 4 hours incubation in whole blood. Data are expressed as means ±
SEM, n = 5 except for TAM UPLVG 0.25 mm and TAM UPLVG 0.4 mm, where n = 4. White bars are controls,
grey bars are APA hollow capsules, blue bars APA solid, and light grey bars TAM capsules. Zymosan values for
IFN-γ and RANTES are 140 ± 14 pg/ml and 7080 ± 2980 pg/ml respectively. *P<0.05.
3.3.9 Statistical analysis
Performing statistical analyses on the data showed no significant difference between the TAM
capsules for any molecule measured, see table 3.2 and 3.3. Thus a change in capsule diameter
between approximately 300 and 600 μm did not affect the biocompatibility of the capsules, as
measured by cytokine, chemokine, growth factor and sTCC levels. Comparing hollow and solid
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APA capsules after 4 hours of incubation in whole blood, a significantly higher sTCC and MCP-
1 response was seen for hollow capsules with PLL, while a significantly lower response was seen
for the same capsules in chemokine levels (except MCP-1) and in inflammatory cytokine levels.
No difference was seen in anti-inflammatory cytokines or growth factors except for VEGF which
was also lower for hollow capsules. Looking at increasing PLL concentration, a higher response
was detected in some cases but not all. Especially sTCC formation seemed to be affected by this,
but also some chemokines and inflammatory cytokines gave a significant increase in response to
higher concentration. Choice of polycation appeared to be of importance for sTCC and MCP-
1 responses as a significantly lower response was detected for these molecules when PLO was
used in the hollow capsules instead of PLL. A significant difference was also observed in IP-10
and IL-1β levels for PLO versus PLL. Looking at alginate type, high M M.pyr alginate or high
G UP-LVG alginate, differences in chemokine levels, cytokine levels, and growth factor levels
could not be observed, with exceptions in IP-10, IL-8, and RANTES levels in some cases, see
table 3.2 and 3.3. sTCC levels appeared to be lower for UP-LVG alginate when 0.05 % PLL
was used, something that might be coupled with the increased stability conferred by the high
G alginate. Finally, the addition of HEPES in the gelling solution did not significantly affect
TCC, chemokine, cytokine, or growth factor responses.
55
T
able
3.2:
Significant
differences
betw
een
cytokine
responses
for
the
different
capsules.
A
ll
m
olecules
w
ere
analyzed
after
4
hours
of
incubation
in
w
hole
blood,
except
IL
-8
and
T
C
C
w
hich
w
ere
also
analyzed
after
1
hour.
IL
-8
IL
-8
T
C
C
T
C
C
M
IP
-1α
M
C
P
-1
M
IF
IP
-10
IL
-1β
T
N
F
α
IL
-6
1h
4h
1h
4h
A
P
A
hollow
,
H
igh
M
A
P
A
hollow
,
H
igh
M
0.10
%
P
L
L
,
0.4
m
m
v
0.14
%
P
L
L
,
0.4
m
m
N
o
N
o
Y
es
Y
es
Y
es
N
o
Y
es
Y
es
N
o
N
o
N
o
A
P
A
hollow
,
H
igh
M
A
P
A
hollow
,
H
igh
M
0.10
%
P
L
L
,
0.4
m
m
v
0.14
%
P
L
O
,
0.4
m
m
N
o
N
o
Y
es
Y
es
N
o
N
o
N
o
Y
es
Y
es
N
o
N
o
A
P
A
hollow
,
H
igh
M
A
P
A
solid,
H
igh
M
0.10
%
P
L
L
,
0.4
m
m
v
0.10
%
P
L
L
,
0.4
m
m
N
o
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
N
o
A
P
A
solid,
H
igh
M
A
P
A
solid,
H
igh
M
0.05
%
P
L
L
,
0.4
m
m
v
0.10
%
P
L
L
,
0.4
m
m
N
o
Y
es
Y
es
N
o
N
o
Y
es
N
o
Y
es
Y
es
Y
es
N
o
A
P
A
solid,
U
P
-LV
G
A
P
A
solid,
U
P
-LV
G
0.05
%
P
L
L
,
0.4
m
m
v
0.10
%
P
L
L
,
0.4
m
m
N
o
N
o
Y
es
Y
es
N
o
N
o
N
o
N
o
N
o
N
o
N
o
A
P
A
solid,
U
P
-LV
G
A
P
A
solid,
U
P
-LV
G
0.05
%
P
L
L
,
0.35
m
m
v
0.10
%
P
L
L
,
0.35
m
m
N
o
N
o
Y
es
Y
es
N
o
Y
es
N
o
Y
es
N
o
N
o
N
o
A
P
A
solid,
H
igh
M
A
P
A
solid,
U
P
-LV
G
0.05
%
P
L
L
,
0.4
m
m
v
0.05
%
P
L
L
,
0.4
m
m
N
o
Y
es
Y
es
Y
es
N
o
N
o
N
o
Y
es
N
o
N
o
N
o
A
P
A
solid,
H
igh
M
A
P
A
solid,
U
P
-LV
G
0.10
%
P
L
L
,
0.4
m
m
v
0.10
%
P
L
L
,
0.4
m
m
N
o
N
o
Y
es
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
A
P
A
solid,
U
P
-LV
G
A
P
A
solid,
U
P
-LV
G
0.05
%
P
L
L
,
0.4
m
m
v
0.05
%
P
L
L
,
0.35
m
m
N
o
Y
es
N
o
Y
es
N
o
N
o
Y
es
Y
es
N
o
N
o
N
o
A
P
A
solid,
U
P
-LV
G
A
P
A
solid,
U
P
-LV
G
0.10
%
P
L
L
,
0.4
m
m
v
0.10
%
P
L
L
,
0.35
m
m
Y
es
N
o
N
o
N
o
N
o
Y
es
N
o
N
o
N
o
N
o
N
o
A
P
A
solid,
U
P
-LV
G
A
P
A
solid,
U
P
-LV
G
N
o
H
E
P
E
S
0.05
%
P
L
L
,
0.35
m
m
v
0.05
%
P
L
L
,
0.35
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
T
A
M
U
P
-LV
G
0.25
m
m
v
T
A
M
U
P
-LV
G
0.35
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
T
A
M
U
P
-LV
G
0.25
m
m
v
T
A
M
U
P
-LV
G
0.40
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
T
A
M
U
P
-LV
G
0.35
m
m
v
T
A
M
U
P
-LV
G
0.40
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
N
o
56
T
ab
le
3.
3:
Si
gn
ifi
ca
nt
di
ffe
re
nc
es
be
tw
ee
n
cy
to
ki
ne
re
sp
on
se
s
fo
r
th
e
di
ffe
re
nt
ca
ps
ul
es
.
A
ll
m
ol
ec
ul
es
w
er
e
an
al
yz
ed
af
te
r
4
ho
ur
s
of
in
cu
ba
ti
on
in
w
ho
le
bl
oo
d.
IL
-1
R
A
IL
-1
0
P
D
G
F
H
G
F
V
E
G
F
IF
N
-γ
R
A
N
T
E
S
A
P
A
ho
llo
w
,
H
ig
h
M
A
P
A
ho
llo
w
,
H
ig
h
M
0.
10
%
P
L
L
,
0.
4
m
m
v
0.
14
%
P
L
L
,
0.
4
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
A
P
A
ho
llo
w
,
H
ig
h
M
A
P
A
ho
llo
w
,
H
ig
h
M
0.
10
%
P
L
L
,
0.
4
m
m
v
0.
14
%
P
L
O
,
0.
4
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
A
P
A
ho
llo
w
,
H
ig
h
M
A
P
A
so
lid
,
H
ig
h
M
0.
10
%
P
L
L
,
0.
4
m
m
v
0.
10
%
P
L
L
,
0.
4
m
m
N
o
N
o
N
o
N
o
Y
es
N
o
N
o
A
P
A
so
lid
,
H
ig
h
M
A
P
A
so
lid
,
H
ig
h
M
0.
05
%
P
L
L
,
0.
4
m
m
v
0.
10
%
P
L
L
,
0.
4
m
m
N
o
N
o
N
o
N
o
Y
es
N
o
N
o
A
P
A
so
lid
,
U
P
-L
V
G
A
P
A
so
lid
,
U
P
-L
V
G
0.
05
%
P
L
L
,
0.
4
m
m
v
0.
10
%
P
L
L
,
0.
4
m
m
Y
es
N
o
N
o
N
o
N
o
N
o
N
o
A
P
A
so
lid
,
U
P
-L
V
G
A
P
A
so
lid
,
U
P
-L
V
G
0.
05
%
P
L
L
,
0.
35
m
m
v
0.
10
%
P
L
L
,
0.
35
m
m
N
o
Y
es
N
o
N
o
N
o
N
o
N
o
A
P
A
so
lid
,
H
ig
h
M
A
P
A
so
lid
,
U
P
-L
V
G
0.
05
%
P
L
L
,
0.
4
m
m
v
0.
05
%
P
L
L
,
0.
4
m
m
N
o
N
o
N
o
N
o
N
o
N
o
Y
es
A
P
A
so
lid
,
H
ig
h
M
A
P
A
so
lid
,
U
P
-L
V
G
0.
10
%
P
L
L
,
0.
4
m
m
v
0.
10
%
P
L
L
,
0.
4
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
A
P
A
so
lid
,
U
P
-L
V
G
A
P
A
so
lid
,
U
P
-L
V
G
0.
05
%
P
L
L
,
0.
4
m
m
v
0.
05
%
P
L
L
,
0.
35
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
A
P
A
so
lid
,
U
P
-L
V
G
A
P
A
so
lid
,
U
P
-L
V
G
0.
10
%
P
L
L
,
0.
4
m
m
v
0.
10
%
P
L
L
,
0.
35
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
A
P
A
so
lid
,
U
P
-L
V
G
A
P
A
so
lid
,
U
P
-L
V
G
N
o
H
E
P
E
S
0.
05
%
P
L
L
,
0.
35
m
m
v
0.
05
%
P
L
L
,
0.
35
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
T
A
M
U
P
-L
V
G
0.
25
m
m
v
T
A
M
U
P
-L
V
G
0.
35
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
T
A
M
U
P
-L
V
G
0.
25
m
m
v
T
A
M
U
P
-L
V
G
0.
40
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
T
A
M
U
P
-L
V
G
0.
35
m
m
v
T
A
M
U
P
-L
V
G
0.
40
m
m
N
o
N
o
N
o
N
o
N
o
N
o
N
o
57
3.4 Leukocyte response towards TAM capsules
Alginate type, and the presence of BaCl2 in the making of the TAM capsules was then investi-
gated. Eight different TAM capsules were tested in 2 donors, together with two APA capsules,
and the plasma was analyzed after 4 hours. The results of these 2 donors should be taken as
no more than a preliminary indication of the biocompatibility of the different capsules. No
statistical significance can be obtained from such a small data set.
3.4.1 Chemokines
It was analyzed for the same molecules on the different TAM capsules as on the first capsule
set. The findings suggested a minimal stimulatory effect of the TAM capsules. MCP-1 levels
showed an overall low response towards the different TAM capsules, with levels lower than APA
capsules, and slightly lower than the saline control. Capsules gelled in the absence of BaCl2
appeared to give a higher response than capsules gelled in with BaCl2. Also, capsules with the
new type of UP-LVG alginate (UP-LVG*, TAM4 capsules) appeared to give a slightly lower
response, however, since the levels were so close to the negative controls and it was only taken
from two donors, no significant results could be concluded. Whole blood from more donors
would have to be tested. For the chemokines MIP-1α and IL-8 the picture was similar to what
had been observed before, with overall low levels, slightly higher without BaCl2 in the gelling
solution, and a concomitant low response for UP-LVG* capsules, figures 3.17 and 3.18.
3.4.2 Inflammatory cytokines
As for the inflammatory cytokines, IL-1β showed a lower response toward TAM capsules than
the saline control, figure 3.19. TAM4 capsules appeared again to give a slightly lower response.
For TNFα and IL-6, the detected levels were at or slightly higher than the saline control, figures
3.20 and 3.21.
3.4.3 Anti-inflammatory cytokines
The anti-inflammatory cytokines IL-1RA and IL-10 were at the same levels for TAM capsules
as had been seen before, with yet again a somewhat lower response towards TAM4 capsules,
showing a similar picture as for the inflammatory cytokines, see figures 3.22 and 3.23.
3.4.4 Growth factors
The growth factors PDGF-BB, HGF, and VEGF were also analyzed and are shown in figures
3.24, 3.25, and 3.26. The same trends could be observed here, as was seen for the other molecules.
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Figure 3.16: MCP-1 results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 119 pg/ml and 179 pg/ml for A and B respectively.
Figure 3.17: MIP-1α results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 2427 pg/ml and 2660 pg/ml for A and B respectively.
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Figure 3.18: IL-8 results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 4879 pg/ml and 5843 pg/ml for A and B respectively.
Figure 3.19: IL-1β results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 4315 pg/ml and 1173 pg/ml for A and B respectively.
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Figure 3.20: TNFα results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 31494 pg/ml and 7362 pg/ml for A and B respectively.
Figure 3.21: IL-6 results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 19255 pg/ml and 9976 pg/ml for A and B respectively
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Figure 3.22: IL-1RA results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 938 pg/ml and 994 pg/ml for A and B respectively.
Figure 3.23: IL-10 results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 12.7 pg/ml and 8.4 pg/ml for A and B respectively.
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Figure 3.24: PDGF-BB results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B).
Zymosan values are 1901 pg/ml and 786 pg/ml for A and B respectively.
Figure 3.25: HGF results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 346.1 pg/ml and 913.9 pg/ml for A and B respectively.
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Figure 3.26: VEGF results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 73 pg/ml and 76 pg/ml for A and B respectively.
Figure 3.27: MIF results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 6889 pg/ml and 19193 pg/ml for A and B respectively.
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Figure 3.28: IP-10 results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 480 pg/ml and 1385 pg/ml for A and B respectively.
Figure 3.29: RANTES results after 4 hour incubation in whole blood for donor 1 (A) and donor 2 (B). Zymosan
values are 18800 pg/ml and 14327 pg/ml for A and B respectively.
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3.4.5 MIF, IP-10, IFN-γ and RANTES
For the molecule MIF, levels were at or below the saline control, figure 3.27. In most cases
the TAM beads gave a lower response than APA capsules. No trend among the TAM beads
could be observed, and changes in response most likely stemmed from donor variations. For
IP-10, figure 3.28, the picture was similar to what had been observed before, with overall low
levels, slightly higher without BaCl2 in the gelling solution, and a concomitant low response for
UP-LVG* capsules. Levels were here about the same as for APA capsules. For RANTES, figure
3.29, as was also the case for the first capsule set, it was harder to detect the same trends seen
before. The secretion of RANTES seemed unaffected by the presence of capsules during the 4
hour incubation period. For the second donor we observed a very high T0, possibly suggesting
contamination of this vial.
To sum up, it appears like the TAM capsules are minimally stimulating with responses at
approximately the same level as the saline control. A general tendency towards an increased
response to capsules without barium, and a slightly lower response for UP-LVG* alginate cap-
sules, were seen, however, it cannot be excluded that these trends are a result of donor and
procedure variations.
3.5 Regulatory complement protein and coagulation cascade protein
deposition on capsule surface
In an attempt to get a better understanding of why TAM capsules triggered such a small
cytokine response compared with APA capsules, TAM and APA capsules were stained for a set
of inhibitory complement proteins, as well as some proteins involved in the coagulation cascade.
TAM capsules (UP-LVG, 0.4 mm) and APA capsules (0.1 % PLL, UP-LVG, 0.4 mm) were
incubated in plasma for 6 hours and overnight, and then stained with antibodies specific for the
different proteins. High factor H adsorption along with vitronectin adsorption was seen on APA
capsules, see figure 3.30. Also, collapsed APA capsules appeared to have a generally higher
adsorption of proteins on their surface than did normal capsules. TAM capsules appeared
more inert regarding protein deposition, as no protein adsorption was detected after 6 hours
incubation, see figure 3.31. No marked increase in protein adsorption could be detected for
APA capsules when incubating overnight. Deposition of vitronectin, plasminogen, fibrinogen,
HMWK, and C1 inhibitor could be detected on a few TAM capsules when incubating overnight,
although most capsules still appeared to be inert, see figure 3.33. Only plasminogen was adsorbed
on a greater number of capsules. Nevertheless, an increase in adsorption was detected on
TAM capsules when incubating overnight in plasma. Observation of protein adsorption after an
even longer incubation period would be preferable, as capsules are destined to a much longer
incubation period when implanted into patients.
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Figure 3.30: Adsorption of regulatory complement proteins and coagulation cascade proteins on APA capsules.
Capsules were incubated for 6 hours in plasma, and stained with sheep anti-human protein antibodies, and sheep
IgG negative control antibodies. Pictures of shrunk and deformed capsules were included as special cases as they
did not represent the general capsule population. Pictures are displayed as cross sections through the equator
and as 3D projections.
68
Figure 3.31: Adsorption of regulatory complement proteins and coagulation cascade proteins on TAM capsules.
Capsules were incubated for 6 hours in plasma, and stained with sheep anti-human protein antibodies, and
sheep IgG negative control antibodies. Pictures are displayed as cross sections through the equator and as 3D
projections.
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Figure 3.32: Adsorption of regulatory complement proteins and coagulation cascade proteins on APA capsules.
Capsules were incubated overnight in plasma, and stained with sheep anti-human protein antibodies, and sheep
IgG negative control antibodies. Pictures of shrunk and deformed capsules were included as special cases as they
did not represent the general capsule population. Pictures are displayed as cross sections through the equator
and as 3D projections.
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Figure 3.33: Adsorption of regulatory complement proteins and coagulation cascade proteins on TAM capsules.
Capsules were incubated overnight in plasma, and stained with sheep anti-human protein antibodies, and sheep
IgG negative control antibodies. Pictures of special cases are included where an increased adsorption was detected,
but do not represent the general capsule population. Pictures are displayed as cross sections through the equator
and as 3D projections.
3.6 Effect of lepirudin on protein adsorption
A concern was raised towards what affect the anti-coagulant lepirudin might have on adsorption
of proteins on the capsules. As lepirudin is a direct thrombin inhibitor, it was debated whether it
could affect the deposition of fibrinogen on the surface of the capsules. Capsules were therefore
incubated in plasma anti-coagulated with different lepirudin concentrations. In the vial with
no lepirudin added, the blood coagulated shortly after being extracted. Pictures of capsules
incubated in plasma without lepirudin might therefore not give an accurate picture of protein
adsorption on the capsules. The clotting process cleaves fibrinogen into fibrin, and cross links
the molecule fibers. The concentration of soluble fibrinogen would therefore be diminished.
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Figure 3.34: Adsorption of fibrinogen with different concentrations of the anti-coagulant lepirudin. Lepirudin
positive samples were incubated in blood anticoagulated with 0.05 mg/ml lepirudin. Lepirudin negative samples
were incubated in blood without anticoagulant. Capsules were incubated for 6 hours and stained with sheep
anti-human fibrinogen antibodies, and sheep IgG negative control antibodies
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Figure 3.35: Adsorption of vitronectin with different concentrations of the anticoagulant lepirudin. Lepirudin
positive samples were incubated in blood anticoagulated with 0.05 mg/ml lepirudin. Lepirudin negative samples
were incubated in blood without anticoagulant. Capsules were incubated for 6 hours and stained with sheep
anti-human vitronectin antibodies, and sheep IgG negative control antibodies
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Figure 3.36: Adsorption of high molecular weight kininogen (HMWK) and negative control on TAM capsules
after 6 hours incubation in plasma. Lepirudin positive samples were incubated in blood anticoagulated with
0.05 mg/ml lepirudin. Lepirudin negative samples were incubated in blood without anticoagulant. Capsules
were stained with sheep anti-human HMWK antibodies, and sheep IgG negative control antibodies. Because
of coagulation in the lepirudin negative sample, there was not enough plasma to test for HMWK adsorption.
Negative controls are performed on TAM capsules at the two extremes, with and without lepirudin.
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4 DISCUSSION
In this work, the biocompatibility of a set of different alginate microcapsules was studied in the
whole blood model. Parameters such as capsule type, alginate type, polycation type, polycation
concentration, and capsule size, were investigated. The goal was to increase our knowledge of
the inflammatory mechanisms potentially involved upon implanting alginate capsules. Some of
the questions raised included how the soluble inner core affects the immune response towards
the capsules, how PLO compares with PLL as a stabilizing polycation layer, if the size of the
capsule plays a role in the response, and why alginate beads incite a lower cytokine response
than does the saline negative control.
4.1 The whole blood model for evaluating biocompatibility
The whole blood model represents a potent tool for unmasking the underlying mechanisms
of biomaterial induced inflammation in vitro. This is based on previous studies where spe-
cific inhibition of proteins and receptors in whole blood has led to discoveries in the secretion
of inflammatory mediators and how they are tied to complement activation [31, 75]. Using
lepirudin-anticoagulated whole blood enables the study of how complement interacts in the in-
flammatory network, as lepirudin is a highly specific thrombin inhibitor that does not interfere
with complement activation. The goal using the whole blood model was to reveal the inflam-
matory potential of different alginate microcapsules, and how changes in capsule composition
affected this potential.
APA capsules, AP capsules, PMCG capsules, and TAM beads have previously been studied
in the whole blood model [20]. The findings showed an increased sTCC response towards APA,
AP, and PMCG, compared to TAM beads and saline negative control. Capsules here were made
with 0.4 mm needles and 0.05 % PLL. Further analyzes on cytokine levels have shown decreased
chemokine secretion and decreased inflammatory cytokine secretion towards TAM beads com-
pared to APA, AP, and PMCG capsules [76]. Additionally, secretion of many of the cytokines
has been observed to be complement dependent, as shown by addition of the C3 inhibitor comp-
statin.
It has also been demonstrated how polyvinyl chloride surfaces, cellulose ester or polyamide
membranes induce a defined inflammatory response in whole blood [75, 77, 78]. Variability in
the cytokine profiles of these materials has been observed, but increased levels of IL-8 have
appeared in all cases. Increased IL-8 response also corresponded with complement activation in
these studies, and might therefore be an important predictor of biomaterial tolerability. In this
work, we observed a higher sTCC response, together with higher IL-8 levels, for the saline control
compared to T0, which is consistent with activation of complement induced by the surface of
the polypropylene vials used. The same could be seen in many of the other cytokine levels.
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4.2 Capsule parameters
As it had been previously observed that changes in capsule parameters could appear to affect
the inflammatory potential of alginate microcapsules [76], the aim of this work was to investigate
different capsule compositions and preparation protocols in a controlled manner. The different
parameters are shown in table 4.1.
Table 4.1: Capsule parameters investigated in this work
Parameter
Capsule type TAM vs APA
hollow vs solid APA
Polycation type PLL vs PLO
Polycation concentration 0.05 %, 0.10 %, and
0.14 % PLL
Alginate type High M vs High G
Capsule size 0.25 mm, 0.35 mm, and
0.40 mm needle size
Gelling conditions With vs without BaCl2in
TAM gelling solution
With vs without HEPES in
gelling solution
4.2.1 Polycation
The first alginate microcapsules used to successfully encapsulate islet cells for the treatment of
Type 1 diabetes in animals were APA microcapsules [19]. The use of a polycation layer in these
capsules enabled them to withstand the harsh conditions involved in transplanting capsules into
the peritoneal cavity without breaking and exposing the encapsulated cells to the host immune
system. However, as the number of experiments has grown in the wake of this pioneering
achievement, the polycation layer has generally come to be regarded as the main contributor
of the bioincompatibility of capsules in vivo [17, 20, 79]. This could also be reflected in the
triggering of leukocyte activation and cytokine production, as well as complement activation, in
the whole blood assay performed in this work. Higher levels of the complement product sTCC,
the chemokines IL-8, MCP-1, and MIP-1α, the inflammatory cytokines TNFα and IL-1β, as
well as the growth factors HGF and VEGF were detected for APA capsules compared to TAM
beads. Exchanging the commonly used PLL with PLO, as well as decreasing the concentration
of PLL, might therefore present a way to decrease the inflammatory potential of the capsules,
and was tested in this work.
78
4.2.2 Alginate type
The type of alginate has a major influence on the microcapsules. The earliest capsules used
for cell encapsulation consisted of high M alginate (86-99.9 % M) which stimulated cytokine
production [10]. Success had been achieved with these capsules in rats [19], but it was first
when the immunostimulating effects of high M alginate was discovered, and capsules were made
with alginate containing a higher fraction of G residues, that capsules started performing better
in larger animals as well [58]. It is not only the immunostimulating properties of the alginate
that has to be taken into account however. Stability of the alginate gel, pore size, and interaction
with the coating layers are of importance. High G alginates tend to form stronger gels than High
M alginates [16], because of the G-blocks having a greater affinity to cations. Conversely, High
G (FG>0.6) alginates has been observed to perform worse in APA capsules than intermediate
G alginate (FG= 0.4-0.6) due to insufficient binding or complexing between alginate and the
PLL coating [21]. Lastly, the size of the capsules has recently been an issue in the microcapsule
community due to indications of over-growth correlating with capsule size [76].
4.2.3 TAM capsules
Improvements in alginate composition and gelling conditions have made it possible to omit
the polycation layer and encapsulate cells directly in a bead consisting only of gelled alginate
[22, 61]. The TAM beads used in this work were from an optimized alginate capsule design using
high molecular weight alginate, with a high content of G, which, in combination with Ca2+ and
a minimal concentration of Ba2+, allows for very strong and stable microcapsules [80]. Also,
the use of mannitol as osmolyte in both the alginate and in the gelling solution results in a
higher concentration of alginate at the capsules surface than at the center [81]. All these factors
improve the stability of the beads, making the polycation layer redundant. The fact that the
TAM beads can be made in one step further tips the scale in their favor as this makes the en-
capsulation process easier with milder conditions for the cells. And, while comparing the beads
to APA capsules, one also removes the presence of collapsed capsules that are always present,
albeit at a very low number, in the APA capsule population. As shown in the protein adsorption
assays in this work, these collapsed capsules have a higher protein deposition on their surface,
and might therefore help further initiate a response.
There are however some draw backs with alginate beads. As only one defense barrier stands
between the encapsulated cells and the host immune system, the stability of the gelled alginate
is crucial. In addition, the beads will have a larger porosity than capsules with a polycation
layer, allowing the diffusion of immunoglobulin G [82] and complement [83] into the cells. This
might pose a problem as antibodies could be generated towards the encapsulated cells, diffuse
into the capsules, bind to the cells, and possibly start a complement reaction. Conversely, an
increased porosity might also to a greater extent allow secreted proteins from the encapsulated
cells, or even residual protein from the alginate itself, to reach the host immune cells. This might
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explain why there have been reported cases where hollow APA capsules with encapsulated tumor
cells have performed better than TAM capsules [76]. The same picture was seen in a recent
study with cynomolgus monkeys, where TAM capsules showed increased over-growth [76]. Still,
microcapsules of similar permeability have previously been shown to protect grafts in mice [57],
indicating no major problem of the bead porosity. In addition, the exposure of the negative
surface charges present in the alginate polymer might stimulate coagulation cascade responses
to a greater extent. This might also be a reason for the observed over-growth seen on capsules in
vivo [76]. Negative surfaces are observed to adsorb factor XII of the coagulation system, which
might then become activated and initiate the coagulation cascade. Use of a layer of zwitter ions
coating the surface has been suggested, as these molecules, having an equal amount of positive
and negative charges, tend to be particularly biocompatible, robust, and environmentally benign
[84, 85].
4.3 Complement activation
The different alginate microcapsules were tested in the whole blood assay. The formation of
sTCC indicates activation of complement as it is the final product of the complement cascade.
It is suggested to be the most sensitive and specific marker of complement activation [20]. A
rapid and strong response was detected for hollow APA capsules compared to solid APA capsules
and TAM beads after 1 hour of incubation in whole blood. For some donors the hollow APA
response was at the same level as the positive control zymosan. After 4 hours, the response
was still high, at about the same level as zymosan, but it appeared like the gap between solid
APA and hollow APA capsules was decreasing. This was further investigated to see if the same
picture could be observed on the surface of the capsules. If the hollow capsules would elicit a
strong sTCC response, then this should most likely also be detected on the capsule surface as an
increase in C3 protein. When this could not be observed, it was debated whether some soluble
molecule diffused out of the hollow APA capsules and triggered the sTCC response. A soluble
PLL-alginate complex was suggested, which perhaps could trigger the spontaneous hydrolyza-
tion of C3 into C3(H2O), and the subsequent sTCC generation. But as the leukocyte CD11b
expression, which is tightly linked to complement activation as it is a receptor for inactivated
C3 and up-regulated by C5a [86], and also the IL-8 levels, could not reflect this strong increase
in sTCC, it might indicate the presence of some molecule diffusing out of the hollow capsules
and which is subsequently detected as sTCC by the complement detection method. Meaning
that it is not actually linked to the complement cascade, but an assay mediated artifact. Still,
this would then also have to explain the higher values of MCP-1 which were detected for the
same hollow APA capsules. Perhaps the slow accumulation of C3 on the surface of the solid
APA capsules is what is required for the cytokine stimulation. That the surface deposition of
C3 facilitates the triggering of monocytes and granulocytes to secrete cytokines.
C3 inhibition studies might clarify if the observed sTCC response is a specific response to-
80
wards sTCC, or an assay mediated artifact. Addition of the C3-binding cyclic synthetic peptide
compstatin would effectively inhibit the generation of C3a and sC5b-9 [87]. Still detectable
sTCC would then be a confirmed artifact of the procedure. Interestingly, a similarly increased
initial sTCC response has been detected for hollow PMCG capsules tested in the whole blood
model [20]. These capsules have also been observed to have higher MCP-1 levels compared to
solid APA capsules [76]. In that case both the sTCC and MCP-1 responses were confirmed to
be of a complement nature [76].
A marked difference was observed in sTCC levels for hollow APA with PLO and with PLL.
Hollow APA with PLO gave a response that was at about the same level as for solid APA
capsules, while levels for hollow APA with PLL were much higher. This could indicate that, if
the above assumption of a soluble artifact detectable as sTCC, or triggering sTCC, is valid, the
PLO polycation might have reduced the permeability of the capsules in some way, preventing
the diffusion of the compound out of the capsule. sTCC response towards TAM beads remained
at or below the saline negative control at both 1 hour and 4 hours of incubation, with no de-
tectable difference in capsule size.
PLL significantly affected complement activation. Increased PLL concentration in the APA
capsules correlated with a significant increase in sTCC response for APA capsules having High-
G alginate, after both 1 hour and 4 hours incubation. For capsules with High-M alginate the
trend appeared to be the opposite. Here a significant decrease was observed for both hollow
and solid APA with increasing PLL after 1 hour. The decrease for the solid APA capsule was
also reflected in CD11b expression, further strengthening the results as CD11b is up-regulated
by complement activation. After four hours, the solid APA capsule appeared to have changed
into an increase in sTCC with an increase in PLL, but the difference was not significant. The
apparent change in sTCC generation upon increasing PLL concentration between High G and
High M alginate, especially after 1 hour, suggested a change in interaction between alginate and
PLL depending on FG, as will be discussed further in section 4.4.5.
4.4 Cytokine secretion and CD11b expression
4.4.1 TAM beads vs APA capsules
TAM beads outperformed solid APA capsules in regard to the majority of cytokine responses,
in complement activation, and in CD11b expression. This was in concordance with comparisons
between TAM and APA performed before [20]. Lower levels of the chemokines IL-8, MCP-1 and
MIP-1α, lower levels of the inflammatory cytokines TNFα and IL-1β, lower levels of the growth
factors HGF and VEGF, and lower levels of the complement complex sTCC was observed. In
many cases the levels were at or below the saline negative control, suggesting activation from
the incubation vials themselves to be the major part of any increase compared to initial blood
values.
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4.4.2 Effect of a soluble core
Hollow APA capsules along with solid APA capsules were tested in the whole blood assay to
determine if there was any observable difference between the two types of capsules. As men-
tioned previously, the complement response showed significantly increased levels for hollow APA
capsules compared to solid APA capsules and TAM beads. For some cytokines, however, the
levels were significantly lower for APA capsules with a soluble core compared to APA capsules
of the same composition but with a solid core. The chemokines IL-8 and MIP-1α showed a
significantly lower response towards hollow APA capsules compared to solid APA capsules after
4 hours of incubation, as did the pro-inflammatory cytokines TNFα and IL-1β, the growth factor
VEGF, and the cytokine MIF. The cytokine IP-10 showed a significantly higher response to-
wards hollow APA capsules. All these responses indicated a lower degree of immune stimulation
for capsules with hollow inner cores. Interestingly however, the chemokine MCP-1 for hollow
capsules showed increased levels compared to solid capsules, reflecting the activating potential
seen for sTCC. As mentioned before, increased MCP-1 and sTCC levels have been observed
previously for hollow PMCG capsules [76, 20]. C3 inhibition with compstatin proved MCP-1 to
be dependent on complement activation as levels decreased when compstatin was added [76].
If sTCC has been produced, then the anaphylatoxins C3a and C5a will also have been pro-
duced as these are split products in the complement cascade. C3a and C5a have been shown
to induce NFkB activation in human peripheral blood monocytes [88], and to up-regulate IL-8,
IL-1β and RANTES mRNA in human umbilical vein endothelial cells [89]. It is therefore
reasonable to assume that the increased sTCC for APA solid capsules compared to TAM beads
and saline controls are linked to the increased cytokine secretion seen for these capsules, through
the anaphylatoxins C3a and C5a. This has also been confirmed through the addition of comp-
statin which lowered the secretion of many cytokines [76] in a recent, as yet unpublished, study.
When it is in this study observed a strong sTCC response for hollow APA capsules, but then
diminished cytokine secretion except for MCP-1 as compared to solid APA capsules, it could be
proposed that the complement cascade split products C3a and C5a perhaps adsorb to these cap-
sules to a greater degree than for solid APA capsules, thereby preventing C3a and C5a to reach
the cells. This has also been seen for hollow PMCG capsules where C3a and C5a levels were
significantly lower than the saline control [20]. Thus, the complement cascade is activated, but
by sequestering the anaphylatoxins C3a and C5a further instigation of inflammatory responses
might be prevented.
4.4.3 PLL vs PLO
For the discussion of polycation type, no significant change in levels of the chemokines IL-8,
MIP-1α, and MCP-1, nor in levels of the inflammatory cytokines TNFα and IL-6, the anti-
inflammatory cytokines IL-1RA and IL-10, or the growth factors PDGF, HGF, and VEGF was
observed by exchanging PLL with PLO. No change was detected in MIF, IFN-γ, or RANTES
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levels either. A change was observed for sTCC as the levels of sTCC for hollow APA with PLO
were about the same as for solid APA, while levels of sTCC for hollow APA with PLL were
much higher. This could indicate that, as discussed earlier, the PLO polycation might have
reduced the permeability of the capsules, preventing the diffusion of soluble molecules out of
the capsule. Or that only the PLL-alginate complex, and not the PLO-alginate complex, was
capable of triggering the sTCC response observed.
Also, a lower response was seen in IP-10, while a higher response was seen in IL-1β, for
capsules with PLO compared to PLL. The chemokine IP-10 is interesting in that increased
IP-10 secretion has recently been shown to be affected by iC3b and C4b. By inhibiting IFN-β,
iC3b and C4b inversely inhibit IP-10 secretion [90]. As the alternative pathway was previously
found to be involved in the complement response towards activating alginate microcapsules
[20], this would suggest iC3b to be the most likely cause for the detected lower values of IP-
10 for APA solid capsules compared to TAM. In some cases IP-10 values for APA solid were
even lower than the saline control. This had also been seen in a previous, as yet unpublished
study [76]. The detected lower values of IP-10 for PLO compared to PLL would thus also
suggest increased iC3b levels. Increased iC3b, the ligand for the receptor CD11b, could not be
reflected in increased expression of CD11b. CD11b is shown to be up-regulated by C5a [86], and
should thus be linked with complement activation. This could suggest that PLO stimulates the
initiation of the complement cascade, but that the cascade then stops before the generation of
the C5 convertase producing C5a. However, CD11b data are from 1 hour incubation while IP-10
data are from 4 hours, and might therefore not be completely comparable. To sum up, from the
findings in this work, no improvement in biocompatibility can be observed by exchanging PLO
with PLL. PLO capsules have been used in implantation experiments before, but have given no
significantly better results than experiments with PLL [91, 92].
4.4.4 Effect of PLL concentration
PLL has been reported to trigger sTCC generation, as well as activation of leukocytes in whole
blood [20]. In this work, an increase in PLL concentration was seen to affect mainly the sTCC
response. For some capsules there was also a significant change in the chemokines IL-8, MCP-1,
IP-10, the inflammatory cytokines IL-1β, TNFα, the anti-inflammatory cytokines IL-1RA, IL-
10, and the growth factor VEGF levels. For High M capsules, an increase in PLL from 0.05 %
to 0.10 % gave an increase in IL-1β and TNFα levels, as well as lower levels of IP-10. As dis-
cussed above, IP-10 has been shown to be inhibited by iC3b and C4b, and lower levels of IP-10
would suggest higher complement activation which could then result in activation of monocytes
increasing the secretion of the inflammatory molecules IL-1β and TNFα. IL-8 levels were also
higher for the 0.10 % capsules, again pointing towards increased complement activation. Higher
sTCC levels after 4 hours of incubation were observed for increasing PLL in this capsule type,
however, the increase was not significant (P<0.05). Furthermore, APA capsules with High G
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not only showed higher sTCC levels with increasing PLL. An increase in MCP-1, as well as a
decrease in IP-10, and a decrease in the anti-inflammatory molecules IL-1RA and IL-10 was also
seen. This all leans towards an increased inflammatory response for High G alginate capsules
with increasing PLL concentration.
There is however a structural benefit to having a higher concentration of polycation. This
was seen when making the hollow APA capsules. Capsules with 0.05 % PLL were first made,
but when treating these capsules with citrate the number of burst and deformed capsules was
too high to be able to test them in the whole blood assay. When increasing the concentration
to 0.10 % PLL, the number of burst capsules went considerably down, but was still higher than
when using 0.14 % PLL hollow capsules.
4.4.5 Effect of alginate composition
A difference could be seen in 0.05 % PLL APA capsules with High M (M. pyr) versus High G
(UP-LVG) alginate, in IL-8 levels, in TCC levels, in IP-10 levels, and in RANTES. An increase
in IL-8 was seen for the High G capsule compared to the High M capsules, while a decrease was
seen for the same capsule in TCC. An increase was seen in RANTES levels towards High G al-
ginate, while a decrease was seen in IP-10 levels. As discussed earlier, IP-10 levels have recently
been showed to correlate with iC3b and C4b generation [90]. This might suggest an increase
in complement activation with High G alginate, however, this was not reflected in sTCC which
decreased for High G alginate. Perhaps the complement cascade was initiated but then stopped
before the final TCC molecule was generated. No difference in cytokine levels was observed for
High M versus High G alginate in 0.10 % PLL APA capsules in this work.
As mentioned in section 4.3, there was a clear change in sTCC generation upon increasing
PLL concentration between High G and High M alginate. For High M capsules, after 1 hour
incubation, the sTCC response went down when increasing the PLL concentration. For High G
capsules, after both 1 hour and 4 hours incubation, the sTCC response went up when increas-
ing the PLL concentration. This suggested a change in interaction between alginate and PLL
depending on FG. As FG > 0.6 alginate has been reported to bind PLL to a lesser extent than
alginate with a lower FG [21], perhaps switching to High G alginate allows more unbound PLL
to leak out of the capsule and thereby result in a higher sTCC formation with higher capsule
PLL concentration. This might also be the reason why we see a higher IL-8 response for High
G compared to High M in the 0.05 % PLL capsule. High G alginates with FG> 0.6 in APA
capsules have been observed to perform worse than intermediate G alginates (FG = 0.4-0.6) [21].
PLL binds to alginate by forming complexes with M-G sequences on the surface of the alginate
beads [93]. Alginates with a lower fraction of M-G sequences might therefore bind insufficiently
to the PLL layer, allowing uncomplexed PLL to leave the capsule and promote inflammation
and over-growth [94, 95]. It might therefore be suggested that the increase in sTCC seen for
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High G compared to High M capsules when increasing the PLL concentration is due to lower
binding of PLL for High G alginate. And that the same effect could explain why we observe
higher IL-8 levels, higher RANTES levels, and lower IP-10 levels for High G compared to High
M alginate 0.05 % PLL capsules. That these increased levels are a consequence of insufficient
binding, or complexing, to PLL, allowing some PLL to leak out of the capsule triggering the
cytokine responses. However, we did observe lower levels of sTCC for the High G capsule com-
pared to the High M capsule.
The lower levels of TCC for High G compared to High M in the 0.05 % PLL capsule might
be linked with the overall shape and surface of the capsules as it was observed a higher capsule
diameter for the High M capsule compared to the High G capsule. The size of the capsule and
degree of swelling might be of importance as the swelling results in weaker and more permeable
capsules that are more likely to break apart with time [96]. When increasing the PLL concen-
tration to 0.10 % on APA capsules in this work, the difference in capsule diameter decreased
probably due to the increase in the stabilizing polycation, and a significant difference between
the two alginates was not observed in any cytokine, and only observed in TCC after 1 hour.
Thus, increasing the PLL to 0.10 % removed all significant difference in cytokine and comple-
ment response levels between High M and High G capsules, when incubated for 4 hours. It
might therefore also be proposed that the observed difference in complement response towards
APA capsules with High M or High G alginate stems from the stabilizing effects of the High G
alginate, and not from any increased immunogenicity of High M alginate. To be able to test
this in a more thorough way, a soluble alginate assay should be performed, incubating soluble
High M and High G alginate in different concentrations in whole blood.
To sum up, the results are very complex with many different factors involved and do not
appear to point in one direction. More experiments would have to be performed to further deduce
the individual contributions to the inflammatory potential of the PLL binding properties of the
alginate, and its stabilizing effects.
4.4.6 Effect of capsule size
No difference in complement, cytokine, or CD11b response levels was seen with varying capsule
diameter on TAM beads. A difference was seen for some APA capsules with varying diameter,
but, as these capsules tended to swell more after preparation, it was harder to get a controlled
comparison of their diameter, as can be seen from table 3.1. Significant differences in some of
the cytokine levels here might be attributed to donor variations, which were quite big in some
cases, especially for IL-8 values. It could also be that an increase in size for the APA capsules
might have resulted in more adsorbed PLL on their surface which consequently might trigger a
higher inflammatory response.
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4.4.7 Effect of HEPES
The addition of HEPES in the gelling solution did not appear to affect the inflammatory poten-
tial of the capsules in regard to complement activation, cytokine secretion, or CD11b expression.
4.5 Cytokine response to TAM beads
As for the different TAM beads, the results only included data from two blood donors and
any significant differences could not be concluded. The responses were in almost all cases at
or slightly below the saline negative control, indicating that any increase in cytokine levels
stemmed from the activating potential of the incubation vials themselves. It did, however, look
like there was an increase in cytokine responses towards beads being gelled without BaCl2. This
might have been because of lower stability [80] resulting in a rougher bead surface and increased
swelling, something that was also reflected in a slightly higher diameter for these beads. Another
explanation might be that as barium further stabilizes the alginate gel, residual contaminants
present in the alginate might to a greater extent leak out of the beads in the absence of barium.
Residual contaminants such as proteins, endotoxins, and fucoidans, have been proven present
even after purification, and might contribute to immunogenicity as well as altered functional
properties of the alginate [97]. It did in any case not look like the presence of barium stimulated
cytokine secretion. There also appeared to be quite good results for the TAM4 beads which
contained the new type of High G alginate, as cytokine levels were in almost all cases slightly
lower than beads with High M alginate. However, it is quite possible that as the response
levels for the TAM beads were very low, any differences seen could solely be the result of assay
variations or irregularities when preparing the beads.
4.6 Protein adsorption on alginate microcapsules
No differences could be observed in surface deposition of the proteins screened for in this work
between plasma and whole blood. In addition, CaCl2 treatment of capsules did not appear
to affect fibrinogen adsorption. CaCl2 treatment prevents the depletion of Ca2+ ions inside
the capsule, and limits the ongoing dissolution of the polymer network. TAM beads appeared
exceedingly inert when it came to deposition of proteins on the surface of the beads. After 6
hours incubation in whole blood and in plasma no complement C3 was found, indicating no
initiation of the complement cascade. No fibrinogen or HMW kininogen was observed, which
are proteins frequently seen to observe to biomaterials and might play a role in cell adhesion
[24, 98]. Alongside this, no inhibitory protein (factor H, vitronectin, factor I, C1 inhibitor)
adsorption was seen on TAM beads either. It was debated whether the observed TAM cytokine
levels, which were often lower than the saline control, could be the result of regulatory proteins
such as factor H binding to the bead surface and preventing the onset of the complement cas-
cade. Lower than saline levels had previously also been observed for complement components
in response to TAM beads [20]. This could not be supported by the protein adsorption findings
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in this work. Instead, it was the APA capsules that displayed the greatest inhibitory effects as
could be seen from heavy factor H and vitronectin adsorption. APA capsules also showed C3
surface adsorption. It might therefore be that the C3 presence in itself attracts the soluble reg-
ulatory proteins factor H and vitronectin, and that they are merely a side effect of the increased
complement activity that is seen.
It was observed a slight increase in protein adsorption on TAM beads when letting the capsules
incubate overnight. It would therefore have been interesting to allow capsules incubate over even
longer periods of time before analyzing the protein deposition, as the capsules are supposed to
stay inside the peritoneal cavity over much longer time than has been tested here, and protein
adsorption might build up and contribute to the observed over-growth seen when explanting
capsules in animal studies. The fact that the alginate polymer is negatively charged might
affect the protein adsorption. Many of the proteins involved in initiation of the coagulation
cascade are observed to bind to negatively charged surfaces [28, 99], and might be a reason
for the increase over time of protein deposition seen here. For the APA capsules, the outer
alginate layer is bound to the polycation layer, and this binding might result in neutralization
of the negative charges, which might be why no increase over time is observed for the APA
capsules. An increase in protein deposition on the capsule surface might allow cells to attach
to the capsules and trigger inflammatory responses that lead to increased fibrosis, and thereby
limit diffusion of nutrients and cell products across the capsule surface. Plasminogen adsorption
on TAM surfaces was the protein that showed the most attachment when letting the capsules
incubate overnight. Plasminogen is a protein involved in hemostasis as it, when cleaved into
activated plasmin, is able to cleave cross-linked fibrin and break up any unwanted blood clots.
4.7 Coagulation and the effect of lepirudin
In order to minimize activation of the immune system from the vials itself, we used low activating
polypropylene tubes. These are still somewhat activating as could be seen from the saline nega-
tive control used as a baseline for showing increased cytokine secretion, complement triggering,
and leukocyte activation. Coagulation when the whole blood was incubated in polypropylene
vials was prevented by addition of the anti-coagulant lepirudin. Lepirudin is a recombinant
hirudin analog derived from yeast cells, and is a direct thrombin inhibitor. As it only binds
thrombin, it should therefore not affect the complement cascade. It does, however, affect the
coagulation cascade and might interfere with the deposit of fibrinogen/fibrin on the capsules as
thrombin is upstream of fibrinogen in the coagulation cascade.
No effect of lepirudin could be seen on fibrinogen, vitronectin, and HMWK adsorption on
capsules, with a decreasing concentration of lepirudin. For the lepirudin negative vial however,
the blood started coagulating when incubated with capsules. It might therefore show a false
picture of coagulation protein deposits as a lot of proteins will become cross-linked in the blood
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clot, and thus might not bind to the capsule. An experiment should therefore be performed
using another way of preventing coagulation in the test vials, for instance by coating the vials
with heparin. This would prevent coagulation without the addition of lepirudin, but might also
affect the complement cascade, as heparin is reported to recruit factor H as well as exerting a
broad binding specificity for plasma proteins and activating various cells in the blood [100].
4.8 Comparisons to in vivo biocompatibility studies
The inflammatory potential observed for the different beads and capsules tested in this work,
corresponds to some extent to what has been seen in in vivo studies previously. For instance, a
marked decrease in chemokine, inflammatory cytokine, and sTCC responses was seen for TAM
beads compared to APA capsules. This might be one reason why APA capsules repeatedly
have shown a higher fibroblast over-growth than TAM beads in rodent models [57, 79, 95, 101].
Nevertheless, some researchers still think the addition of a permselective polycation layer such
as PLL is required in larger animals to prevent the entrance of cytokines, Ig and complement
[96]. In 2009, an attempt to implant human islet cells encapsulated in barium alginate capsules
was made [61]. Prolonged detection of C-peptide (used as an indicator of insulin production)
was evident in only one of four patients. The result after 16 months was capsules surrounded
by fibrous tissue, and which contained necrotic islet cells. Over-growth has also been observed
on TAM beads to a greater extent than on PMCG capsules in a recent, as yet unpublished,
study in cynomolgus monkeys [76], suggesting that the alginate bead design is at present not
sufficiently optimized. Because it performs so well in the whole blood model, it might indicate
that the presence of encapsulated cells plays a major role by, for instance, secreting proteins
which might stimulate an immune response leading to increased over-growth. In this aspect,
hollow APA capsules might be promising as they contain the permselective polycation layer,
but at the same time outperform solid APA capsules in the whole blood assay as seen in this
work. Hollow APA capsules with PLL did, however, elicit a greater sTCC and MCP-1 response.
Hollow APA capsules with PLO, which did not elicit the same response, could therefore be of
interest.
4.9 Future perspectives
The use of more complex and advanced coating layers, in an attempt to increase the stabil-
ity of the alginate capsule and make them more biocompatible, are constantly being pursued.
Whether it be the use of PLO instead of PLL in an attempt to decrease the immunogenisity of
the capsules, the use of stabilizing PMCG (poly-methylene-co-guanidine) complexed with cellu-
lose sulfate, or the introduction of biocompatible zwitterions in the coating layer of the capsule.
These are all very interesting ideas which could further our search toward fully biocompatible
alginate microcapsules. But as the procedure becomes more complex, with an increasing number
of capsule parameters, it will at the same time be increasingly difficult to analyze the results
gained from different labs. This has been one of the major obstacles when deciding what cap-
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sules to make, because slight differences in alginate composition, capsule size, gelling conditions,
and polycation, as well as different encapsulation procedures, makes it harder to compare the
insulin independence achieved by the different research groups. A standardized capsule protocol
should therefore be developed, in order to get the most out of the experiments performed, and
minimize the time until we actually do come up with a satisfactory alginate capsule capable of
curing Type 1 diabetes. This is why the TAM bead is so promising. It is simple to make, it is
biocompatible as tested in the in vitro whole blood assay, and it appears to be stable enough for
implantation into the peritoneal cavity. Further research into different alginate types should be
continued, in order to minimize over-growth which limits the diffusion of nutrients and insulin
in and out of the capsules.
Further studies could be performed with isolated monocytes to observe how they attach to
the capsule surface. Incubating different capsules with cells, and observing capsules daily over
a longer period of time, would tell us to what degree cells start attaching to the capsule surface.
If the cells develop into macrophages, we might observe “frustrated phagocytosis”, a process in
which the macrophages are not able to engulf the target capsule, and will release toxic chemicals
[27] capable of inducing inflammation and over-growth. By co-culturing the macrophages with
fibroblasts, over-growth could be studied with a higher level of precision. Cytokine expression
of biomaterial adherent macrophages in vivo has previously been found to be dependent on the
surface chemistry of the material [102]. Performing RT-PCR on macrophages incubated with
capsules would therefore show the cytokine expression profile of the cells, and how it might
change with different capsule parameters. Up-regulation of tissue factor on macrophages would
also be interesting to look for, as this might help trigger the extrinsic pathway of coagulation.
The protein adsorption assay performed here was an initial screening of proteins present in
the plasma that could possibly affect complement activation, coagulation cascade triggering,
and leukocyte attachment. As the proteins screened for were mostly zymogens, it would also
be possible to extend this screen to look for their activated counterparts, such as for instance
plasmin instead of plasminogen and fibrin instead of fibrinogen. Screening for further coagulation
components such as factor XIIa might also present interesting results.
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5 CONCLUSION
The present study has demonstrated the inflammatory potential of different parameters of al-
ginate microcapsules and microbeads in the whole blood assay. The results showed the following:
Polycation containing solid APA microcapsules triggered complement activation, increased
secretion of chemokines, inflammatory cytokines, and growth factors, as well as up-regulation
of CD11b expression on leukocytes.
TAM alginate microbeads did not incite any significant complement activation or cytokine
secretion. For almost all cytokines tested for, as well as the complement component sTCC, and
CD11b expression, responses towards TAM beads were at or slightly below the saline control,
indicating no activation beyond the auto-activation of the incubation vials themselves.
Hollow APA capsules with PLL triggered a rapid and strong sTCC response, as well as sig-
nificantly increased secretion of the chemokine MCP-1. At the same time, a significant decrease
in secretion of chemokines, cytokines, and growth factors pointed at a reduced inflammatory
potential of these capsules. It was suggested that either the detected sTCC was the result of an
assay mediated artifact, or that these capsules adsorbed the anaphylatoxins C3a and C5a, thus
preventing the complement mediated activation of leukocytes and the subsequent secretion of
cytokines.
No increased surface adsorption of C3 was detected for hollow APA capsules compared to
solid APA capsules. Instead, the C3 adsorption was higher on solid APA capsules, thus not
reflecting the increased sTCC generation seen for hollow APA capsules.
No apparent change in inflammatory potential could be observed by exchanging the polyca-
tion PLL with PLO, except for abolishing the strong sTCC response observed for hollow APA
capsules with PLL as well as lowering the MCP-1 response.
Increasing PLL concentration resulted in increased sTCC production for High G alginate
APA capsules. The same could not be observed for High M alginate capsules, however, the
chemokine IL-8 and the inflammatory cytokines IL-1β and TNFα increased with increasing PLL
concentration, suggesting increased inflammation with increasing PLL concentration.
No change in inflammatory potential could be detected with varying alginate microbead di-
ameter. Nor could any change in inflammatory potential be observed by the addition of HEPES
in the gelling solution.
TAM microbeads appeared exceedingly inert with regard to protein adsorption on the bead
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surface. No detectable protein deposition of the ones screened for after 6 hours of incubation in
plasma was observed. A slight increase in adsorption was detected (especially for plasminogen)
when incubating overnight. Solid APA capsules displayed heavy C3 deposition, as well as
vitronectin and factor H on the capsules surface, suggesting increased complement activity on
these capsules.
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A Materials and instruments
A list of materials and instruments are shown in tables A.1, A.2, and A.3 below.
Table A.1: List of the reagents used in the experiments
Reagent Producer Catalogue number Additional Information
UP-LVG Pronova, NovaMatrix, Batch: FP-603-04 FG=0.67, FGG=0.55,
Norway NG>1=12
UP-LVG* Pronova, NovaMatrix, Batch: BP-1108-01 FG=0.67, FGG=0.55,
Norway NG>1=12
UP-100M Pronova, NovaMatrix, Batch: FP-209-02 FG=0.44
Norway
Poly-L-Lysine Sigma-Aldrich Corp., P2658-1G DP(vis)=127, MW(vis)=20900,
Hydrochloride St. Louis, MO, USA DP(MALLS)=69,
MW(MALLS)=11400
Poly-L-Ornithine Sigma-Aldrich Corp., P-3530 DP(vis)=118, MW(vis)=2300
Hydrobromide St. Louis, MO, USA DP(LALLS)=102,
MW(LALLS)=19900
CaCl2, BaCl2, Merck, Darmstadt,
Na-citrate Germany
D-mannitol BDH Anala R., VWR HPLC degree
International Ltd, Pool,
England
LPS from E.coli Invivogen, San Diego, USA tlrl-pelps
strain 0111:B4
Zymosan Sigma-Aldrich Corp., St. Louis, Z4250
MO, USA
Phosphate-buffered Oxoid, Hampshire, BR0014G
saline, PBS England
Bovine serum Sigma-Aldrich Corp., A7030-50G
albumin, BSA St. Louis, MO, USA
Dulbecco’s Phosphate- Sigma-Aldrich Corp., D8537
Buffered Saline, DPBS St. Louis, MO, USA
Refludan (Lepirudin) Celgene Corporation, PZN-2480375
Summit, NJ, USA
EDTA, 510 mM 300410
Paraformaldehyde, Sigma-Aldrich Corp., St. Louis, P6148-1KG
PFA MO, USA
LDS-751 Life Technologies, New York, L7595
USA
Color reagent CD14 BD Biosciences, USA 345784
Color reagent CD11b BD Biosciences, USA 333142
EasyLyse Dako Cytomation, Glostrup, Erythrocyte lysis
Denmark buffer
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Table A.2: List of the reagents used in the experiments
Reagent Producer Catalogue number Additional Information
αC3c Ab Dako Cytomation, Glostrup, FO210 FITC labeled rabbit
Denmark anti-human C3c
αFibrinogen Ab Dako Cytomation, Glostrup, FO111 FITC labeled rabbit
Denmark anti-human fibrinogen
Neg. Control Dako Cytomation, Glostrup, FO261 FITC labeled rabbit
Denmark anti-mouse IgG
αFactorH The Binding Site Grout Ltd, PC030 Sheep anti-human factor H
Birmingham, UK
αFactor I The Binding Site Grout Ltd, PC031 Sheep anti-human factor I
Birmingham, UK
αPlasminogen The Binding Site Grout Ltd, PC065 Sheep anti-human
Birmingham, UK plasminogen
αVitronectin The Binding Site Grout Ltd, PC111 Sheep anti-human
Birmingham, UK vitronectin
αHMW Kininogen The Binding Site Grout Ltd, PC115 Sheep anti-human HMW
Birmingham, UK Kininogen
αFibrinogen The Binding Site Grout Ltd, PC056 Sheep anti-human
Birmingham, UK fibrinogen
αC1 inactivator The Binding Site Grout Ltd, PC019 Sheep anti-human C1-i
Birmingham, UK
Neg. Control Sigma-Aldrich Corp., St. Louis, I5131 Sheep IgG
MO, USA
2º Ab Sigma-Aldrich Corp., St. Louis, SAB4600134 CF 633 labeled donkey
MO, USA anti-sheep IgG
Human CXCL8/IL-8 DuoSet R&D Systems, USA DY208
ELISA kit
Human TNF-α DuoSet R&D Systems, USA DY210
ELISA kit
Tween20
TCC primary antibody, AntiBodyShop, Gentofte, DIA 011-01
anti-C5b-9 Denmark
Biotinylated Monoclonal Quidel, San Diego, A711
Anti-human USA
SC5b-9 (TCC secondary
antibody)
Streptavidin-PE BioLegend, San Diego, 405210
USA
Substrate reagent A R&D Systems, Minneapolis, DY999
USA
Substrate reagent B R&D Systems, Minneapolis, DY999
USA
1 M H2SO4 R&D Systems, Minneapolis, DY994
USA
Bio-plex kit (17-plex) Bio-Rad Laboratories, Inc., M50-0003IYV
Hercules, California, USA
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Table A.3: List of equipment used in the experiments
Equipment Producer Catalogue number
Centrifuge Kubota Corporation, Tokyo, Japan
Epics XL-MCL Flow cytometer Beckman Coulter, Inc., Brea, California, USA WS-EPICSXL
LSM 510 Meta Carl Zeiss, Jena, Germany
Confocal Microscope
Bio-Plex Pro Wash Station Bio-Rad Laboratories, Inc., 300-34376
Hercules, California, USA
Plate shaker Heidolph Instruments, Schwabach, Germany
Bio-Plex 200 System Bio-Rad Laboratories, Inc.,
Hercules, California, USA
DynaMag Spin Invitrogen, Carlsbad, California, USA 123.20D
Magnetic separator
1.8 mL Cryo tubes Nunc, Roskilde, Denmark 366656
24-well culture plates Nunc, Roskilde, Denmark 145387
96-well storage plates Nunc, Roskilde, Denmark
1.8 mL polypropylene tubes Nunc, Roskilde, Denmark 363401
Falcon flow tubes
ELISA plates R&D Systems, Minneapolis, USA DY990
ELISA Plate Sealers R&D Systems, Minneapolis, USA DY992
Bio-Rad Plate reader Bio-Rad Laboratories, Inc.,
Hercules, California, USA
Microplate Manager Bio-Rad Laboratories, Inc.,
Software, version 6.1 Hercules, California, USA
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B Individual donors
A comparison of IL-8 secretion, sTCC formation, and leukocyte CD11b expression for three
individual donors after 1 hour incubation in whole blood is shown in figure B.1. The comparison
shows the variation present in the IL-8 data, which makes it hard to detect any trends. The sTCC
data are much more stable. It appears like sTCC generation is strongest for hollow capsules
with PLL, with PLO hollow capsules showing a smaller response. CD11b expression reflect the
sTCC data to a certain degree. Interpreting the CD11b results may not be as straightforward,
as it could be that some capsules acitvated the cells but that the cells then attached to the
capsule surface, and were therefore not detected by the flow cytometer. Use of PLO in hollow
capsules appeared to affect the up-regulation of the receptor to a lesser extent than when using
PLL. In addition, the same decrease in up-regulation was seen when increasing the PLL content
from 0.05 % to 0.10 % in the high M capsules, a trend that was also seen in sTCC formation.
This effect was inverted when the alginate was changed to high G, where an increase in PLL
resulted in an increased sTCC generation, as well as increased CD11b up-regulation.
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C ELISA data
IL-8 and sTCC levels in plasma after incubating alginate microcapsules in whole blood for 1
and 4 hours are shown in tables C.1-C.4 below.
C.1 IL-8 1 h
Table C.1: IL-8 levels for 5 donors after 1 hour incubation in whole blood. Values are in pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 18.91 2.84 2.07 2.83 5.65
Saline 25.73 14.58 4.21 9.79 10.01
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 58.96 28.67 28.41 24.68 28.39
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 68.55 17.90 24.69 32.20 47.27
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 24.70 21.23 40.44 29.97 28.46
Solid, M. pyr, 0.05 % PLL, 0.4 mm 50.78 16.11 19.33 22.60 37.69
Solid, M. pyr, 0.10 % PLL, 0.4 mm 100.16 23.12 48.63 17.66 24.93
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 45.26 36.97 44.50 26.81 37.56
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 86.70 31.09 97.05 82.81 41.50
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 18.23 68.02 17.81 25.71 19.92
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 22.72 23.43 17.60 74.62 39.43
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 24.30 17.78 19.33 42.34 30.27
No Hepes
TAM, UP-LVG, 0.25 mm - 9.72 8.86 9.31 20.69
TAM, UP-LVG, 0.35 mm 10.57 11.71 7.94 11.81 23.66
TAM, UP-LVG, 0.40 mm - 8.06 13.37 10.98 17.84
Zymosan 229.28 459.83 236.57 354.70 468.72
LPS 383.06 83.98 120.65 186.44 155.64
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C.2 IL-8 4 h
Table C.2: IL-8 levels for 5 donors after 4 hour incubation in whole blood. Values are in pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 1.39 2.64 8.67 3.25 4.47
Saline 690.61 294.87 352.98 257.3 155.13
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 1189.7 944.09 1208.51 403.59 1478.59
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 1148.1 2467.1 1080.83 362.37 1100.26
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 1869.15 185.69 868.57 659.84 977.29
Solid, M. pyr, 0.05 % PLL, 0.4 mm 3851.47 4304.11 1557.54 686.93 2168.65
Solid, M. pyr, 0.10 % PLL, 0.4 mm 5367.82 6879.56 2171.52 2790.91 4792.96
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 6598.7 6802 2007.47 3117.16 2375.64
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 10065.59 5344.2 1597.2 3260.5 2725.64
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 6216.19 3453.91 1176.64 419.15 2221.74
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5335.63 4023.72 1225.66 1976.23 2917.54
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 3951.62 6128.61 753.95 741.17 2888.94
No Hepes
TAM, UP-LVG, 0.25 mm - 127.87 160.79 295.5 171.86
TAM, UP-LVG, 0.35 mm 116.11 165.28 135.55 294.24 145.91
TAM, UP-LVG, 0.40 mm - 208.42 93.31 266.02 377.67
Zymosan 9595.97 12191.85 8063.48 4852 11370.28
C.3 sTCC 1 h
Table C.3: sTCC levels for 5 donors after 1 hour incubation in whole blood. Values are in
pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 0.16 0.39 0.46 0.18 0.42
Saline 3.04 2.81 1.19 3.43 1.17
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 35.91 46.41 61.98 119.19 51.67
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 33.50 31.62 57.23 92.08 50.01
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 16.83 9.06 13.53 26.85 11.03
Solid, M. pyr, 0.05 % PLL, 0.4 mm 16.30 3.40 10.03 18.99 6.09
Solid, M. pyr, 0.10 % PLL, 0.4 mm 7.16 2.70 2.19 4.56 3.06
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 2.98 2.51 3.12 3.76 2.26
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 7.41 3.44 12.20 25.36 9.41
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 3.53 3.28 10.08 23.38 2.25
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 6.86 7.53 12.04 35.67 9.41
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5.01 3.54 11.98 25.42 1.54
No Hepes
TAM, UP-LVG, 0.25 mm 1.81 1.14 1.21 0.88
TAM, UP-LVG, 0.35 mm 2.80 1.60 1.41 2.11 0.80
TAM, UP-LVG, 0.40 mm 1.79 0.93 1.57 1.23
Zymosan 54.47 63.72 75.30 147.85 71.39
LSP 6.53 2.43 3.55 7.01 2.00
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C.4 sTCC 4 h
Table C.4: sTCC levels for 5 donors after 4 hour incubation in whole blood. Values are in
pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 0.46 0.39 0.41 0.61 0.24
Saline 31.36 14.08 11.04 23.47 6.30
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 65.19 224.98 170.40 163.98 111.70
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 59.98 152.65 161.39 163.88 105.97
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 38.70 35.50 32.64 72.03 35.78
Solid, M. pyr, 0.05 % PLL, 0.4 mm 37.81 47.57 81.10 82.01 38.62
Solid, M. pyr, 0.10 % PLL, 0.4 mm 33.78 73.48 127.77 92.94 50.29
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 19.57 13.34 45.06 22.06 7.20
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 29.58 86.13 72.31 65.59 53.09
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 20.29 36.00 66.32 52.69 20.80
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 29.28 118.86 96.97 122.94 42.59
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 20.09 32.75 94.39 106.36 14.63
No Hepes
TAM, UP-LVG, 0.25 mm 3.30 3.18 14.11 4.62
TAM, UP-LVG, 0.35 mm 8.53 2.96 4.30 12.37 4.47
TAM, UP-LVG, 0.40 mm 3.18 3.70 15.06 3.74
Zymosan 134.51 128.22 116.78 193.61 149.99
LPS 40.73 9.80 10.41 22.38 6.36
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D Bio-plex data
Cytokine levels in plasma after incubating alginate microcapsules in whole blood for 4 hours are
shown in tables D.1-D.28 below.
D.1 MIP-1α
Table D.1: MIP-1α levels for 5 donors. Values are in pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 2.84 1.72 4.99 1.36 2.04
Saline 32.68 43.08 76.11 30.3 31.81
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 76.23 21.34 46.64 32.51 131.08
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 78.09 134.57 79.90 32.96 139.63
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 91.56 34.95 74.40 65.14 95.26
Solid, M. pyr, 0.05 % PLL, 0.4 mm 439.32 722.80 231.34 121.22 239.48
Solid, M. pyr, 0.10 % PLL, 0.4 mm 611.82 365.44 345.18 330.94 558.93
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 551.19 410.65 369.65 384.09 493.94
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 1332.41 341.76 123.80 374.21 247.56
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 532.37 483.59 161.19 67.91 444.59
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 635.24 372.72 167.12 207.29 305.89
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 339.16 819.67 153.68 94.2 509.65
No Hepes
TAM, UP-LVG, 0.25 mm - 35.09 60.68 84.13 76.29
TAM, UP-LVG, 0.35 mm 33.37 31.22 47.16 79.96 60.18
TAM, UP-LVG, 0.40 mm - 49.84 43.34 80.14 124.39
Zymosan 3310.35 2995.8 1841.37 3107.1 3677.83
Table D.2: MIP-1α levels for 2 donors. Values are in pg/ml. * = value extrapolated beyond
standard range
Sample Donor 1 Donor 2
T0 1.93 *0.29
Saline 234.3 120.06
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 381.29 242.34
Solid, M. pyr, 0.05 % PLL, 0.4 mm 386.36 133.51
TAM, UP-LVG, 0.4 mm, No BaCl2 168.32 101.36
TAM, UP-LVG, 0.4 mm 147.81 76.98
TAM, M. pyr, 0.4 mm 179.65 106.5
TAM4, UP-LVG*, 0.4 mm 140.89 73.28
TAM, UP-LVG, 0.35 mm, No BaCl2 263.93 140.89
TAM, UP-LVG, 0.35 mm 179.07 44.28
TAM, M. pyr, 0.35 mm 151.96 95.63
TAM4, UP-LVG*, 0.35 mm 107.88 58.45
Zymosan 2426.92 2660.28
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D.2 MCP-1
Table D.3: MCP-1 levels for 5 donors. Values are in pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 66.29 69.08 49.61 63.26 94.58
Saline 151.19 114.74 73.27 86.65 81.72
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 479.36 538.99 195.77 124.54 369.72
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 460.32 586.26 200.39 142.37 415.07
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 384.25 123.07 95.56 132.92 227.94
Solid, M. pyr, 0.05 % PLL, 0.4 mm 347.53 355.1 146.25 115.94 253.77
Solid, M. pyr, 0.10 % PLL, 0.4 mm 171.48 202.87 144.18 115.64 238.41
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 221.57 386.48 155.67 120.71 218.06
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 163.44 384.78 132.63 140.13 248.75
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 199.39 334.26 128.32 109.88 243.24
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 275.28 488.29 138.59 165.03 349.26
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 286.83 451.04 110.33 110.49 217.82
No Hepes
TAM, UP-LVG, 0.25 mm 138.31 70.37 87.15 99.25
TAM, UP-LVG, 0.35 mm 95.56 150.37 68.16 82.92 93.12
TAM, UP-LVG, 0.40 mm 162.37 68.34 86.48 114.74
Zymosan 328.36 284.91 114.74 111.4 307.64
Table D.4: MCP-1 levels for 2 donors. Values are in pg/ml.
Sample Donor 1 Donor 2
T0 64.22 62.18
Saline 132.7 92.96
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 207.24 198.12
Solid, M. pyr, 0.05 % PLL, 0.4 mm 189.07 149.86
TAM, UP-LVG, 0.4 mm, No BaCl2 121.28 107.4
TAM, UP-LVG, 0.4 mm 104.83 85.21
TAM, M. pyr, 0.4 mm 116.99 90.56
TAM4, UP-LVG*, 0.4 mm 80.95 73.12
TAM, UP-LVG, 0.35 mm, No BaCl2 120.43 102.23
TAM, UP-LVG, 0.35 mm 83.52 71.73
TAM, M. pyr, 0.35 mm 85.84 82.88
TAM4, UP-LVG*, 0.35 mm 64.22 67.68
Zymosan 118.89 178.84
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D.3 MIF
Table D.5: MIF levels for 5 donors. Values are in pg/ml. OOR < = out of range below.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 164.66 1874.77 3837.06 OOR < 251.87
Saline 1855.48 2733.36 1191.63 1971.11 1903.7
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 3818.51 3781.41 2229.94 1280.48 649.33
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 13644.98 22329.12 4133.11 1681.27 771.5
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5742.49 10670.44 9387.1 9563.45 463.54
Solid, M. pyr, 0.05 % PLL, 0.4 mm 22110.45 15864.78 1642.42 9774.83 505.14
Solid, M. pyr, 0.10 % PLL, 0.4 mm 17496.93 16634.96 3985.24 21099.63 1496.29
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 16771.67 22942.45 7040.35 13817.74 4620.9
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 13212.55 11378.68 8706.4 10267.07 1720.06
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 13056.69 9545.82 5197.06 5651.79 690.18
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 12014.88 21672.75 2258.59 4031.48 2115.12
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 12397.44 19933.86 2865.44 3632.79 3632.79
No Hepes
TAM, UP-LVG, 0.25 mm 16540.93 10468.86 23806.31 1865.13
TAM, UP-LVG, 0.35 mm 3837.06 12883.38 14007.63 1632.7 1211.41
TAM, UP-LVG, 0.40 mm 13549.91 6789.11 2105.53 2657.73
Zymosan 7568.15 14050.77 1894.06 4831.68 3911.19
Table D.6: MIF levels for 2 donors. Values are in pg/ml.
Sample Donor 1 Donor 2
T0 4288.47 2444.65
Saline 8234.98 19980.84
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 13983.94 15591.76
Solid, M. pyr, 0.05 % PLL, 0.4 mm 12979.37 22536.01
TAM, UP-LVG, 0.4 mm, No BaCl2 3443.43 23459.69
TAM, UP-LVG, 0.4 mm 9336.49 12374.79
TAM, M. pyr, 0.4 mm 8024.07 17634.54
TAM4, UP-LVG*, 0.4 mm 7057.96 11684.01
TAM, UP-LVG, 0.35 mm, No BaCl2 9962.69 12643.37
TAM, UP-LVG, 0.35 mm 7383.26 14354.15
TAM, M. pyr, 0.35 mm 4476.9 12313.95
TAM4, UP-LVG*, 0.35 mm 7304.71 9604.72
Zymosan 6889 19193.25
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D.4 IP-10
Table D.7: IP-10 levels for 5 donors. Values are in pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 198.57 68.26 211.34 171.61 120.89
Saline 408.76 232.37 501.94 273.53 185.35
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 1241.47 586.79 772.2 474.97 293.08
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 505.13 343.02 392.35 319.56 228.93
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 412.82 395.1 515.28 386.14 205.91
Solid, M. pyr, 0.05 % PLL, 0.4 mm 519.7 520.33 593.51 247.55 155.1
Solid, M. pyr, 0.10 % PLL, 0.4 mm 154.04 78.7 318.07 165.53 75.34
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 202.26 184.39 331.37 157.22 98.5
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 102.68 255.8 404.68 157.22 99.9
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 218.46 520.96 1076.95 318.07 146.46
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 207.73 305.31 311.34 259.88 115.88
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 325.49 849.45 422.93 260.69 120.89
No Hepes
TAM, UP-LVG, 0.25 mm 1424.81 698.47 237.48 172.61
TAM, UP-LVG, 0.35 mm 380.59 2639.3 522.22 175.59 144.25
TAM, UP-LVG, 0.40 mm 1080.32 683.08 198.57 163.47
Zymosan 1646.18 926.97 1458.41 1071.34 1001.61
Table D.8: IP-10 levels for 2 donors. Values are in pg/ml.
Sample Donor 1 Donor 2
T0 308.77 105.08
Saline 320.65 279.62
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 352.71 130.29
Solid, M. pyr, 0.05 % PLL, 0.4 mm 380.32 276.73
TAM, UP-LVG, 0.4 mm, No BaCl2 402.25 440.14
TAM, UP-LVG, 0.4 mm 327.88 269.94
TAM, M. pyr, 0.4 mm 335.04 313.36
TAM4, UP-LVG*, 0.4 mm 291.05 155.18
TAM, UP-LVG, 0.35 mm, No BaCl2 347.44 519.45
TAM, UP-LVG, 0.35 mm 724.9 325.17
TAM, M. pyr, 0.35 mm 418.86 307.84
TAM4, UP-LVG*, 0.35 mm 275.77 267.99
Zymosan 480.25 1384.57
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D.5 IL-1β
Table D.9: IL-1β levels for 5 donors. Values are in pg/ml. OOR < = out of range below. * =
value extrapolated beyond standard range
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 OOR < *0.32 1.18 *0.14 1.01
Saline 2.5 5.55 6.49 2.5 1.84
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 1.68 2.66 2.99 1.68 4.99
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 2.66 14.56 4.99 1.51 4.75
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 2.42 4.59 5.07 6.57 7.75
Solid, M. pyr, 0.05 % PLL, 0.4 mm 7.28 57.39 6.18 11.48 6.97
Solid, M. pyr, 0.10 % PLL, 0.4 mm 45.99 58.89 11.33 78.34 12.41
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 44.04 47.87 24.31 79.32 12.87
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 85.64 21.13 9.31 48.99 7.91
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 30.96 27.64 6.65 2.17 13.02
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 11.33 28.39 4.59 23.55 10.63
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 20.29 59.42 5.23 5.23 44.19
No Hepes
TAM, UP-LVG, 0.25 mm 2.33 4.59 8.84 3.15
TAM, UP-LVG, 0.35 mm 2.42 3.63 3.79 5.31 1.68
TAM, UP-LVG, 0.40 mm 6.18 3.15 6.49 6.81
Zymosan 2612.78 1453.3 1050.04 2223.46 2461.21
Table D.10: IL-1β levels for 2 donors. Values are in pg/ml. OOR < = out of range below.
Sample Donor 1 Donor 2
T0 OOR < OOR <
Saline 17.11 12.88
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 15.57 19.57
Solid, M. pyr, 0.05 % PLL, 0.4 mm 11.96 16.05
TAM, UP-LVG, 0.4 mm, No BaCl2 8.98 10.07
TAM, UP-LVG, 0.4 mm 7.06 8.2
TAM, M. pyr, 0.4 mm 11.96 11.75
TAM4, UP-LVG*, 0.4 mm 4.49 8.09
TAM, UP-LVG, 0.35 mm, No BaCl2 10.71 8.76
TAM, UP-LVG, 0.35 mm 6.35 6.71
TAM, M. pyr, 0.35 mm 5.75 8.31
TAM4, UP-LVG*, 0.35 mm 3.42 3.7
Zymosan 4315.38 1172.97
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D.6 TNF-α
Table D.11: TNF-αlevels for 5 donors. Values are in pg/ml. * = value extrapolated beyond
standard range
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 *0.72 *3.18 8.2 15.81 8.2
Saline 15.81 36.33 55.74 20.91 10.72
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 28.6 5.68 33.75 59.64 132.97
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 36.33 49.26 64.84 41.49 119.81
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 20.91 31.18 33.75 44.08 59.64
Solid, M. pyr, 0.05 % PLL, 0.4 mm 90.95 375.52 143.52 111.93 256.3
Solid, M. pyr, 0.10 % PLL, 0.4 mm 388.97 409.17 188.48 117.18 515.96
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 313.78 138.25 193.79 337.91 171.27
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 1686.57 183.18 62.24 308.42 257.64
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 383.59 265.64 125.08 33.75 375.52
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 287.01 162.01 83.1 256.3 273.65
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 167.3 244.31 109.3 127.71 366.1
No Hepes
TAM, UP-LVG, 0.25 mm 41.49 28.6 33.75 57.04
TAM, UP-LVG, 0.35 mm 10.72 38.91 28.6 88.33 62.24
TAM, UP-LVG, 0.40 mm 44.08 33.75 88.33 80.49
Zymosan 21741.64 8902.01 15655.88 6429.36 10888.81
Table D.12: TNF-α levels for 2 donors. Values are in pg/ml. OOR < = out of range below.
Sample Donor 1 Donor 2
T0 OOR < OOR <
Saline 124.63 50.49
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 366.32 245.35
Solid, M. pyr, 0.05 % PLL, 0.4 mm 264.28 105
TAM, UP-LVG, 0.4 mm, No BaCl2 133 85.16
TAM, UP-LVG, 0.4 mm 130.21 110.62
TAM, M. pyr, 0.4 mm 119.04 107.81
TAM4, UP-LVG*, 0.4 mm 72.28 41.62
TAM, UP-LVG, 0.35 mm, No BaCl2 166.21 164.84
TAM, UP-LVG, 0.35 mm 133 7.63
TAM, M. pyr, 0.35 mm 73.72 149.65
TAM4, UP-LVG*, 0.35 mm 120.44 92.27
Zymosan 31494.05 7362.18
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D.7 IL-6
Table D.13: IL-6 levels for 5 donors. Values are in pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 0.95 1.51 3.2 0.4 2.07
Saline 3.2 10.05 7.18 10.33 17.54
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 6.04 12.35 6.9 26.83 50.24
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 9.47 18.7 14.07 26.54 66.76
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 6.61 9.47 8.9 38.5 39.09
Solid, M. pyr, 0.05 % PLL, 0.4 mm 9.47 28.87 18.12 56.43 52.6
Solid, M. pyr, 0.10 % PLL, 0.4 mm 22.47 15.23 14.07 67.35 42.9
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 16.96 19.28 13.79 54.07 36.16
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 149.27 18.41 11.2 68.24 41.43
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 10.05 29.74 19.28 47.3 55.54
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 16.38 18.7 15.23 59.08 43.78
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 7.18 21.89 10.05 49.36 34.99
No Hepes
TAM, UP-LVG, 0.25 mm 11.77 7.18 22.18 22.18
TAM, UP-LVG, 0.35 mm 3.2 13.5 6.61 23.92 21.02
TAM, UP-LVG, 0.40 mm 19.86 5.47 24.5 32.07
Zymosan 11228.55 8895.68 5039.91 7068.08 13173.34
Table D.14: IL-6 levels for 2 donors. Values are in pg/ml. OOR < = out of range below.
Sample Donor 1 Donor 2
T0 1.28 1.28
Saline 24.73 28.79
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 44.14 26.36
Solid, M. pyr, 0.05 % PLL, 0.4 mm 44.52 42.2
TAM, UP-LVG, 0.4 mm, No BaCl2 51.78 41.43
TAM, UP-LVG, 0.4 mm 30.4 21.84
TAM, M. pyr, 0.4 mm 29.19 33.98
TAM4, UP-LVG*, 0.4 mm 31.6 23.08
TAM, UP-LVG, 0.35 mm, No BaCl2 39.48 26.36
TAM, UP-LVG, 0.35 mm 37.53 18.9
TAM, M. pyr, 0.35 mm 35.96 26.36
TAM4, UP-LVG*, 0.35 mm 26.36 15.48
Zymosan 19254.85 9975.65
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D.8 IL-1RA
Table D.15: IL-1RA levels for 5 donors. Values are in pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 38 114.35 467.88 38 153.03
Saline 289.87 1110.71 787.83 231 231
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 627.41 667.44 388.54 231 507.67
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 807.94 1272.96 507.67 270.21 309.55
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 428.17 1557.96 667.44 467.88 309.55
Solid, M. pyr, 0.05 % PLL, 0.4 mm 1070.22 2645.93 868.32 667.44 467.88
Solid, M. pyr, 0.10 % PLL, 0.4 mm 1741.78 2254.51 908.63 787.83 388.54
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 1232.35 2172.29 1232.35 828.05 547.52
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 1212.06 1967.03 747.65 587.44 507.67
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 1070.22 2460.35 627.41 507.67 667.44
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 828.05 2254.51 587.44 787.83 507.67
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 1110.71 3080.02 587.44 567.47 787.83
No Hepes
TAM, UP-LVG, 0.25 mm 908.63 1029.77 607.42 388.54
TAM, UP-LVG, 0.35 mm 329.26 1374.6 807.94 507.67 270.21
TAM, UP-LVG, 0.40 mm 1517.17 707.52 547.52 547.52
Zymosan 1232.35 3038.61 1191.77 667.44 868.32
Table D.16: IL-1RA levels for 2 donors. Values are in pg/ml. OOR < = out of range below.
Sample Donor 1 Donor 2
T0 91.35 15.86
Saline 593.7 710.36
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 1077.98 652.29
Solid, M. pyr, 0.05 % PLL, 0.4 mm 881.92 564.19
TAM, UP-LVG, 0.4 mm, No BaCl2 994.43 825.14
TAM, UP-LVG, 0.4 mm 767.97 767.97
TAM, M. pyr, 0.4 mm 825.14 767.97
TAM4, UP-LVG*, 0.4 mm 652.29 593.7
TAM, UP-LVG, 0.35 mm, No BaCl2 1105.69 825.14
TAM, UP-LVG, 0.35 mm 1105.69 825.14
TAM, M. pyr, 0.35 mm 994.43 652.29
TAM4, UP-LVG*, 0.35 mm 652.29 414.1
Zymosan 938.35 994.43
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D.9 IL-10
Table D.17: IL-10 levels for 5 donors. Values are in pg/ml. * = value extrapolated beyond
standard range
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 1.49 4.02 3.16 *1.22 2.03
Saline 2.17 5.79 2.87 *1.22 *1.22
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 4.31 7.14 2.45 *1.22 2.59
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 3.16 7.9 1.76 1.49 2.31
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 3.01 6.54 3.01 1.76 2.03
Solid, M. pyr, 0.05 % PLL, 0.4 mm 2.03 8.06 2.03 1.76 2.31
Solid, M. pyr, 0.10 % PLL, 0.4 mm 3.73 4.31 2.31 1.9 2.03
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 3.16 7.29 2.03 2.03 2.03
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 4.02 7.6 3.16 1.76 2.31
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 3.44 7.29 3.16 1.76 2.87
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 3.01 6.69 2.03 *1.22 2.59
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5.34 8.98 2.31 1.49 3.44
No Hepes
TAM, UP-LVG, 0.25 mm 6.23 2.73 1.49 2.31
TAM, UP-LVG, 0.35 mm 3.16 8.21 3.44 1.76 2.31
TAM, UP-LVG, 0.40 mm 8.83 2.59 *1.22 1.9
Zymosan 11.64 9.45 6.69 5.19 10.07
Table D.18: IL-10 levels for 2 donors. Values are in pg/ml. OOR < = out of range below.
Sample Donor 1 Donor 2
T0 0.9 0.39
Saline 1.36 0.9
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 1.36 0.9
Solid, M. pyr, 0.05 % PLL, 0.4 mm 1.79 1.79
TAM, UP-LVG, 0.4 mm, No BaCl2 1.36 1.36
TAM, UP-LVG, 0.4 mm 2.6 0.39
TAM, M. pyr, 0.4 mm 2.6 1.36
TAM4, UP-LVG*, 0.4 mm 0.9 0.39
TAM, UP-LVG, 0.35 mm, No BaCl2 2 1.79
TAM, UP-LVG, 0.35 mm 1.79 1.36
TAM, M. pyr, 0.35 mm 3.38 1.36
TAM4, UP-LVG*, 0.35 mm 0.9 0.39
Zymosan 12.73 8.38
117
D.10 PDGF-BB
Table D.19: PDGF-BB levels for 5 donors. Values are in pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 11.47 105.19 1050.37 62.92 298.55
Saline 579.45 1101.31 983.02 245.01 374.76
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 676.96 770.08 618.6 432.79 389.98
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 555.61 1696.59 1226.42 492.73 277.54
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 487.02 1311.73 1172.11 710.51 337.63
Solid, M. pyr, 0.05 % PLL, 0.4 mm 741.23 2148.3 839.49 624.33 207.55
Solid, M. pyr, 0.10 % PLL, 0.4 mm 1339.6 1533.18 1586.77 595.68 355.72
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 1458.66 3194.42 1662.95 546.07 433.74
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 1343.59 1957.06 1674.16 553.7 382.37
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 1233.35 2021.58 1469.71 500.35 746.04
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 773.93 2428.51 1258.11 860.75 945.08
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 1098.37 3299.27 1214.56 490.83 357.63
No Hepes
TAM, UP-LVG, 0.25 mm 1291.85 1974.72 437.54 252.68
TAM, UP-LVG, 0.35 mm 977.18 2639.87 1027.89 296.64 166.95
TAM, UP-LVG, 0.40 mm 3654.76 1396.51 344.3 367.15
Zymosan 1011.29 2953.46 1313.72 1067.98 1048.41
Table D.20: PDGF-BB levels for 2 donors. Values are in pg/ml. OOR < = out of range below.
Sample Donor 1 Donor 2
T0 81.25 63.3
Saline 746.57 337.76
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 1519.6 767.58
Solid, M. pyr, 0.05 % PLL, 0.4 mm 1761.99 800.62
TAM, UP-LVG, 0.4 mm, No BaCl2 1070.14 659.59
TAM, UP-LVG, 0.4 mm 1197.84 317.49
TAM, M. pyr, 0.4 mm 1173.46 396.27
TAM4, UP-LVG*, 0.4 mm 1240.58 225.52
TAM, UP-LVG, 0.35 mm, No BaCl2 983.37 622.61
TAM, UP-LVG, 0.35 mm 2365.33 599.63
TAM, M. pyr, 0.35 mm 1736.87 480.6
TAM4, UP-LVG*, 0.35 mm 1047.91 144.05
Zymosan 1900.81 785.6
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D.11 HGF
Table D.21: HGF levels for 5 donors. Values are in pg/ml.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 66.59 210.08 167.76 34.56 89.24
Saline 686.53 833.95 734.93 345.18 378.29
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 1487.7 673.33 462.06 334.14 963.87
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 1005.74 1173.41 550.13 294.34 519.31
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 899.99 732.73 748.13 267.77 462.06
Solid, M. pyr, 0.05 % PLL, 0.4 mm 1712.2 2477.07 972.68 281.06 776.73
Solid, M. pyr, 0.10 % PLL, 0.4 mm 990.31 2346.17 1127.05 435.62 1104.98
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 1538.75 1779.06 886.78 387.12 919.81
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 1268.43 1917.47 796.54 320.88 906.6
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 1350.3 2163.93 825.14 274.42 1104.98
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 1264.01 2211.12 585.33 356.22 1023.37
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 1087.33 2542.65 708.53 294.34 1027.78
No Hepes
TAM, UP-LVG, 0.25 mm 530.32 86.98 66.59 289.92
TAM, UP-LVG, 0.35 mm 267.77 345.18 232.29 48.34 210.08
TAM, UP-LVG, 0.40 mm 391.53 102.77 93.76 241.17
Zymosan 1412.31 2029.36 1184.45 360.64 1241.9
Table D.22: HGF levels for 2 donors. Values are in pg/ml. OOR < = out of range below. * =
value extrapolated beyond standard range
Sample Donor 1 Donor 2
T0 OOR < OOR <
Saline 508.62 891.76
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 446.73 674.46
Solid, M. pyr, 0.05 % PLL, 0.4 mm 441 1098.18
TAM, UP-LVG, 0.4 mm, No BaCl2 497.51 648.38
TAM, UP-LVG, 0.4 mm 259.47 199.61
TAM, M. pyr, 0.4 mm 412.02 611.48
TAM4, UP-LVG*, 0.4 mm 131.87 136.21
TAM, UP-LVG, 0.35 mm, No BaCl2 321.23 807.14
TAM, UP-LVG, 0.35 mm 382.47 469.47
TAM, M. pyr, 0.35 mm 199.61 627.35
TAM4, UP-LVG*, 0.35 mm *89.42 295.74
Zymosan 346.11 913.93
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D.12 VEGF
Table D.23: VEGF levels for 5 donors. Values are in pg/ml. OOR < = out of range below. *
= value extrapolated beyond standard range
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 OOR < *1.11 21.66 OOR < OOR <
Saline 26.03 67.73 68.48 18.76 5.22
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 51.94 29.7 42.25 20.94 23.84
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 56.81 147.69 63.95 22.39 13.72
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 30.43 38.91 74.54 28.23 14.44
Solid, M. pyr, 0.05 % PLL, 0.4 mm 46.71 225.09 95.11 45.97 36.69
Solid, M. pyr, 0.10 % PLL, 0.4 mm 71.51 240.29 149.25 62.45 66.97
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 69.24 199.63 136.78 62.45 54.94
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 88.23 257.16 88.99 55.69 44.85
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 72.64 196.06 93.96 40.03 45.97
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 74.54 221.1 82.89 61.32 48.95
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 48.21 281.38 100.85 43.74 57.56
No Hepes
TAM, UP-LVG, 0.25 mm 48.21 35.96 44.48 16.23
TAM, UP-LVG, 0.35 mm 17.32 41.51 34.11 27.5 14.44
TAM, UP-LVG, 0.40 mm 72.26 41.51 37.43 27.13
Zymosan 18.76 129.79 73.02 30.43 22.39
Table D.24: VEGF levels for 2 donors. Values are in pg/ml. OOR < = out of range below. *
= value extrapolated beyond standard range
Sample Donor 1 Donor 2
T0 12.69 13.66
Saline 68.06 91.4
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 69.86 86.03
Solid, M. pyr, 0.05 % PLL, 0.4 mm 67.61 158.16
TAM, UP-LVG, 0.4 mm, No BaCl2 44.46 67.16
TAM, UP-LVG, 0.4 mm 56.3 56.3
TAM, M. pyr, 0.4 mm 54.94 61.28
TAM4, UP-LVG*, 0.4 mm 41.71 54.49
TAM, UP-LVG, 0.35 mm, No BaCl2 53.58 94.98
TAM, UP-LVG, 0.35 mm 56.3 36.2
TAM, M. pyr, 0.35 mm 32.96 64.9
TAM4, UP-LVG*, 0.35 mm 29.71 54.49
Zymosan 72.56 76.16
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D.13 IFN-γ
Table D.25: IFN-γ levels for 5 donors. Values are in pg/ml. OOR < = out of range below.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 OOR < 36.98 178.06 OOR < 196.48
Saline 93.83 93.83 138.59 36.98 36.98
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 67.92 67.92 158.82 OOR < 178.06
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 117.09 138.59 93.83 67.92 36.98
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 67.92 138.59 158.82 67.92 67.92
Solid, M. pyr, 0.05 % PLL, 0.4 mm 93.83 138.59 93.83 67.92 67.92
Solid, M. pyr, 0.10 % PLL, 0.4 mm 158.82 93.83 128.02 93.83 67.92
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 93.83 214.23 138.59 67.92 36.98
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 117.09 138.59 138.59 67.92 67.92
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 158.82 117.09 178.06 117.09 93.83
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 117.09 105.72 117.09 117.09 67.92
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 67.92 158.82 128.02 36.98 67.92
No Hepes
TAM, UP-LVG, 0.25 mm 158.82 196.48 93.83 36.98
TAM, UP-LVG, 0.35 mm 67.92 231.4 214.23 OOR < 36.98
TAM, UP-LVG, 0.40 mm 158.82 222.88 36.98 67.92
Zymosan 138.59 168.55 138.59 158.82 93.83
Table D.26: IFN-γ levels for 2 donors. Values are in pg/ml. OOR < = out of range below. * =
value extrapolated beyond standard range
Sample Donor 1 Donor 2
T0 OOR < OOR <
Saline OOR < OOR <
Solid, UP-LVG, 0.05 % PLL, 0.4 mm OOR < OOR <
Solid, M. pyr, 0.05 % PLL, 0.4 mm OOR < OOR <
TAM, UP-LVG, 0.4 mm, No BaCl2 OOR < OOR <
TAM, UP-LVG, 0.4 mm OOR < OOR <
TAM, M. pyr, 0.4 mm OOR < OOR <
TAM4, UP-LVG*, 0.4 mm OOR < OOR <
TAM, UP-LVG, 0.35 mm, No BaCl2 OOR < OOR <
TAM, UP-LVG, 0.35 mm OOR < OOR <
TAM, M. pyr, 0.35 mm OOR < OOR <
TAM4, UP-LVG*, 0.35 mm OOR < OOR <
Zymosan OOR < OOR <
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D.14 RANTES
Table D.27: RANTES levels for 5 donors. Values are in pg/ml. OOR < = out of range below.
Sample Donor 1 Donor 2 Donor 3 Donor 4 Donor 5
T0 1196.96 1950.06 8902.54 639.6 8335.7
Saline 2242.41 2563.29 3181.1 393.18 2154.91
Hollow, M. pyr, 0.10 % PLL, 0.4 mm 4201.94 1746.32 1877.78 753.29 1816.12
Hollow, M. pyr, 0.14 % PLL, 0.4 mm 3831.84 4118.89 4751.03 1158.62 1284.44
Hollow, M. pyr, 0.14 % PLO, 0.4 mm 1615.59 5088.22 4158.88 1567.19 988.39
Solid, M. pyr, 0.05 % PLL, 0.4 mm 3266.68 5005.73 1987.24 1146.22 713.71
Solid, M. pyr, 0.10 % PLL, 0.4 mm 10565.36 4464.6 4121.21 1413.63 967.24
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 14514.06 13743.4 4613.39 1335.93 1156.32
Solid, UP-LVG, 0.10 % PLL, 0.4 mm 12724.58 7769.95 3574.16 1327.11 1275.43
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 7798.78 5810.25 5079.67 916.81 1362.84
Solid, UP-LVG, 0.10 % PLL, 0.35 mm 3305.1 7694.54 3223.79 1906.67 2411.88
Solid, UP-LVG, 0.05 % PLL, 0.35 mm 6901.57 15257.58 3383.33 1034.85 889.61
No Hepes
TAM, UP-LVG, 0.25 mm 2871.14 7177.31 1189.69 1216.97
TAM, UP-LVG, 0.35 mm 4206.67 12475.71 3842.73 929.87 840.07
TAM, UP-LVG, 0.40 mm 5222.12 4001.35 878.08 1514.03
Zymosan 7732.13 17196.74 3189.33 4140.84 3141.22
Table D.28: RANTES levels for 2 donors. Values are in pg/ml. OOR < = out of range below.
* = value extrapolated beyond standard range
Sample Donor 1 Donor 2
T0 2130.71 4514.63
Saline 4684.63 1112.63
Solid, UP-LVG, 0.05 % PLL, 0.4 mm 6252.28 3294.14
Solid, M. pyr, 0.05 % PLL, 0.4 mm 9087.33 4238.61
TAM, UP-LVG, 0.4 mm, No BaCl2 5733.86 2469.85
TAM, UP-LVG, 0.4 mm 4404.95 2436.72
TAM, M. pyr, 0.4 mm 7875.23 2703.2
TAM4, UP-LVG*, 0.4 mm 7397.35 2169.87
TAM, UP-LVG, 0.35 mm, No BaCl2 8177.66 2098.23
TAM, UP-LVG, 0.35 mm 10176.63 1875.89
TAM, M. pyr, 0.35 mm 8898.75 3367.28
TAM4, UP-LVG*, 0.35 mm 4848.15 1144.46
Zymosan 18800.01 14327.31
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E Flow cytometer data
CD11b expression data for monocytes and granulocytes after incubation of capsules in whole
blood for 1 hour are shown in table E.1. The data consist of samples from 3 blood donors.
Table E.1: CD11b expression on leukocytes, measured as median fluorescence intensity. MC =
monocytes, GC = granulocytes
Sample Donor 1 Donor 4 Donor 5
MC GC MC GC MC GC
T0 35.5 26.7 99.1 59.9 101.8 54.7
Saline 116.5 171.5 378.6 414.2 184.3 79.1
Hollow, M. pyr, 0.10 % PLL, 433.2 547.4 577.7 1144.4 562.3 679.3
0.4 mm
Hollow, M. pyr, 0.14 % PLL, 403.2 500.3 547.4 1134 552.3 736.5
0.4 mm
Hollow, M. pyr, 0.14 % PLO, 226.7 392.4 620.8 791.5 385.4 342.9
0.4 mm
Solid, M. pyr, 0.05 % PLL, 453.2 552.3 827.9 964.7 465.6 305.1
0.4 mm
Solid, M. pyr, 0.10 % PLL, 361.9 491.4 770.4 697.8 237.1 145.9
0.4 mm
Solid, UP-LVG, 0.05 % PLL, 352.3 425.5 588.2 609.8 355.5 302.3
0.4 mm
Solid, UP-LVG, 0.10 % PLL, 417.9 593.5 1229.8 1625.3 518.6 388.9
0.4 mm
Solid, UP-LVG, 0.05 % PLL, 259.5 375.2 1027.4 1197.1 271.4 167
0.35 mm
Solid, UP-LVG, 0.10 % PLL, 342.9 504.8 1065 1625.3 661.2 537.6
0.35 mm
Solid, UP-LVG, 0.05 % PLL, 327.8 465.6 1084.3 1186.4 214.8 90.6
0.35 mm, No Hepes
TAM, UP-LVG, 0.25 mm 212.9 104.6 189.4 82
TAM, UP-LVG, 0.35 mm 107.5 104.6 392.4 257.1 186 71.7
TAM, UP-LVG, 0.40 mm 239.3 109.4 222.7 117.6
Zymosan 593.5 691.6 1826.9 1860.1 1382.4 1218.8
LPS 588.2 637.8 1762.4 1553.8 1345.6 964.7
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F Statistical analysis
Statistical analysis was performed on the cytokine levels after incubating the different capsules
in whole blood for 4 hours. The software SPSS Statistics (v. 20, IBM) was used to perform
Wilcoxon signed-rank tests. Differences were considered significant at P<0.05. SPSS output is
shown in tables F.1-F.36 below.
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F.1 IL-8 1h
Table F.1: Descriptive Statistics - IL-8 1h
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 6.4608 7.09282 2.07 18.91
Saline 5 12.8650 8.07949 4.21 25.73
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 33.8208 14.15141 24.68 58.96
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 38.1197 20.21119 17.90 68.55
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 28.9627 7.26258 21.23 40.44
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 29.3043 14.57915 16.11 50.78
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 42.8985 34.14061 17.66 100.16
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 38.2206 7.43530 26.81 45.26
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 67.8293 29.48448 31.09 97.05
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 29.9368 21.52463 17.81 68.02
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 35.5620 23.32162 17.60 74.62
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 26.8040 9.96256 17.78 42.34
No Hepes
R TAM, UP-LVG, 0.25 mm 4 12.1456 5.70644 8.86 20.69
S TAM, UP-LVG, 0.35 mm 4 13.7830 6.82969 7.94 23.66
T TAM, UP-LVG, 0.40 mm 4 12.5619 4.13615 8.06 17.84
Zymosan 5 349.8204 115.78078 229.28 468.72
Table F.2: Test Statisticsa - IL-8 1h
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -.674b -.135c -.674c -.405b -.944b -1.483b
Asymp. Sig. (2-tailed) .500 .893 .500 .686 .345 .138
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.674b -.674b -.944b -1.483b -.674c -2.023c
Asymp. Sig. (2-tailed) .500 .500 .345 .138 .500 .043
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -1.461b .000c -.730c -2.023c -2.023c -1.753c
Asymp. Sig. (2-tailed) .144 1.000 .465 .043 .043 .080
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -2.023c -2.023c -2.023c -2.023c -1.753c -1.753c
Asymp. Sig. (2-tailed) .043 .043 .043 .043 .080 .080
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan
Z -1.753c -.405b -.135c -.135c -2.023c
Asymp. Sig. (2-tailed) .080 .686 .893 .893 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
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F.2 IL-8 4h
Table F.3: Descriptive Statistics - IL-8 4h
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 4.0840 2.79369 1.39 8.67
Saline 5 350.1780 203.48883 155.13 690.61
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 1044.8960 405.35893 403.59 1478.59
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 1231.7320 763.04898 362.37 2467.10
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 912.1080 615.10078 185.69 1869.15
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 2513.7400 1530.16230 686.93 4304.11
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 4400.5540 1923.18766 2171.52 6879.56
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 4180.1940 2336.14126 2007.47 6802.00
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 4598.6260 3344.80163 1597.20 10065.59
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 2697.5260 2273.96003 419.15 6216.19
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 3095.7560 1632.52191 1225.66 5335.63
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 2892.8580 2280.11908 741.17 6128.61
No Hepes
R TAM, UP-LVG, 0.25 mm 4 189.0050 73.41369 127.87 295.50
S TAM, UP-LVG, 0.35 mm 4 185.2450 73.70063 135.55 294.24
T TAM, UP-LVG, 0.40 mm 4 236.3550 118.45137 93.31 377.67
Zymosan 5 9214.7160 2916.06639 4852.00 12191.85
Table F.4: Test Statisticsa - IL-8 4h
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -.674b -.674b -.135b -2.023b -2.023b -.135b
Asymp. Sig. (2-tailed) .500 .500 .893 .043 .043 .893
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.944b -.405b -2.023b -.405c -2.023c -1.753c
Asymp. Sig. (2-tailed) .345 .686 .043 .686 .043 .080
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -.365b -.730c -.730c -2.023c -2.023c -1.753c
Asymp. Sig. (2-tailed) .715 .465 .465 .043 .043 .080
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -2.023c -2.023c -2.023c -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .043 .043 .043 .043 .043 .043
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan
Z -2.023c -.730b -1.483b -.365b -2.023c
Asymp. Sig. (2-tailed) .043 .465 .138 .715 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
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F.3 sTCC 1h
Table F.5: Descriptive Statistics - sTCC 1h
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 .3221 .14132 .16 .46
Saline 5 2.3275 1.07014 1.17 3.43
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 63.0329 32.76967 35.91 119.19
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 52.8888 24.44967 31.62 92.08
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 15.4614 7.00075 9.06 26.85
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 10.9616 6.60872 3.40 18.99
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 3.9328 2.00556 2.19 7.16
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 2.9263 .58164 2.26 3.76
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 11.5635 8.34680 3.44 25.36
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 8.5032 8.87290 2.25 23.38
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 14.3007 12.11173 6.86 35.67
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 9.4963 9.72817 1.54 25.42
No Hepes
R TAM, UP-LVG, 0.25 mm 4 1.2602 .39400 .88 1.81
S TAM, UP-LVG, 0.35 mm 4 1.4790 .54117 .80 2.11
T TAM, UP-LVG, 0.40 mm 4 1.3814 .37764 .93 1.79
Zymosan 5 82.5438 37.36303 54.47 147.85
Table F.6: Test Statisticsa - sTCC 1h
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -2.023b -2.023b -2.023b -2.023b -2.023b -2.023c
Asymp. Sig. (2-tailed) .043 .043 .043 .043 .043 .043
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -2.023c -1.483c -2.023b -2.023c -1.753c -.674c
Asymp. Sig. (2-tailed) .043 .138 .043 .043 .080 .500
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -.730b -.730b -.730c -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .465 .465 .465 .043 .043 .043
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -2.023c -1.753c -1.214c -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .043 .080 .225 .043 .043 .043
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -2.023c -1.826b -1.753b -1.461b -2.023c -1.753c
Asymp. Sig. (2-tailed) .043 .068 .080 .144 .043 .080
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
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F.4 sTCC 4h
Table F.7: Descriptive Statistics - sTCC 4h
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 .4213 .13422 .24 .61
Saline 5 17.2501 10.07845 6.30 31.36
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 147.2494 60.93740 65.19 224.98
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 128.7753 45.05308 59.98 163.88
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 42.9312 16.41020 32.64 72.03
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 57.4229 22.36119 37.81 82.01
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 75.6500 36.79900 33.78 127.77
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 21.4456 14.40741 7.20 45.06
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 61.3385 21.38792 29.58 86.13
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 39.2189 20.14846 20.29 66.32
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 82.1278 43.56215 29.28 122.94
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 53.6435 43.37009 14.63 106.36
No Hepes
R TAM, UP-LVG, 0.25 mm 4 6.3028 5.24281 3.18 14.11
S TAM, UP-LVG, 0.35 mm 4 6.0266 4.28397 2.96 12.37
T TAM, UP-LVG, 0.40 mm 4 6.4188 5.76905 3.18 15.06
Zymosan 5 144.6234 29.89242 116.78 193.61
Table F.8: Test Statisticsa - sTCC 4h
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -2.023b -2.023b -2.023b -2.023b -1.753c -2.023c
Asymp. Sig. (2-tailed) .043 .043 .043 .043 .080 .043
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -2.023c -.405c -2.023b -.944b -2.023c -1.214c
Asymp. Sig. (2-tailed) .043 .686 .043 .345 .043 .225
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -.730b -.365c -.000d -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .465 .715 1.000 .043 .043 .043
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -2.023c -2.023c -.135b -1.753c -1.753c -1.753c
Asymp. Sig. (2-tailed) .043 .043 .893 .080 .080 .080
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -1.483c -1.826b -2.023c -1.826b -2.023c -.405b
Asymp. Sig. (2-tailed) .138 .068 .043 .068 .043 .686
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.5 MIP-1α
Table F.9: Descriptive Statistics - MIP-1α
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 2.5900 1.44869 1.36 4.99
Saline 5 42.7960 19.29429 30.30 76.11
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 61.5600 43.96702 21.34 131.08
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 93.0300 44.44417 32.96 139.63
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 72.2620 24.23221 34.95 95.26
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 350.8320 237.48137 121.22 722.80
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 442.4620 132.36338 330.94 611.82
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 441.9040 77.76742 369.65 551.19
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 483.9480 484.18320 123.80 1332.41
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 337.9300 208.89467 67.91 532.37
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 337.6520 184.98150 167.12 635.24
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 383.2720 293.52836 94.20 819.67
No Hepes
R TAM, UP-LVG, 0.25 mm 4 64.0475 21.62608 35.09 84.13
S TAM, UP-LVG, 0.35 mm 5 50.3780 20.23506 31.22 79.96
T TAM, UP-LVG, 0.40 mm 4 74.4275 36.96783 43.34 124.39
Zymosan 5 2986.4900 690.79113 1841.37 3677.83
Table F.10: Test Statisticsa - MIP-1α
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -2.023c -.674b -.674c -2.023b -.674b -.674c
Asymp. Sig. (2-tailed) .043 .500 .500 .043 .500 .500
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.135c -.674b -.674b -.135c -1.214c -.405c
Asymp. Sig. (2-tailed) .893 .500 .500 .893 .225 .686
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -1.826c -.365b -1.095b -.674c -2.023c -1.214c
Asymp. Sig. (2-tailed) .068 .715 .273 .500 .043 .225
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -2.023c -2.023c -2.023c -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .043 .043 .043 .043 .043 .043
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -2.023c -.730c -.405c -1.095c -2.023c
Asymp. Sig. (2-tailed) .043 .465 .686 .273 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
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F.6 MCP-1
Table F.11: Descriptive Statistics - MCP-1
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 68.5640 16.35280 49.61 94.58
Saline 5 101.5140 31.83197 73.27 151.19
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 341.6760 178.26439 124.54 538.99
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 360.8820 185.15174 142.37 586.26
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 192.7480 118.10103 95.56 384.25
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 243.7180 110.80518 115.94 355.10
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 174.5160 48.17226 115.64 238.41
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 220.4980 102.12423 120.71 386.48
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 213.9460 106.07488 132.63 384.78
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 203.0180 90.98065 109.88 334.26
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 283.2900 142.62251 138.59 488.29
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 235.3020 142.03844 110.33 451.04
No Hepes
R TAM, UP-LVG, 0.25 mm 4 98.7700 28.89767 70.37 138.31
S TAM, UP-LVG, 0.35 mm 5 98.0260 31.18579 68.16 150.37
T TAM, UP-LVG, 0.40 mm 4 107.9825 40.97784 68.34 162.37
Zymosan 5 229.4100 107.31595 111.40 328.36
Table F.12: Test Statisticsa - MCP-1
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -1.214c -1.753c -2.023c -2.023c -2.023c -.405c
Asymp. Sig. (2-tailed) .225 .080 .043 .043 .043 .686
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -2.023c -.674b -.405c -.944b -1.214c -2.023b
Asymp. Sig. (2-tailed) .043 .500 .686 .345 .225 .043
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -.365c -.730b -1.826b -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .715 .465 .068 .043 .043 .043
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -2.023c -2.023c -2.023c -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .043 .043 .043 .043 .043 .043
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -2.023c -1.095c -.135b -.730c -2.023c
Asymp. Sig. (2-tailed) .043 .273 .893 .465 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.7 MIF
Table F.13: Descriptive Statistics - MIF
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 4 1532.0900 1726.18504 164.66 3837.06
Saline 5 1931.0560 547.38170 1191.63 2733.36
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 2351.9340 1436.66309 649.33 3818.51
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 8511.9960 9260.25349 771.50 22329.12
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 7165.4040 4180.65487 463.54 10670.44
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 9979.5240 9234.56494 505.14 22110.45
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 12142.6100 8788.69975 1496.29 21099.63
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 13038.6220 7407.18894 4620.90 22942.45
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 9056.9520 4418.05025 1720.06 13212.55
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 6828.3080 4687.73383 690.18 13056.69
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 8418.5640 8448.84796 2115.12 21672.75
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 8492.4640 7500.84398 2865.44 19933.86
No Hepes
R TAM, UP-LVG, 0.25 mm 4 13170.3075 9302.15929 1865.13 23806.31
S TAM, UP-LVG, 0.35 mm 5 6714.4360 6237.65135 1211.41 14007.63
T TAM, UP-LVG, 0.40 mm 4 6275.5700 5280.71162 2105.53 13549.91
Zymosan 5 6451.1700 4712.82989 1894.06 14050.77
Table F.14: Test Statisticsa - MIF
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -2.023b -1.753b -.674c -2.023b -.944b -1.753c
Asymp. Sig. (2-tailed) .043 .080 .500 .043 .345 .080
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.135b -.405b -1.214b -.944c -2.023c -.405c
Asymp. Sig. (2-tailed) .893 .686 .225 .345 .043 .686
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -1.095c -1.461c -.365b -.674c -1.214c -1.753c
Asymp. Sig. (2-tailed) .273 .144 .715 .500 .225 .080
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -1.483c -1.753c -2.023c -1.753c -1.753c -2.023c
Asymp. Sig. (2-tailed) .138 .080 .043 .080 .080 .043
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -2.023c -1.461c -1.214c -1.826c -2.023c
Asymp. Sig. (2-tailed) .043 .144 .225 .068 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.8 IP-10
Table F.15: Descriptive Statistics - IP-10
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 154.1340 59.22838 68.26 211.34
Saline 5 320.3900 131.29056 185.35 501.94
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 673.7020 361.93355 293.08 1241.47
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 357.7980 101.47420 228.93 505.13
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 383.0500 111.69641 205.91 515.28
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 407.2380 193.13764 155.10 593.51
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 158.3360 98.50811 75.34 318.07
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 194.7480 85.87974 98.50 331.37
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 204.0560 128.69208 99.90 404.68
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 456.1800 374.52086 146.46 1076.95
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 240.0280 80.92764 115.88 311.34
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 395.8900 276.27343 120.89 849.45
No Hepes
R TAM, UP-LVG, 0.25 mm 4 633.3425 577.24748 172.61 1424.81
S TAM, UP-LVG, 0.35 mm 5 772.3900 1055.00892 144.25 2639.30
T TAM, UP-LVG, 0.40 mm 4 531.3600 436.06891 163.47 1080.32
Zymosan 5 1220.9020 313.89697 926.97 1646.18
Table F.16: Test Statisticsa - IP-10
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -2.023b -2.023c -.674b -2.023b -2.023b -.365c
Asymp. Sig. (2-tailed) .043 .043 .500 .043 .043 .715
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -2.023b -.135b -2.023b -.944c -2.023c -1.214c
Asymp. Sig. (2-tailed) .043 .893 .043 .345 .043 .225
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -.365c -1.826c -.365b -2.023c -.944c -2.023c
Asymp. Sig. (2-tailed) .715 .068 .715 .043 .345 .043
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -1.214c -2.023b -2.023b -1.753b -.944c -1.214b
Asymp. Sig. (2-tailed) .225 .043 .043 .080 .345 .225
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -.674b -.730c -.405b -.730c -2.023c
Asymp. Sig. (2-tailed) .500 .465 .686 .465 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.9 IL-1β
Table F.17: Descriptive Statistics - IL-1β
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 4 .6625 .50953 .14 1.18
Saline 5 3.7760 2.09268 1.84 6.49
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 2.8000 1.35652 1.68 4.99
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 5.6940 5.16487 1.51 14.56
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 5.2800 2.02884 2.42 7.75
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 17.8600 22.19390 6.18 57.39
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 41.3920 29.30937 11.33 78.34
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 41.6820 25.45775 12.87 79.32
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 34.5960 32.96033 7.91 85.64
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 16.0880 12.71637 2.17 30.96
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 15.6980 9.88550 4.59 28.39
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 26.8720 24.18347 5.23 59.42
No Hepes
R TAM, UP-LVG, 0.25 mm 4 4.7275 2.89644 2.33 8.84
S TAM, UP-LVG, 0.35 mm 5 3.3660 1.39339 1.68 5.31
T TAM, UP-LVG, 0.40 mm 4 5.6575 1.69134 3.15 6.81
Zymosan 5 1960.1580 676.66763 1050.04 2612.78
Table F.18: Test Statisticsa - IL-1β
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -1.214b -2.023c -.135c -2.023b -2.023b -.674c
Asymp. Sig. (2-tailed) .225 .043 .893 .043 .043 .500
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.405c -.944b -1.483b -.674c -1.753c -.944c
Asymp. Sig. (2-tailed) .686 .345 .138 .500 .080 .345
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -1.095b -.730c -1.461c -.948b -.674c -.405c
Asymp. Sig. (2-tailed) .273 .465 .144 .343 .500 .686
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -1.753c -2.023c -2.023c -2.023c -1.483c -1.753c
Asymp. Sig. (2-tailed) .080 .043 .043 .043 .138 .080
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -1.753c .000d -.674b -1.095c -2.023c
Asymp. Sig. (2-tailed) .080 1.000 .500 .273 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.10 TNF-α
Table F.19: Descriptive Statistics - TNF-α
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 7.2220 5.79397 .72 15.81
Saline 5 27.9020 18.27779 10.72 55.74
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 52.1280 49.09326 5.68 132.97
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 62.3460 33.87986 36.33 119.81
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 37.9120 14.67873 20.91 59.64
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 195.6440 119.08012 90.95 375.52
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 323.9520 165.42660 117.18 515.96
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 231.0000 89.21476 138.25 337.91
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 499.6100 669.96224 62.24 1686.57
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 236.7160 154.38014 33.75 383.59
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 212.4140 87.32563 83.10 287.01
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 202.9440 104.91768 109.30 366.10
No Hepes
R TAM, UP-LVG, 0.25 mm 4 40.2200 12.40176 28.60 57.04
S TAM, UP-LVG, 0.35 mm 4 54.5200 26.57212 28.60 88.33
T TAM, UP-LVG, 0.40 mm 4 61.6625 26.79479 33.75 88.33
Zymosan 5 12723.5400 6072.72124 6429.36 21741.64
Table F.20: Test Statisticsa - TNF-α
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -.674b -.730c -1.753c -2.023b -2.023b -.674b
Asymp. Sig. (2-tailed) .500 .465 .080 .043 .043 .500
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.674c -.944c -.135b -.135c -.405b -1.214c
Asymp. Sig. (2-tailed) .500 .345 .893 .893 .686 .225
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -1.069b -1.826b -1.604b -.674c -2.023c -.674c
Asymp. Sig. (2-tailed) .285 .068 .109 .500 .043 .500
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -2.023c -2.023c -2.023c -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .043 .043 .043 .043 .043 .043
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -2.023c -.730c -.674c -1.095c -2.023c
Asymp. Sig. (2-tailed) .043 .465 .500 .273 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.11 IL-6
Table F.21: Descriptive Statistics - IL-6
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 1.6260 1.07797 .40 3.20
Saline 5 9.6600 5.25779 3.20 17.54
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 20.4720 18.60784 6.04 50.24
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 27.1080 23.04553 9.47 66.76
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 20.5140 16.72379 6.61 39.09
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 33.0980 20.76782 9.47 56.43
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 32.4040 22.69997 14.07 67.35
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 28.0520 16.92676 13.79 54.07
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 57.7100 55.82746 11.20 149.27
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 32.3820 18.94862 10.05 55.54
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 30.6340 19.77923 15.23 59.08
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 24.6940 17.63142 7.18 49.36
No Hepes
R TAM, UP-LVG, 0.25 mm 4 15.8275 7.57080 7.18 22.18
S TAM, UP-LVG, 0.35 mm 4 13.6500 8.92435 3.20 23.92
T TAM, UP-LVG, 0.40 mm 4 20.4750 11.19781 5.47 32.07
Zymosan 5 9081.1120 3231.71071 5039.91 13173.34
Table F.22: Test Statisticsa - IL-6
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -1.753b -.135b -.944b -1.214b -.135b -1.214c
Asymp. Sig. (2-tailed) .080 .893 .345 .225 .893 .225
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.135c -1.753b -1.214b -.674c -.674c -.405b
Asymp. Sig. (2-tailed) .893 .080 .225 .500 .500 .686
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -.730c -1.461c -1.095c -1.753c -2.023c -1.753c
Asymp. Sig. (2-tailed) .465 .144 .273 .080 .043 .080
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -2.023c -2.023c -2.023c -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .043 .043 .043 .043 .043 .043
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -2.023c -1.604c -1.461c -1.461c -2.023c
Asymp. Sig. (2-tailed) .043 .109 .144 .144 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.12 IL-1RA
Table F.23: Descriptive Statistics - IL-1RA
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 162.2520 177.95030 38.00 467.88
Saline 5 530.0820 400.05150 231.00 1110.71
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 484.4120 178.81394 231.00 667.44
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 633.6660 415.96114 270.21 1272.96
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 686.2000 504.08971 309.55 1557.96
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 1143.9580 869.12087 467.88 2645.93
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 1216.2580 761.15754 388.54 2254.51
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 1202.5120 614.71259 547.52 2172.29
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 1004.3700 603.38547 507.67 1967.03
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 1066.6180 807.33690 507.67 2460.35
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 993.1000 717.76298 507.67 2254.51
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 1226.6940 1058.78387 567.47 3080.02
No Hepes
R TAM, UP-LVG, 0.25 mm 4 733.5900 290.59707 388.54 1029.77
S TAM, UP-LVG, 0.35 mm 4 657.9360 451.95346 270.21 1374.60
T TAM, UP-LVG, 0.40 mm 4 829.9325 464.32526 547.52 1517.17
Zymosan 5 1399.6980 945.49409 667.44 3038.61
Table F.24: Test Statisticsa - IL-1RA
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -.944b -1.214c -.365c -1.753b -.405b -2.023c
Asymp. Sig. (2-tailed) .345 .225 .715 .080 .686 .043
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.674c -1.753b -.674b -1.753c -.944c .000d
Asymp. Sig. (2-tailed) .500 .080 .500 .080 .345 1.000
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -.365b -.365c -1.095c -.730b -.944c -1.483c
Asymp. Sig. (2-tailed) .715 .715 .273 .465 .345 .138
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -2.023c -2.023c -2.023c -1.753c -1.753c -1.753c
Asymp. Sig. (2-tailed) .043 .043 .043 .080 .080 .080
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -1.753c -1.095c -2.023c -1.473c -2.023c
Asymp. Sig. (2-tailed) .080 .273 .043 .141 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.13 IL-10
Table F.25: Descriptive Statistics - IL-10
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 2.3840 1.17878 1.22 4.02
Saline 5 2.6540 1.88601 1.22 5.79
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 3.5420 2.29270 1.22 7.14
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 3.3240 2.63650 1.49 7.90
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 3.2700 1.91349 1.76 6.54
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 3.2380 2.70259 1.76 8.06
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 2.8560 1.09228 1.90 4.31
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 3.3080 2.27915 2.03 7.29
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 3.7700 2.30625 1.76 7.60
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 3.7040 2.10355 1.76 7.29
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 3.1080 2.11159 1.22 6.69
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 4.3120 2.98241 1.49 8.98
No Hepes
R TAM, UP-LVG, 0.25 mm 4 3.1900 2.09106 1.49 6.23
S TAM, UP-LVG, 0.35 mm 5 3.7760 2.56740 1.76 8.21
T TAM, UP-LVG, 0.40 mm 4 3.6350 3.50820 1.22 8.83
Zymosan 5 8.6080 2.61729 5.19 11.64
Table F.26: Test Statisticsa- IL-10
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -.674b -1.084c -.405c -.944b .000d -1.753c
Asymp. Sig. (2-tailed) .500 .279 .686 .345 1.000 .080
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -2.023b -.944c .000d -1.753c -1.461c -1.753b
Asymp. Sig. (2-tailed) .043 .345 1.000 .080 .144 .080
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -1.604b -.365c -.730c -1.461cc -.944cc -2.023c
Asymp. Sig. (2-tailed) .109 .715 .465 .144 .345 .043
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -.944c -.674c -1.219c -2.023c -2.023c -1.289c
Asymp. Sig. (2-tailed) .345 .500 .223 .043 .043 .197
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -1.483c -1.461c -2.023c -1.069c -2.023c
Asymp. Sig. (2-tailed) .138 .144 .043 .285 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.14 PDGF
Table F.27: Descriptive Statistics - PDGF
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 305.7000 430.20408 11.47 1050.37
Saline 5 656.7100 373.86802 245.01 1101.31
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 577.6820 161.84339 389.98 770.08
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 849.7780 591.69759 277.54 1696.59
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 803.8000 424.26766 337.63 1311.73
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 912.1800 731.75499 207.55 2148.30
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 1082.1900 567.60539 355.72 1586.77
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 1459.1680 1111.06676 433.74 3194.42
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 1182.1760 689.78614 382.37 1957.06
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 1194.2060 600.88921 500.35 2021.58
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 1253.2760 681.91501 773.93 2428.51
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 1292.1320 1181.89921 357.63 3299.27
No Hepes
R TAM, UP-LVG, 0.25 mm 4 989.1975 797.83815 252.68 1974.72
S TAM, UP-LVG, 0.35 mm 5 1021.7060 984.48007 166.95 2639.87
T TAM, UP-LVG, 0.40 mm 4 1440.6800 1555.48674 344.30 3654.76
Zymosan 5 1478.9720 832.83366 1011.29 2953.46
Table F.28: Test Statisticsa - PDGF
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -.674c -1.214b -.405c -1.753b -.674b -1.214c
Asymp. Sig. (2-tailed) .500 .225 .686 .080 .500 .225
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.135b -.674c -1.753b -1.214b -.944c -.135b
Asymp. Sig. (2-tailed) .893 .500 .080 .225 .345 .893
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -.365c -.365b -1.826b -.405b -1.214c -1.214c
Asymp. Sig. (2-tailed) .715 .715 .068 .686 .225 .225
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -.944c -1.753c -2.023c -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .345 .080 .043 .043 .043 .043
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -1.753c -1.461c -1.214c -1.461c -2.023c
Asymp. Sig. (2-tailed) .080 .144 .225 .144 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.15 HGF
Table F.29: Descriptive Statistics - HGF
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 113.6460 72.95950 34.56 210.08
Saline 5 595.7760 220.46853 345.18 833.95
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 784.2200 459.84071 334.14 1487.70
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 708.5860 366.36570 294.34 1173.41
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 622.1360 253.23307 267.77 899.99
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 1243.9480 860.07007 281.06 2477.07
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 1200.8260 699.33887 435.62 2346.17
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 1102.3040 556.71505 387.12 1779.06
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 1041.9840 595.04540 320.88 1917.47
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 1143.7540 696.81063 274.42 2163.93
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 1088.0100 721.93043 356.22 2211.12
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 1132.1260 849.08652 294.34 2542.65
No Hepes
R TAM, UP-LVG, 0.25 mm 4 243.4525 216.19141 66.59 530.32
S TAM, UP-LVG, 0.35 mm 5 220.7320 109.16265 48.34 345.18
T TAM, UP-LVG, 0.40 mm 4 207.3075 140.12580 93.76 391.53
Zymosan 5 1245.7320 597.69957 360.64 2029.36
Table F.30: Test Statisticsa - HGF
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -.135b -.944c -.944c -1.214b -.405b -.944c
Asymp. Sig. (2-tailed) .893 .345 .345 .225 .684 .345
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.944b -.405c -.674c -1.214c -.135b -.674b
Asymp. Sig. (2-tailed) .345 .686 .500 .225 .893 .500
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -.730c -.730c -.365b -.405c -.944c -.405c
Asymp. Sig. (2-tailed) .465 .465 .715 .686 .345 .686
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -1.753c -2.023c -2.023c -1.753c -1.753c -1.483c
Asymp. Sig. (2-tailed) .080 .043 .043 .080 .080 .138
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -1.214c -1.826b -2.023b -1.826b -2.023c
Asymp. Sig. (2-tailed) .225 .068 .043 .068 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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F.16 VEGF
Table F.31: Descriptive Statistics - VEGF
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 2 11.3850 14.53104 1.11 21.66
Saline 5 37.2440 29.14632 5.22 68.48
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 33.7340 13.05595 20.94 51.94
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 60.9120 53.07426 13.72 147.69
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 37.3100 22.59121 14.44 74.54
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 89.9140 78.94619 36.69 225.09
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 118.0940 77.10795 62.45 240.29
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 104.6080 62.36850 54.94 199.63
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 106.9840 86.19750 44.85 257.16
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 89.7320 63.24764 40.03 196.06
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 97.7600 70.14865 48.95 221.10
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 106.3480 100.43217 43.74 281.38
No Hepes
R TAM, UP-LVG, 0.25 mm 4 36.2200 14.27884 16.23 48.21
S TAM, UP-LVG, 0.35 mm 5 26.9760 11.32249 14.44 41.51
T TAM, UP-LVG, 0.40 mm 4 44.5825 19.41848 27.13 72.26
Zymosan 5 54.8780 47.16626 18.76 129.79
Table F.32: Test Statisticsa - VEGF
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -1.214c -.135b -.405c -2.023b -2.023b -.135b
Asymp. Sig. (2-tailed) .225 .893 .686 .043 .043 .893
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -1.214c -.944b -.944b -.674c -1.753c -1.214c
Asymp. Sig. (2-tailed) .225 .345 .345 .500 .080 .225
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -1.826c -1.095b -1.826b -.405b -1.483c -.674c
Asymp. Sig. (2-tailed) .068 .273 .068 .686 .138 .498
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -2.023c -2.023c -2.023c -2.023c -2.023c -2.023c
Asymp. Sig. (2-tailed) .043 .043 .043 .043 .043 .043
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -2.023c -.365b -.674b -.365c -1.483c
Asymp. Sig. (2-tailed) .043 .715 .500 .715 .138
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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Table F.33: Descriptive Statistics - IFN-γ
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 3 137.1733 87.25739 36.98 196.48
Saline 5 80.0420 43.34962 36.98 138.59
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 4 118.1800 58.56438 67.92 178.06
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 90.8820 40.01338 36.98 138.59
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 100.2340 44.82211 67.92 158.82
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 92.4180 28.87969 67.92 138.59
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 108.4840 35.32098 67.92 158.82
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 110.3100 69.00166 36.98 214.23
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 106.0220 35.87260 67.92 138.59
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 132.9780 34.41518 93.83 178.06
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 104.9820 21.29523 67.92 117.09
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 91.9320 49.87290 36.98 158.82
No Hepes
R TAM, UP-LVG, 0.25 mm 4 121.5275 70.53141 36.98 196.48
S TAM, UP-LVG, 0.35 mm 4 137.6325 99.41542 36.98 231.40
T TAM, UP-LVG, 0.40 mm 4 121.6500 85.01969 36.98 222.88
Zymosan 5 139.6760 28.74202 93.83 168.55
Table F.34: Test Statisticsa - IFN-γ
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -.365b -.447c -.535b -.365b -.730c .000d
Asymp. Sig. (2-tailed) .715 .655 .593 .715 .465 1.000
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -1.826b -1.483b -1.069c .000d -.674c .000d
Asymp. Sig. (2-tailed) .068 .138 .285 1.000 .500 1.000
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -1.342b .000d .000d .000d -.552b -1.490b
Asymp. Sig. (2-tailed) .180 1.000 1.000 1.000 .581 .136
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -.557b -1.461b -1.342b -1.841b -2.023b -1.483b
Asymp. Sig. (2-tailed) .577 .144 .180 .066 .043 .138
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -.730b -1.604b -1.069b -1.604b -1.826b
Asymp. Sig. (2-tailed) .465 .109 .285 .109 .068
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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Table F.35: Descriptive Statistics - RANTES
Sample Capsule parameters N Mean Std. Deviation Minimum Maximum
Abr.
T0 5 4204.9720 4061.24060 639.60 8902.54
Saline 5 2106.9780 1039.19459 393.18 3181.10
Ab Hollow, M. pyr, 0.10 % PLL, 0.4 mm 5 2079.0900 1273.24905 753.29 4201.94
A2b Hollow, M. pyr, 0.14 % PLL, 0.4 mm 5 3028.9640 1683.71691 1158.62 4751.03
Db Hollow, M. pyr, 0.14 % PLO, 0.4 mm 5 2683.6540 1817.92478 988.39 5088.22
Eb Solid, M. pyr, 0.05 % PLL, 0.4 mm 5 2423.9160 1740.97762 713.71 5005.73
Fb Solid, M. pyr, 0.10 % PLL, 0.4 mm 5 4306.4080 3832.49301 967.24 10565.36
Gb Solid, UP-LVG, 0.05 % PLL, 0.4 mm 5 7072.6200 6592.31304 1156.32 14514.06
Hb Solid, UP-LVG, 0.10 % PLL, 0.4 mm 5 5334.2460 4903.53749 1275.43 12724.58
I2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 4193.6700 2964.22650 916.81 7798.78
J2b Solid, UP-LVG, 0.10 % PLL, 0.35 mm 5 3708.3960 2302.93318 1906.67 7694.54
K2b Solid, UP-LVG, 0.05 % PLL, 0.35 mm 5 5493.3880 5975.95389 889.61 15257.58
No Hepes
R TAM, UP-LVG, 0.25 mm 4 3113.7775 2820.82498 1189.69 7177.31
S TAM, UP-LVG, 0.35 mm 5 4459.0100 4750.32923 840.07 12475.71
T TAM, UP-LVG, 0.40 mm 4 2903.8950 2050.54674 878.08 5222.12
Zymosan 5 7080.0520 5959.52314 3141.22 17196.74
Table F.36: Test Statisticsa - RANTES
A2b-Ab Db-Ab Db-A2b Fb - Ab Fb - Eb Hb - Gb
Z -.944b -.405c -.405b -1.483c -1.214c -1.483b
Asymp. Sig. (2-tailed) .345 .686 .686 .138 .225 .138
J2b - I2b K2b - I2b Gb - Eb Hb - Fb I2b - Gb J2b - Hb
Z -.135c -.405b -2.023c -.944c -.944b -.135b
Asymp. Sig. (2-tailed) .893 .686 .043 .345 .345 .893
S-R T-R T-S Saline-Ab Saline-A2b Saline-Db
Z -.365b -.365b .000d -.135c -1.483b -.944b
Asymp. Sig. (2-tailed) .715 .715 1.000 .893 .138 .345
Saline-Eb Saline-Fb Saline-Gb Saline-Hb Saline-I2b Saline-J2b
Z -.135b -1.214b -1.483b -1.483b -1.483b -2.023b
Asymp. Sig. (2-tailed) .893 .225 .138 .138 .138 .043
Saline-K2b Saline-R Saline-S Saline-T Saline-Zymosan Saline-LPS
Z -1.214b -.730b -1.214b -1.095b -2.023b
Asymp. Sig. (2-tailed) .225 .465 .225 .273 .043
a. Wilcoxon Signed Ranks Test
b. Based on negative ranks.
c. Based on positive ranks.
d. The sum of negative ranks equals the sum of positive ranks.
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